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Summary 
Oesophageal adenocarcinoma (OAC), a cancer with dismal prognosis, has 
been increasing rapidly in incidence over the last 30 years, nowhere more so 
than in the UK. Intriguingly, it is a disease predominantly among white males, 
but there is a paucity of data from England.  
In performing a range of epidemiological studies, it has been confirmed that 
OAC has risen five-fold in the West Midlands, UK, five times more common 
among men, and predominantly a disease among Caucasians. A reduced 
incidence of OAC was identified among subjects with prostate cancer, 
suggesting a protective effect of anti-androgen therapy. 
Examination of a general practice database revealed a negative association 
with aspirin, non-steroidal anti-inflammatories and statins with OAC, and a 
positive association with inhaled steroids, increasing number of drugs with a 
side effect of reducing the lower oesophageal sphincter, and drugs used for 
asthma/COPD. 
Finally, a region wide case-control study, confirmed the positive association 
seen with increasing body mass index, waist circumference, smoking and 
reflux symptoms, with negative associations seen with a diet high in fruit and 
vegetables. 
This work has identified potentially modifiable risk factors that may be 
employed to reduce the incidence of oesophageal adenocarcinoma, and 
better help stratify those most likely to benefit from endoscopic surveillance.
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Chapter 1 
 
An Introduction to the aetiology of oesophageal adenocarcinoma
 2 
1 Introduction 
Oesophageal adenocarcinoma (OAC) is a neoplastic growth arising from the 
glandular cells of the oesophageal mucosa. Siewart et al defined the 
classification of oesophagus and gastro-oesophageal junction cancers: type 1 
lesions originate in the oesophagus and may infiltrate to the GOJ, type 2 
lesions orginate at the cardia/GOJ, and type 3 lesions originate from the sub-
cardia region and extend up to the GOJ (Siewert and Stein, 1998). The 
aetiology of each of these types of cancer is different (Siewert and Stein, 
1998); this thesis is focusing on true oesophageal adenocarcinoma, including 
type 1 lesions. While OAC is not one of the more common malignancies such 
as lung and breast cancer, it has the fastest growing incidence for any cancer 
in the western world, and despite advances in management, both surgical and 
chemotherapeutic, prognosis remains poor with less than 40% surviving 12 
months from diagnosis and a 5-year survival of 12-13% (Rachet et al., 2009).  
 
Furthermore, the disease has a five-fold greater incidence among males, and 
is predominantly a disease among the Caucasian population, in contrast to 
oesophageal squamous cell carcinoma (OSCC). OSCC incidence rates have 
been static or more recently declining, affecting the black population more 
readily than the Caucasian. 
 
While OSCC is associated with deprivation (Brown et al., 2001), the 
association of OAC with socio-economic status has been more mixed in the 
literature. In Sweden, OAC is associated with deprivation (Jansson et al., 
 3 
2005b), with a similar finding in the USA (Brown et al., 1994). However, in 
Scotland (Brewster et al., 2000) and Europe (Nagel et al., 2007), no 
association was identified between socioeconomic status and OAC.  
 
Existing studies into the aetiology of oesophageal adenocarcinoma have 
examined potential associated risk factors including gastro-oesophageal reflux 
disease and its complications (Lagergren et al., 1999a, Yanke et al., 2006), 
namely Barrett’s oesophagus (BO), the influence of increasing body mass 
index (BMI) and other body parameters including waist circumference 
(Anderson et al., 2007, Merry et al., 2007), increasing number of drugs taken 
that reduce lower oesophageal sphincter (LOS) resting pressures (Lagergren 
et al., 2000, Vaughan et al., 1998), and smoking (Anderson et al., 2007, 
Solaymani-Dodaran et al., 2004), and also those reported to be negatively 
associated including medication usage including aspirin and non-steroidal 
anti-inflammatory drugs (NSAIDs), Helicobacter pylori infection (de Martel et 
al., 2005), and a diet high in fruit and vegetables (Brown et al., 1995). 
However all these studies have been performed outside mainland UK, where 
the observed rapidly rising incidence is greatest. 
 
1.1 Gastro-oesophageal reflux disease symptoms 
Symptoms of gastro-oesophageal reflux (GOR) are common, affecting over 
one-third of adults, complaining mainly of heartburn (75% of reflux 
patients(Dent, 1999)) and/or acid regurgitation (Jankowski et al., 2000, 
Spechler et al., 2001). Epidemiology has revealed that the prevalence of 
 4 
GORD is greater in Europe and the USA than in Asia (Vakil et al., 2006). 
While heartburn and acid regurgitation are the most common presentations of 
GOR (Dent, 1999), about 50% of patients identified with reflux oesophagitis 
complain of other symptoms, including dyspepsia, dysphagia, chest pain, and 
extra-oesophageal symptoms such as cough, laryngitis and bronchospasm 
(Vakil et al., 2006), indicating how heterogenous a diagnosis of GORD may 
be. Furthermore, many individuals do not seek medical opinion for reflux 
symptoms despite being present for years, with 50% of over the counter 
(OTC) antacid users being found to have reflux oesophagitis at gastroscopy. 
 
The Genval workshop (Dent, 1999), and Montreal definition and classification 
of GORD (Vaughan et al., 2005) sought to overcome the semantics and 
confusion surrounding reflux symptoms and their sequelae: “Heartburn is 
defined as a burning sensation in the retrosternal area (behind the 
breastbone)” and “regurgitation is defined as the perception of flow of refluxed 
gastric content into the mouth or hypopharynx” (Dent, 1999), definitions 
derived due to misinterpretation by patients and requiring detailed history 
taking (Carlsson et al., 1998). The term gastro-oesophageal reflux disease 
(GORD) similarly has been determined by the Genval workshop “to include all 
individuals who are exposed to the risk of physical complications from gastro-
oesophageal reflux, or who experience clinically significant impairment of 
health related well being (quality of life) due to reflux related symptoms, after 
adequate reassurance of the benign nature of their symptoms” (Dent, 1999). 
This is in keeping with the Montreal definition and classification of GORD, 
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indicating that if reflux symptoms were not troublesome, then the term GORD 
should not be used (Vakil et al., 2006). 
 
1.2 Reflux symptoms and oesophageal adenocarcinoma 
With chronic GORD potentially developing into Barrett’s oesophagus (BO), a 
known pre-cursor to OAC, reflux symptoms, whilst common, are an identified 
risk factor for development of OAC. It has been estimated that gastro-
oesophageal reflux accounts for 29.7% of OAC through analysis of population 
attributable risks (Engel et al., 2003). Furthermore, laryngopharyngeal reflux 
symptoms such as cough, hoarse voice and sore throat are associated with 
OAC to a greater degree than heartburn alone, suggesting that more proximal 
reflux/regurgitation may well present a greater aetiological factor (Reavis et 
al., 2004). Early work from Sweden revealed that those with severe and long 
duration of symptoms were at a vastly increased risk of developing OAC 
(Odds ratio (OR) 43.5, 95% confidence intervals (CI) 18.3-103.5), but not 
OSCC (Lagergren et al., 1999a). Further research in USA revealed not only 
the association of OAC with reflux symptoms (OR 3.61, 95% CI 2.49-5.25), 
but that the presence of a hiatus hernia without reflux symptoms was also 
strongly associated with OAC (OR 5.85, 95% CI 3.18-10.75). A combination of 
hiatus hernia with reflux symptoms was the strongest association with OAC of 
all (OR 8.11, 95% CI 4.75-13.87) (Wu et al., 2003). Subsequent population 
studies have been unable to reproduce the impressive OR of association seen 
in Sweden, but meta-analysis has provided further supportive evidence that 
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increasing frequency of reflux symptoms are clearly associated with OAC 
(weekly symptoms with 5-fold and daily symptoms 7-fold increased risk). 
However duration of symptoms in meta-analysis produced varying results 
(Rubenstein and Taylor, 2010). 
 
1.3 Mechanisms of gastro-oesophageal reflux 
The mechanism of reflux symptoms is the contact of oesophageal mucosa 
with gastric contents, namely acid and pepsin (Dent, 1999), with studies 
indicating the increased time that the oesophageal mucosa is exposed to acid 
is associated with frequency of reflux symptoms. The natural barriers to reflux 
of gastric contents into the oesophagus are the anatomy of the hiatus and the 
LOS.  
 
1.3.1 Hiatus hernia 
The hiatus is the opening within the diaphragm allowing the oesophagus and 
vagal nerve to pass from the thorax to the abdomen, being formed by the right 
crura. The oesophagus is tethered to the diaphragm by the phreno-
oesophageal ligament inserting around the distal oesophagus at the level of, 
and approximately 1cm above the gastro-oesophageal junction (proximal 
margin of the gastric folds (GOJ)), preventing herniation of the stomach into 
the thoracic cavity (Kahrilas et al., 2008). The oesophagus will shorten by 
approximately 2cm during a swallow and returns to its original position 
 7 
through the elasticity of the phreno-oesophageal ligament (Mittal, 1997), the 
mechanism derived from interaction of both longitudinal and circular muscle 
fibres of the oesophagus (Dodds et al., 1973). The phreno-oesophageal 
ligament looses elasticity with increasing age, an explanation for the increase 
prevalence of the sliding hiatus hernia (type 1) observed among older 
individuals (Kahrilas et al., 2008, Menon and Trudgill, 2011). There are no 
gender differences in the prevalence of hiatal hernias, but there is an 
increasing incidence with increasing BMI (Stene-Larsen et al., 1988), however 
the mechanism is unclear, whether through greater intra-abdominal pressure 
or increased laxity of the ligament and structures of the hiatus (Gordon et al., 
2004). 
 
The presence of a hiatus hernia is associated with GORD, present in 62% of 
subjects with reflux symptoms compared with only 14% of controls (Stal et al., 
1999). Sliding hiatus hernias are far more common than the paraoesophageal 
types and are associated with GORD as there is disruption of the combined 
effect of the LOS and normal hiatus anatomy (Kahrilas et al., 2008, Kahrilas et 
al., 1999). The presence of a hiatus hernia, the ‘acid pocket’ normally found in 
the upper stomach even in the postprandial phase may be displaced above 
the diaphragm, promoting GORD (Kahrilas et al., 1999, Boeckxstaens, 2010, 
Fletcher et al., 2001). This increases the risk of GORD during transient LOS 
relaxations (see below) (Boeckxstaens, 2010). Additionally, with larger hiatus 
hernias, reduced oesophageal peristalsis occurs, leading to reduced 
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clearance of refluxate from the oesophagus (Fein et al., 1999, Patti et al., 
1996, Kahrilas et al., 1999).  
 
1.3.2 Lower oesophageal sphincter 
The LOS is formed by the distal 4cm of circular muscle of the oesophagus, 
with the proximal 2cm above the hiatus in the thorax, and the distal 2cm 
below, in the abdomen. The LOS forms approximately 90% of the pressure at 
the gastro-oesophageal junction (GOJ) (Farre and Sifrim, 2008, 
Boeckxstaens, 2005, Boeckxstaens, 2010), amounting to 15-30mmHg in 
healthy subjects (Richter et al., 1987). Reflux may occur typically when the 
LOS falls below 5-6mmHg (with due consideration to a functioning hiatus) 
(Pandolfino et al., 2006). The LOS has intrinsic pressure, as illustrated by 
administration of tetradotoxin, blocking neurological influence, had little impact 
upon LOS pressure (Goyal and Rattan, 1976). The LOS relaxes for four to six 
seconds during each normal swallow, via the action (inhibitory) of nitric oxide 
on the myenteric plexus. Other neurotransmitters are involved in the 
parasympathetic (vagus) autonomic control of the sphincter tone including 
muscarinic, nicotinic and 5-HT receptors (Farre and Sifrim, 2008). The role of 
the sympathetic nervous system is less clear (DiMarino and Cohen, 1973, 
Farre and Sifrim, 2008). Longer relaxations of the LOS occur between 5-30 
seconds that are related to distension of the upper stomach/gastric cardia 
rather than primary peristalsis and known as transient LOS relaxation 
(TLOSR) (Dent et al., 1980, Kessing et al., 2011). During these episodes 
 9 
belching can occur, but pathologically, reflux of gastric contents may occur 
(Bredenoord et al., 2006, Grossi et al., 2001). Studies of oesophageal 
manometry over long periods have illustrated that 98% of reflux episodes in 
asymptomatic individuals are associated with TLOSRs whilst just 66% of 
reflux events in those with RO (Kahrilas and Gupta, 1990). This suggests that 
it must be the association of acid with TSLOR that is implemental in the 
pathophysiology of GORD and might be explained by factors that reduce the 
overall LOS by other mechanisms including diet, smoking, medication and the 
function of the hiatus (Kessing et al., 2011).  
 
1.3.2.1 Factors affecting the lower oesophageal sphincter 
GORD is more prevalent with increasing age, a finding noted with greater 
laxity of the phreno-oesophageal ligament leading to hiatus herniation (Menon 
and Trudgill, 2011, Kahrilas et al., 2008), but also increasing age was found to 
be significantly associated with shortening of the LOS, reduction of LOS 
pressure and increased oesophageal dysmotility (Lee et al., 2007a). 
 
1.3.2.2 Diet and gastro-oesophageal reflux 
Whilst increasing BMI may be independent of diet and exercise as risk factor 
for reflux symptoms, diet is implicated in the aetiology of symptomatic reflux 
(Nandurkar et al., 2004). Smaller meals are less likely to induce reflux 
symptoms (Yamada), but this is independent of calorie density, with no 
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association seen between increasing calorie ingestion and reduction in LOS 
pressures (Pehl et al., 2001). Certain foods such as chocolate, coffee, tea, 
tomatoes, citrus fruit and onions precipitate reflux, mediated through 
relaxation of the LOS (Yamada). Alcohol precipitates dysmotility within the 
oesophagus (Grande et al., 1996), with reduced LOS pressures and greater 
incidence of reflux symptoms seen among those with chronically higher 
consumption (Ferdinandis et al., 2006). 
 
GORD and RO are seen more commonly among those with diets high in fat, 
specifically saturated fat (El-Serag et al., 2005), and reduction of fat intake is 
often recommended to patients (Yamada). Moreover, saturated fat, and 
cholesterol, increases the sensation of reflux symptoms occurring (Shapiro et 
al., 2007). Three hours post-high fat ingestion the LOS pressures remains 
unchanged (Penagini et al., 1998), and while direct introduction of fat directly 
to the duodenum decreases LOS pressure this is not to a resting pressure 
associated with reflux (Holloway et al.). Neither does fat increase the 
frequency of TLOSRs, but it is noted to increase the likelihood of reflux 
occurring during TLOSR (Holloway et al., 1997)  
 
1.3.2.3 Smoking and gastro-oesophageal reflux 
Smoking is associated with GORD through multiple mechanisms. The acute 
effect of smoking has been difficult to establish due to the respiratory efforts 
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required to smoke altering the analytical methods. However, the longer-term 
LOS pressures are significantly lower among smokers with reflux symptoms 
than smokers without reflux symptoms and also lower than non-smokers 
(7mmHg vs 9mmHg vs 14mmHg) (Kahrilas and Gupta, 1990). Smokers have 
more TLOSRs, however these TLOSRs were not associated with reflux, 
where as all the TLOSRs among non-smokers produced reflux. Despite this, 
there were more reflux episodes noted among smokers, which were 
associated with deep inspiration or coughing (Kahrilas and Gupta, 1990). 
Furthermore, reduced salivation occurs among smokers, reducing the ability 
to neutralize and clear the acid refluxate from the oesophagus (Pandolfino 
and Kahrilas, 2000). The pharmacological mechanism is via the action of 
nicotine, as transdermal patches produce similar results to smoking 
(Pandolfino and Kahrilas, 2000). 
 
1.3.2.4 Drugs affecting the lower oesophageal sphincter 
The main inhibitory control of the intrinsic LOS pressure is mediated via the 
actions of nitric oxide (Farre and Sifrim, 2008).  Nitroglycerine reduces LOS 
pressure among patients with achalasia, improving oesophageal emptying 
(Wong et al., 1987). Isosorbide dinitrate, a longer-term nitric oxide providing 
drug, taken over 3 days by healthy volunteers, does not alter oesophageal 
motility, but does significantly reduce LOS as compared with placebo (Stacher 
et al., 1997). 
Other neurotransmitters acting upon the LOS include those acting upon the 
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muscarinic and nicotinic receptors (Farre and Sifrim, 2008). Anti-cholinergic 
drugs (eg propantheline bromide, pirenzepine and atropine) reduce LOS 
pressure significantly (Hongo et al., 1984b, Fang et al., 1999, Aggestrup and 
Jensen, 1991). In comparing anticholinergics that act both peripherally and 
centrally (atropine) and only peripherally (methscopolamine bromide), it is 
clear that both induce LOS relaxation, but atropine, through its centrally acting 
properties, reduces the frequency of reflux symptoms through reduced 
frequency of TLOSRs. However, anticholinergics reduce salivation and 
oesophageal peristalsis amplitude, inhibiting oesophageal clearance of 
refluxate, as well as reducing LOS pressure, and are thus implicated in GORD 
(Fang et al.). 
 
While early studies did suggest that diazepam, a benzodiazepine, may 
actually increase LOS pressure (Weihrauch et al., 1979), it is now widely 
accepted that benzodiazepines reduce pressure at the LOS (Yamada), with a 
dose-response effect (Rushnak and Leevy, 1980). Caution must therefore be 
used when commenting on the laxity of the LOS during gastroscopy under 
benzodiazepine induced sedation (Rushnak and Leevy). 
 
Beta-agonists reduce LOS pressures through their action upon smooth 
muscle, but the dose required to induce reflux symptoms is likely to be higher 
than standard therapeutic inhaled doses (Ayres and Miles, 1996, Berquist et 
al., 1984). While terbutaline reduces LOS pressure, it also improves 
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oesophageal clearance, a further explanation that, when taken in isolation, β -
agonists may affect LOS pressures without precipitating reflux (Wong et al., 
1987). Theophyllines reduce LOS pressure (Ayres and Miles, 1996), by up to 
25% of resting levels (Stein et al., 1980), and to a greater degree than some 
beta-blockers (Wong et al., 1987, Ruzkowski et al., 1992). Moreover, 
theophyllines have been identified to cause reflux symptoms (Ayres and 
Miles), with the LOS pressure reduction occurring at time of detectable blood 
levels of theophylline (Stein et al., 1980). 
 
With intracellular influx of calcium in myocytes leading to contraction, inhibition 
through use of calcium channel blockers induces muscle relaxation (Lake and 
Wong, 2006). Calcium channel blockers not only reduces LOS pressure 
(Hongo et al., 1984b), but does so in a dose response manner (Hongo et al., 
1984a). Calcium channel blockers also reduce the magnitude of contractility 
within the oesophagus (Hongo et al., 1984a, Konrad-Dalhoff et al., 1991). 
 
1.4 Complications of gastro-oesophageal reflux 
Predicting who will develop complications from reflux symptoms is challenging 
with symptoms not always being reliable (Dent, 1999). It has been identified 
that reduced LOS pressure, poor oesophageal acid clearance and gastric acid 
production are independent risk factors (Cadiot et al., 1997). Half of those 
taking OTC antacids developed reflux oesophagitis (RO) and conversely 
frequent heartburn only produces mucosal breaks in less than 50% (Dent, 
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1999). While frequent reflux symptoms often lead to RO, and duration of reflux 
symptoms has been shown to result in RO in 50%, this is not consistent, with 
some larger studies showing duration of symptoms failing to correlate with 
RO, but doing so with BO (Lieberman et al., 1997, Conio et al., 2002).  
 
RO underwent formal definition as the presence of mucosal breaks at or 
above the gastro-oesophageal junction due to reflux of gastric acid, forming 
the Los Angeles (LA) criteria (Armstrong et al., 1996), which correlate well 
with symptoms, pH levels, response to treatment and sustainability of 
remission (Lundell et al., 1999).    
 
Nocturnal reflux symptoms, while among the less common features of GORD 
(Mann et al., 1995), are a marker of severity of RO, occurring more frequently 
in LA grade C and D (Robertson et al., 1987). Comparison of day and night 
time symptoms revealed that nocturnal, especially experiencing both day and 
nocturnal reflux, was significantly associated with a greater degree of RO 
(Demeester et al., 1976). This is due to the supine position and the increased 
exposure to acid within the distal oesophagus due to poor or slow clearance 
(Demeester et al., 1976, Orr et al., 1994). 
 
In addition to frequency of reflux symptoms including nocturnal episodes, 
Kulig et al described demographic and lifestyle risk factors for developing RO 
among a cohort of subjects with reflux symptoms (Kulig et al., 2004). 
Increasing age and BMI, male gender, family history of GORD and smoking 
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were associated with GORD, in addition to severity of symptoms (as already 
discussed). It is of note that while reflux symptoms are equally present among 
men and women (Mohammed et al., 2005), the complications of GORD are 
more common among men. 
 
Complications of GORD may include reflux or peptic strictures (Yamada, 
1999) and BO, the latter a precursor of OAC (Orr et al., 1994). Strictures may 
form following deep ulceration, leading to fibrin formation, and scarring, and 
may be accompanied by symptoms of dysphagia. 
 
1.4.1 Barrett’s Oesophagus 
First described by Norman Barrett in the 1950’s, Barrett’s oesophagus (BO) is 
the sequela of chronic gastro-oesophageal reflux with metaplasia of the 
stratified squamous epithelium of the oesophagus to columnar mucosa. 
Approximately 10-11% of individuals with chronic reflux symptoms develop 
BO (Kulig et al., 2004, Attwood et al., 2008), rising to 13% among higher risk 
individuals (Caucasian men over the age of fifty) (Westhoff et al., 2005). The 
length of the Barrett’s segment is defined by the Prague criteria, with the ‘C’ 
length representing the maximum distance of circumferential columnar lined 
mucosa from the GOJ and the ‘M’ length the maximum overall length of BO, 
including tongues (Sharma et al., 2006). Short segment Barrett’s oesophagus 
(SSBO) (circumferential length <3cm) (Sharma et al., 1998) is twice as more 
frequent as long segment Barrett’ oesophagus (LSBO) (C >3cm) (Westhoff et 
al., 2005). Increasing reflux symptom duration and frequency are significantly 
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associated with the development of BO (Conio et al., 2002), with evidence of 
greater oesophageal acid exposure (determined by 24 hour pH monitoring) 
seen among patients with BO than those with just reflux symptoms or RO 
(Buttar and Falk, 2001). As with the risk of developing RO, nocturnal 
symptoms are a risk factor for the development of BO (Orr et al., 1988). 
Furthermore, reflux of both gastric and bile acids act in combination, possibly 
synergistically, to drive the metaplasia-dysplasia sequence (Jankowski and 
Anderson, 2004, Wiseman and Ang, 2011).  
 
It is possibly unsurprising that the presence of a hiatus hernia is a risk factor 
for BO (Kulig et al., 2004, Gillessen et al., 2010, Conio et al., 2002) given its 
implication in the development of GORD.  Smoking too is associated with BO, 
but more notably a combination of smoking and reflux symptom has a 
synergistic effect upon the aetiology of BO (Smith et al., 2005, Cook et al., 
2012). Moreover, reflux symptoms and increased BMI are shown to act 
similarly in increasing the risk of developing BO (Smith et al., 2005). As with 
OAC, BO is more common among Caucasian men, increasing age, and 
appears to also be associated with affluence (Ford et al., 2005, Wong and 
Fitzgerald, 2005, Westhoff et al., 2005).  
 
The incidence of BO is increasing rapidly, at a greater rate that the number of 
gastroscopies performed in Northern Ireland (Coleman et al., 2011), forming a 
plausible explanation of the increasing incidence of OAC. However, in the US 
where primary care physician practice includes screening patients with GORD 
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for BO (Chey et al., 2005), this may in part be due to increased use of 
gastroscopy as a diagnostic tool (Conio et al., 2001). Furthermore some of the 
increasing incidence of BO is seen among asymptomatic individuals (Conio et 
al., 2001, Shaheen, 2005), with 90% of those developing OAC never having 
had a prior diagnosis of BO (Ouatu-Lascar et al., 1999). Asymptomatic BO 
may be a result of the columnar lined mucosa being less sensitive to lower pH 
than normal squamous lined oesophagus (Byrne et al., 2003). 
 
BO is recognised as a pre-malignant condition that, through development from 
metaplasia, low-grade and high-grade dysplasia (HGD), may progress to 
adenocarcinoma. It is postulated that all OAC arises from BO (Theisen et al., 
2002), with those cases of adenocarcinoma without obvious columnar lined 
oesophagus present likely to have tumour overgrowth of any precursor 
Barrett’s mucosa (Hamilton et al., 1988). Overall rates of progression have 
been estimated to vary between 0.2-2% per annum (Murray et al., 2003). 
Patients with BO are 30-125 fold more likely to develop OAC than the general 
population (Solaymani-Dodaran et al., 2004). The identification of LGD at 
index gastroscopy is associated with neoplastic progression (Dulai et al., 
2005, de Jonge et al., 2010, Oberg et al., 2005, Hvid-Jensen et al., 2011). 
HGD more so, progressing to OAC in up to 50% of cases within 5 years 
(Altorki et al., 1991, DeMeester, 2002), with OAC often being present at first 
diagnosis of BO with HGD (Ell et al., 2000). The greater the length of Barrett’s 
mucosa, the greater the risk of developing HGD and adenocarcinoma (Slehria 
and Sharma, 2003). 
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While certain parameters are understood to increase the risk of progression 
from BO to OAC, such as increasing length of Barrett’s segment and 
presence of dysplasia, current BSG guidance (Watson, 2005) does not 
incorporate any other criteria or risk factors other than LGD. Studies of the risk 
factors associated with the progression of BO to OAC are often limited by the 
inherent selection bias in studying those undergoing endoscopic surveillance 
rather than an unselected cohort (El-Serag et al., 2004, Nguyen et al., 2009). 
 
A diagnosis of BO is not only associated with development of OAC, but also 
has significant deleterious impact upon quality of life, and increased anxiety 
and depression. Much of this surrounds the understanding of the disease and 
of the risks of developing cancer, which may be alleviated with patient 
education and surveillance directed at those patients with BO at greater risk of 
progression to OAC (Cooper et al., 2009). 
 
1.5 Genetic influences upon reflux and its sequelae 
Reflux symptoms are observed to be common among families (Trudgill et al., 
1999) but teasing the environmental from genetic factors can be challenging. 
Several concordance studies among monozygotic and dizygotic twins have 
revealed that approximately 31-43% of reflux symptoms have some form of 
heritability (Mohammed et al., 2003, Cameron et al., 2002). While a few 
published reports of strong family histories of BO and OAC are present in the 
literature (Drovdlic et al., 2003, Prior and Whorwell, 1986, Gelfand, 1983), 
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they are without consistent inherited genetic cause identified (Fitzgerald, 
2005). More evidence surrounds the acquired genetic and epigenetic 
phenomena that may influence the metaplasia-dysplasia-adenocarcinoma 
sequence, with a wealth of studies examining the influence of various factors 
such as chromosomal imbalances (Walch et al., 2000, Wu et al., 1998), 
disordered proliferation (e.g. cyclin D1, TGFα, telomerase), loss of apoptosis 
(e.g. p53, COX-2, Bcl), loss of response to anti-growth signals (e.g. p16, APC) 
and invasive potential (e.g. VEGF/VEGF-R, effects upon E-cadherins and β-
catenins) (Feith et al., 2004, Schneider et al., 2000, Younes et al., 1997, 
Fitzgerald, 2005, Wiseman and Ang, 2011). None of these individually identify 
those at greater risk of developing OAC, and currently have limited clinical 
value; the use as a reliable biomarker to identify those at greatest risk of 
neoplastic progression remains elusive (Wiseman and Ang, 2011, Fitzgerald, 
2005). 
 
1.6 Helicobacter pylori 
This common pathogenic micro-organism is found worldwide, leading to a 
number of gastro-duodenal diseases, including gastro-duodenal ulceration 
and gastric cancer (Go, 2002). Importantly, it is negatively associated with the 
development of OAC. 
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1.6.1 Helicobacter pylori and atrophic gastritis 
H.pylori is a common aetiological factor for chronic gastritis (Sipponen et al., 
1996b). H.pylori was the identified cause in 26-48% of identified atrophic 
gastritis cases (Annibale et al., 1997, Kuwahara et al., 2000), inferring a ten-
fold increased risk (Kuwahara et al., 2000). Even if H.pylori is eradicated, and 
gastric antral mucosa heals (Sipponen et al., 1996b), atrophic gastritis can 
persist in the corpus of the stomach (Sipponen et al., 1996b, Kokkola et al., 
2003a). 
 
Helicobacter pylori species show genetic differences, with a 40kb genomic 
region known as the cag pathogenicity island coding for 41 genes related to 
inflammation and virulence. The cagA (cytotoxin-associated gene A) gene 
forms a cylindrical protein that is ‘injected’ into host cells where it undergoes 
tyrosine phosphorylation, and is implicated in increasing inflammation 
compared to cagA negative H.pylori (Go, 2002). cagA positive H.pylori 
produces greater inflammation with gastritis, leading to a greater degree of 
chronic atrophic gastritis (Maaroos et al., 1999, Oksanen et al., 2000, Sande 
et al., 2001). 
 
Atrophic gastritis (notably of the corpus) results in hypochlorhydria (Sipponen 
et al., 1996b, Derakhshan et al., 2006). Increased atrophy is associated with a 
reduced maximal acid output (Derakhshan et al., 2006, Sipponen et al., 
1996a), specifically ascorbic rather than uric acid (Capurso et al., 2003). 
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Furthermore, cagA positive H.pylori strains of infection were associated with 
gastric atrophy (Beales et al., 1996). 
 
1.6.2 Implications of gastric atrophy: gastro-oesophageal reflux 
It has been proposed that H.pylori cagA positive infection reduces the 
incidence of gastro-oesophageal reflux symptoms and subsequent potential 
complications, including BO and OAC, by the development of atrophic gastritis 
and subsequent hypochlorhydria (Richter et al., 1998). There are suggestions 
that this hypothesis is not supported in the literature (Pace and Bianchi Porro, 
1998, Peters et al., 1999), but few studies have examined the impact of cagA 
status with sufficient power (Vicari et al., 1998). The incidence of H.pylori was 
much lower in subjects with GORD and BO than control subjects in one study 
with a large enough sample size to derive a significant result (Werdmuller and 
Loffeld, 1997). Furthermore, these findings were reproduced, albeit not to 
significance, but accompanied by evidence that cagA positive H.pylori induced 
greater gastric mucosal damage, supporting the hypothesis of atrophic 
gastritis induced hypochlorhydria, reducing reflux (Vicari et al., 1998). 
 
A case report elegantly demonstrates that healing of known H.pylori induced 
atrophic corpus gastritis subsequently developed into RO and 5 years later 
BO developed (Kokkola et al., 2003b). This observation is not in isolation; an 
observational study revealed those with SSBO and LSBO were less likely to 
have cagA positive H.pylori infection than control or RO subjects (Vaezi et al., 
2000).  
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1.6.3 Implications of gastric atrophy: iron absorption and iron deficiency 
Population studies have revealed an increase prevalence of iron deficiency 
anaemia (IDA) associated with H.pylori infection (Berg et al., 2001, Milman et 
al., 1998, Parkinson et al., 2000). The risk of IDA attributable to H.pylori 
infection has been found to be almost 3-fold that of non-infected (Choe et al., 
2001), a 40% increase in the USA (Cardenas et al., 2006), with upper gastro-
intestinal blood loss excluded from the aetiology (Hacihanefioglu et al., 2004, 
Annibale et al., 1999). Eradication of H.pylori results in reversal of IDA without 
the need for iron supplementation (Hacihanefioglu et al., 2004, Annibale et al., 
1999, Kurekci et al., 2005). Furthermore, formal iron absorption testing 
revealed significantly poorer iron absorption among those infected than those 
who were not colonised with H.pylori, and that the iron absorption tests 
reverted to normal once successful eradication had occurred (Ciacci et al., 
2004). 
 
While some strains of H.pylori can compete for available gastric iron (Waidner 
et al., 2002, Annibale et al., 2000), the presence of atrophic gastritis is the 
more likely aetiology (Annibale et al., 2000). Examination of the presence of 
H.pylori induced chronic gastritis and IDA has revealed close association, 
suggesting this mechanism of action (Annibale et al., 1999, Nahon et al., 
2003). Furthermore, intra-gastric pH is significantly higher among subjects 
with H.pylori induced gastritis (Annibale et al., 2003, Capurso et al., 2001, 
Baysoy et al., 2004), notably with reduced ascorbic acid (Baysoy et al., 2004, 
Annibale et al., 2003). This finding was most marked among subjects with 
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cagA positive H.pylori infection (Baysoy et al., 2004). Gastric acid is important 
in the reduction of dietary iron predominantly in the ferrous (Fe2+) form to the 
absorbable ferric (Fe3+) form. 
 
1.6.4 Epidemiology of Helicobacter pylori 
Helicobacter pylori (H.pylori) is transmitted person-to-person either by oral-
oral or faecal-oral transmission, with approximately 50% of children infected 
worldwide (Go, 2002). Transmission occurs particularly among siblings of a 
similar age (Goodman and Correa, 2000), and is seen more commonly with 
increased number of siblings per household (Ford et al., 2007). Indeed 
household crowding, including the sharing of a bed with a parent appears to 
have strong association (Rothenbacher et al., 2002, McCallion et al., 1996), 
leading to observations that H.pylori infection appears to cluster in families 
and is associated with lower socio-economic status (Dominici et al., 1999, 
Murray et al., 1997, Moayyedi et al., 2002, Webb et al., 1994). It is observed 
that the prevalence of H.pylori increases with age (Murray et al., 1997, 
Macenlle Garcia et al., 2006, Everhart et al., 2000). Whilst prevalence 
increases with age, it is close person-to-person contact in childhood that 
influences infection into adulthood and beyond (Webb et al., 1994, Fall et al., 
1997). In Northern Ireland overall prevalence was approximately 50%, 23.4% 
among young teenagers, rising to 72.7% in those in their early sixties (Murray 
et al., 1997).  
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H.pylori infection is associated with black ethnicity (compared to Caucasians) 
(Malaty et al., 1992, Everhart et al., 2000), and smoking (Murray et al., 1997), 
particularly heavy smokers (Moayyedi et al., 2002). Failure to thrive among 
infant boys may be related to H.pylori infection (Fall et al., 1997); moreover an 
association is observed with infection and reduced height among women 
(Murray et al., 1997, Moayyedi et al., 2005). It is possible that reduced height 
may be due to confounding (Moayyedi et al., 2005) such as lower socio-
economic status and subsequent poorer diet, but it has been observed that 
taller individuals produce greater quantities of gastric acid that may protect 
against H.pylori colonisation (Axon, 2004). 
 
During the last thirty to forty years the incidence of OAC has been rising 
rapidly. It is also noted that during this time frame that the prevalence of 
H.pylori infection has been falling steadily in developed countries (Lee et al., 
2007b, Rehnberg-Laiho et al., 2001, Kosunen et al., 1997), with a fall from 
approximately 55% to 30% from the 1970s to the 1990s (Kosunen et al., 
1997, Haruma et al., 1997). Most notably, the falling prevalence among the 
different strains is significantly greater reduction in cagA positive rather than 
negative H.pylori (Perez-Perez et al., 2002). 
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1.7 Body Habitus 
1.7.1 Obesity 
Obesity has been increasing western world, including USA and UK, and the 
same time as the observed increase in incidence of OAC. Increasing body 
mass index is associated with OAC (Anderson et al., 2007, Wu et al., 2001, 
Chow et al., 1998), and with BO (Stein et al., 2005). “Population attributable 
risks” estimate that a BMI above the lowest quartile accounts for 41.1% of 
OAC (Engel et al., 2003). There are two main mechanisms: firstly the impact 
upon GORD and secondly the biologically active nature of visceral adiposity 
associated with male pattern obesity. 
 
Nilsson and Lagergren reviewed the literature finding that the majority of 
papers found an association between increasing BMI and reflux symptoms 
and/or oesophagitis (Nilsson and Lagergren, 2004). As compared with BMI 
<25, there was a doubling of OR for reflux symptoms being overweight, and 
three- to four-fold in those with a BMI 30-35 regardless of gender. This finding 
was reproduced in larger meta-analysis with OR 1.43 for overweight (BMI 25-
30) and OR 1.94 for the obese (BMI >30) (Hampel et al., 2005). Increasing 
BMI >30 is associated with greater frequency and length of reflux episodes, 
and greater time overall with a pH<4 (El-Serag et al., 2007). It is less clear as 
to the mechanism by which obesity affects reflux, but it is clear the weight loss 
reduces symptoms (Nilsson et al., 2003). The role of obesity increasing intra-
abdominal pressure, thus compressing the stomach and producing pressures 
that may overcome those at the LOS is postulated but not readily reproduced 
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in the literature (Nilsson and Lagergren, 2004, Hampel et al., 2005). However 
there is evidence of increased oesophageal dysmotility among the obese, with 
reduction in resting LOS pressures and an increase in post-prandial TLOSRs 
associated with reflux (Sise and Friedenberg, 2008). Obesity is associated 
with an increased frequency of hiatal herniation (Stene-Larsen et al., 1988), 
another risk for GORD. 
 
Visceral adipose tissue is biologically active, and shown to increase insulin-
like growth factor 1 (IGF-1) levels (Donohoe et al., 2012, Doyle et al., 2012). 
IGF-1 has been shown to reduce apoptosis and enhance the process of DNA-
damage to cells, thus increasing potential in neoplastic progression 
(Sheppard, 2004). Intriguingly that whilst IGF-1 levels are risen in obese 
individuals with oesophageal squamous cell carcinoma as well as OAC, it was 
only the OAC cell lines that responded to IGF-1 with increasing cell 
proliferation (Doyle et al., 2012). Moreover, those OAC patients with higher 
expression of IGF-1 had a poorer prognosis (Orr et al., 1994). Leg length is a 
marker of pre-pubertal growth and is related to IGF-1 levels, a known 
mitogen(Sheppard, 2004). 
 
1.7.2 Height  
Taller individuals (Axon, 2004), and those with greater body mass have a 
higher gastric acid production than shorter and lower BMI individuals. It is 
observed that during the last 30-50 years not only has the incidence of OAC 
and obesity risen, but that population height is increasing in the European 
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countries at a rate of 1cm per decade(Axon, 2004). Moreover, H.pylori 
infection is associated with shorter stature (Moayyedi et al., 2005, Murray et 
al., 1997). 
 
1.8 Influence of medications upon oesophageal adenocarcinoma 
1.8.1 Medication with potential negative association with OAC 
1.8.1.1Acid suppression 
Proton pump inhibitors (PPI) are highly effective at managing reflux symptoms 
due to gastric acid reflux, and treating RO, both potential precursors of BO. 
The role of PPI in BO is theoretically sound, and if patients with BO are 
symptomatic, the dose of PPI should be increased to completely supress 
symptoms 24 hours a day. However, Barrett’s mucosa, by the very nature of 
the columnar epithelium, may fail to produce symptoms (Byrne et al., 2003); in 
this situation symptomatic relief may not necessarily reflect complete acid 
suppression. There is some evidence that sufficient rising of oesophageal pH 
can improve oesophageal mucosal cell differentiation and reduce proliferation 
(Ouatu-Lascar et al., 1999), however it only requires short periods of acid 
exposure for damage to subsequently occur. 
 
Both the BSG (Watson, 2005) and American Gastroenterology Association 
(AGA) (Sharma et al., 2004) recommend the use of PPIs in patients with BO, 
but also acknowledge that the evidence for reducing the progression to OAC 
is yet to be proven. 
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1.8.1.2 Aspirin and non-steroidal anti-inflammatory drugs 
Early case-control studies showed a negative association with aspirin and the 
development of OC (Funkhouser and Sharp, 1995), and in a subsequent 
study examining morphology the effect was most marked for OAC (OR 0.37) 
rather than OSCC (OR 0.49) (Farrow et al., 1998). Regular use of aspirin and 
NSAIDs reduced the risk of OAC and gastric cardia adenocarcinomas 
(combined group) significantly (Duan et al., 2008). More detailed examinations 
of associations between aspirin and OAC revealed a 60% reduction in risk 
(Fortuny et al., 2007), and a dose-response relationship to this negative 
association (Jayaprakash et al., 2006). This finding was not only reproduced 
with both aspirin and NSAIDs, but also concluded that there was no significant 
increased risk of upper gastro-intestinal haemorrhage (Tsibouris et al., 2004). 
Meta-analysis confirms the negative association with NSAIDs with OAC 
(Corley et al., 2003, Liao et al., 2012), and OSCC (Corley et al., 2003), and 
with aspirin and both morphologies of OC (Corley et al., 2003).  
 
Findings comparing BO and OAC with community control subjects and use of 
aspirin and NSAIDs revealed a negative association with both disease groups 
and usage. This has been suggested to reveal that aspirin and NSAIDs may 
exert their proposed protective effect earlier in the metaplasia-dyplasia-
neoplasia sequence (Anderson et al., 2006). However, two cohort studies 
(Vaughan et al., 2005, Kastelein et al., 2011) and one nested case-control 
study (Nguyen et al., 2009) have illustrated that fewer patients with BO 
progress to OAC when taking aspirin and NSAIDs. 
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Further modelling showed those benefiting most from aspirin/NSAIDs were 
those with frequent reflux symptoms (Sadeghi et al., 2008, Pandeya et al., 
2010). Aspirin/NSAIDs act by inducing apoptosis via lipooxygenase and cyclo-
oxygenase inhibitors (Shureiqi et al., 2001) and COX-2 expression in BO 
increases from metaplasia, dysplasia to neoplasia (Morris et al., 2001). 
Further evidence exists showing that aspirin and NSAIDs are most likely to 
exert their protective influence upon those with adenocarcinomas that 
overexpress cyclin D1, a cell-cycle control gene (Gammon et al., 2004). 
 
1.8.1.3 Statins 
Statins, or 3-Hydroxy-3-methylgutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors, reduce mevalonate. Reducing mevalonate not only decreases 
cholesterol, but also reduce proteins involved in growth control (eg 
farnesylated proteins), and as such have been postulated as 
chemopreventative agents (Goldstein and Brown, 1990, Chan et al., 2003). 
Populations taking statins have a reduced incidence of cancer after just four 
years of use (Graaf et al., 2004), specifically colorectal cancer (Poynter et al., 
2005). This proposed mechanism of action has been identified in Barrett’s and 
OAC cells, inhibiting cell growth and proliferation, and inducing apoptosis 
(Sadaria et al., 2011, Ogunwobi and Beales, 2008, Konturek et al., 2007); 
moreover statins appear to inhibit COX-2, a mechanism already described for 
aspirin, NSAIDs and COX-2 inhibitors (Ogunwobi and Beales, 2008). Whilst a 
retrospective study of medication use among Barrett’s oesophagus patients 
failed to show a potentially protective effect of statins (Nguyen et al., 2009), 
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larger prospective cohort studies have identified a reduced risk of progression 
from BO to OAC (Kantor et al., 2012, Kastelein et al., 2011). 
 
1.8.2 Medication with potential positive association with OAC 
1.8.2.1Drugs that reduce lower oesophageal sphincter pressure 
Many drugs can exert a reduction in the pressure at the LOS, promoting 
gastro-oesophageal reflux e.g. nitrates, theophyllines, benzodiazepines, β-
agonists anti-cholinergic drugs and calcium-channel blockers. Their influence 
has been examined identifying that ever versus never taking any LOS relaxing 
drug and taking of cumulative numbers of drugs with a LOS side effect is 
associated with OAC. Most notably, 84% of those taking drugs that had a side 
effect of relaxing the LOS experienced reflux symptoms at least once per 
week, more often than control subjects (Lagergren et al., 2000). This has 
been subsequently reproduced (Ranka et al., 2006). 
 
Of those drugs that have a side effect of reducing LOS pressure, use of β-
agonists and theophyllines, both used in asthma, have been identified to be 
associated with OAC (Vaughan et al., 1998, Ranka et al., 2006). 
Theophyllines have also been shown in meta-analysis to be associated with 
OAC (Alexandre et al., 2012). Identifying whether this is due to asthma or the 
LOS side effect profile is difficult to ascertain (Vaughan et al., 1998, 
Ladanchuk et al., 2010). 
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1.9 Diet 
The diet is a strong modifiable factor in the development of cancer, with 
approximately 35% (estimate 20-60%) reduction of fatal cancers proposed as 
achievable with reduction of fat, and increasing non-digestible carbohydrates 
and fruit consumed (Doll, 1992). 
 
1.9.1 Fruit and vegetables 
Diets higher in foods of a plant origin, including fruit and vegetables, are 
negatively associated with OAC (Mayne and Navarro, 2002, Brown et al., 
1995, Tzonou et al., 1996, Navarro Silvera et al., 2011, Chen et al., 2002) and 
BO (Thompson et al., 2009, Kubo et al., 2010, Kubo et al., 2008b). However 
data are mixed. The NIH-AARP Diet and Health study failed to show 
association with fruit and vegetables and OAC overall, but when sub-
analysed, it did reveal a negative association with “dark green vegetables” 
(Freedman et al., 2007). Analysis of EPIC data, including dietary information 
from 23 centres in ten European countries, revealed an inverse association 
with vegetable and citrus fruit consumption, but significance was not reached, 
with the relatively low incidence of OAC in the countries analysed as the 
cause for reduced power (Gonzalez et al., 2006b). Higher consumption of fruit 
and vegetables has been shown to reduce the risk of OAC by 50%, with the 
authors estimating that 20% of cases of OAC in Sweden were attributable to a 
diet of less than 3 portions of fruit and vegetables per day. This however 
translated into an estimate of over 25 000 subjects having to alter their diet to 
prevent one case of OAC per year (Terry et al., 2001). A similar study based 
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in USA revealed population attributable risk of 15.3% due to low consumption 
of fruit and vegetables (Engel et al., 2003). 
 
Biochemical explanations exist for the proposed protective role of dark green 
(Freedman et al., 2007) and cruciferous vegetables (Brown et al., 1995) in the 
development of OAC. Isothiocyanates, found in broccoli, Brussel sprouts, 
cauliflower and cabbage, inducing cell cycle arrest and apoptosis (Myzak and 
Dashwood, 2006). Indole-3-carbinols are also present in cruciferous 
vegetables, inhibiting cell growth at multiple levels, including transcription 
factors and apoptosis (Kim and Milner, 2005). A more detailed consistent 
finding revealed high fibre diets are inversely associated with OAC (Tzonou et 
al., 1996, Brown et al., 1995, Kabat et al., 1993, Zhang et al., 1997, Mayne et 
al., 2001). Antioxidant use is negatively associated with OAC (Terry et al., 
2000), and most notably with OAC subjects with reflux, suggesting the effect 
of antioxidant reduce the oesophageal mucosal reactive stress during gastro-
oesophageal reflux (Terry et al., 2000). Furthermore, similar dietary negative 
associations exist with BO (Kubo et al., 2010, Kubo et al., 2008a).  
 
Specific nutrient analysis does reveal further negative association between 
diet and OAC: vitamins A, B6, and C, and folate (Mayne et al., 2001, Tzonou 
et al., 1996, Zhang et al., 1997, Murphy et al., 2010, Dong et al., 2008).  
 
While the negative association of dietary folate is confirmed with additional 
research, a positive association was seen with selected B vitamins, and 
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intriguingly folate supplementation (not dietary in origin) was positively 
associated with BO with dysplasia (Ibiebele et al., 2011).  
 
Other antioxidants such as vitamin E fail to show any association (Carman et 
al., 2009, Murphy et al., 2010), and dietary supplementation of foods high in 
antioxidants failed to show any change in cellular antioxidant levels, nor 
reduction of oxidative stress (Aiyer et al., 2011). The results with vitamin E are 
however inconsistent, with supplement of vitamin E negatively associated with 
OAC in a study in the USA (Dong et al., 2008). Moreover, vitamin E 
supplementation has been identified as a cause of increased all-cause 
mortality (Miller et al., 2005). Lycopene, a carotenoid found predominantly in 
tomatoes, is protective of gastro-intestinal cancers at all sites, except those of 
the oesophagus (Franceschi et al., 1994). Investigation of selenium, a mineral 
associated with the aetiology of many cancers including those of the prostate, 
has only shown a negative association with oesophageal cancers (not sub-
divided by morphology) in a population with virtually global selenium deficient 
state in an area of China, Linxian, that also has a very high incidence of 
OSCC (Mark et al., 2000). 
 
Carbonated soft drinks were hypothesised to be positively associated with 
OAC due to their potential for causing gastro-oesophageal reflux. However no 
overall association was identified, but use of ‘diet fizzy drinks’ were negatively 
associated with OAC, but this finding could be due to confounding factors 
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such as social class and lower overall calorie consumption (Mayne et al., 
2006).  
 
1.9.2 Meat and fat 
Associations with dietary red meat and OAC are variable. When analysed by 
the principle component of the diet, meat and dietary nitrite intake were 
associated with OAC (Navarro Silvera et al., 2011), as were meat and fat 
predominant diets (Ibiebele et al., 2012), and animal protein (Mayne et al., 
2001). However, other studies failed to show any association with dietary fat 
(O'Doherty et al., 2012) and red meat (Chen et al., 2002), including analysis of 
EPIC data (Gonzalez et al., 2006a), which did however illustrate an 
association of processed meats with OAC. 
 
It is believed the inconsistencies seen with the data examining associations of 
meat and OAC are due to type of meat (e.g. lean cuts), the nitrite and nitrate 
content following any processing and the method of cooking. Meat cooked at 
high temperatures forms heterocylic amines and polycyclic aromatic 
hydrocarbons, known carcinogenic agents (Kubo et al., 2010). 
 
Diets high in fat overall (Mayne et al., 2001) and of a dairy source are 
positively associated with OAC (Ibiebele et al., 2012). Polyunsaturated fat 
intake, at least among subjects with a normal BMI, have a negative 
association with OAC (O'Doherty et al., 2012), thus suggesting that fat intake 
may have a significant impact upon BMI as its mode of action in the 
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development of OAC (Kubo et al., 2010). Furthermore, supplementation with 
n-3 polyunsaturated fatty acids in subjects with BO increases the epithelial 
concentration of these fatty acids, reducing COX-2 expression (Mehta et al., 
2008). The role of n-3 fatty acids has not been evaluated in enough detail to 
draw any conclusions (Kubo et al., 2010) 
 
1.9.3 Alcohol 
Despite high consumption of alcohol leading to oesophageal dysmotility and 
gastro-oesophageal reflux (Ferdinandis et al., 2006, Grande et al., 1996), the 
association with OAC is variable among studies, with positive association 
seen (Vaughan et al., 1995), as well as no association (Steevens et al., 2010), 
and a negative association among those of modest consumption (Freedman 
et al., 2011). Meta-analysis showed no association between alcohol and OAC 
(Tramacere et al., 2012). 
 
1.10 Exercise and physical activity 
There is a paucity of information surrounding any associations between 
exercise, physical activity and OAC. While the EPIC study failed to reveal any 
association between physical activity and OAC, there were only 80 cases 
(Huerta et al., 2010). In larger studies a negative association was revealed 
between increasing exercise/physical activity and OAC (Vigen et al., 2006), 
albeit with the first failing to achieve significance (Leitzmann et al., 2009). A 
prospective intervention trial of exercise among subjects with BO should shed 
further light upon this area (Winzer et al., 2010) 
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1.11 Nitrosative stress 
The gastro-intestinal tract is exposed to N-nitrosamine compounds from 
various sources, with 85% arising from nitrates in the diet and water, and 
other routes such as smoking. Foodstuffs high in nitrates include meat, 
especially processed and smoked/cured meat, smoked fish and preserved 
vegetables. Nitrates are more concentrated in vegetables grown in low light 
but warm temperatures found often in greenhouses. However with the 
increased use of fertilisers, drinking water concentrations of nitrates have 
been at risk of higher levels, as have any crop grown with fertiliser 
use.(McKnight et al., 1999, Craddock, 1992, Jakszyn and Gonzalez, 2006) 
 
While these N-nitrosamines may have anti-bacterial properties (McKnight et 
al., 1999), they have been shown to be carcinogenic (Jakszyn and Gonzalez, 
2006). Ingested nitrates are first reduced to nitrites by oral bacteria and then 
converted to N-nitrosamines in the stomach in the presence of ascorbic acid 
and amines. Several studies have revealed that the creation of N-
nitrosamines occurs maximally at the gastric fundus and cardia (Moriya et al., 
2002, Iijima et al., 2002, Iijima et al., 2003a, Suzuki et al., 2003). It is at the 
gastric fundus and cardia where the ‘acid pocket’ is normally found, and when 
displaced above the diaphragm, promotes GORD. Nocturnal GORD especially 
predisposes to RO and BO as discussed. It is with interest to note that 
salivary nitrosamine concentration peaks at night, being more pronounced in 
older men (Mirvish et al., 2000). During acid reflux, the majority of nitrosative 
stress occurs within the distal oesophagus (Winter et al., 2007). N-
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nitrosamines undergo entero-salivary circulation, with a ten-fold concentration 
from plasma to salivary gland, resulting in further upper gastro-intestinal tract 
exposure (Lowenfels et al., 1978, McKnight et al., 1999). The meeting of acid 
refluxate and saliva rich in nitrosamines in the distal oesophagus provides the 
environment for nitrosative stress to occur, promoting the carcinogenic 
potential to developing OAC (Suzuki et al., 2005). Nitrosative stress is 
believed to drive dysplasia seen within Barrett’s mucosa through DNA 
damage, gene dysregulation and influencing metalloproteinases, implemental 
in “extracellular matrix remodelling and invasion” (Clemons et al., 2010). 
 
1.11.1 Factors affecting N-nitrosamine 
While PPI treatment increases pH, a subsequent increase in nitrosamine 
forming bacteria are seen, there is no significant change in nitrosamine 
formation (Verdu et al., 1994, Viani et al., 2000). Furthermore, H.pylori is not 
responsible for the formation of N-nitrosamines (Vermeer et al., 2002, 
Ziebarth et al., 1997). However, combination of a PPI and H.pylori increases 
pH sufficiently for nitrosamine forming bacteria to proliferate (Mowat et al., 
2000, Mowat and McColl, 2001). In a neutral pH environment, the nitrites are 
no longer converted to nitric oxide, which is ordinarily readily absorbed by the 
stomach, and thus leaves a high intra-gastric nitrite level, promoting the 
formation of nitrosamines (Mowat and McColl, 2001) 
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1.12 Smoking and oesophageal adenocarcinoma 
The effect of smoking upon reflux has been discussed with reduced LOS 
pressures, and increased reflux associated with coughing (Kahrilas and 
Gupta, 1990, Pandalfino and Kahrilas, 2000). Furthermore, tobacco forms 
nitrosamines (McKnight et al., 1999) and other carcinogens including 
polycyclic aromatic hydrocarbons (Kamangar et al., 2009). While the 
association of tobacco and oesophageal cancer is strongest with OSCC, the 
evidence of a weaker association with OAC is clear among the studies in the 
literature, averaging at least a doubling of risk (Kamangar et al., 2009). In 
population attributable risk analysis, smoking accounts for 39.7% of the 
aetiology of OAC (Engel et al., 2003, Kamangar et al., 2009). 
 
1.13 Male predominance of OAC 
With OAC more common in men, occupational hazards must be considered in 
aetiological factors. However many studies fail to differentiate oesophageal 
cancer by morphology (Kamangar et al., 2009). With the importance of 
nitrosamine in the aetiology of OAC, it is noted that there was no increase in 
overall cancer rates among nitrate fertiliser workers (Hagmar et al., 1991), but 
with the relatively low incidence of OAC the study may not be powered for this 
detection. However a Swedish study revealed significant association with 
OAC and exposure to cement dust and asbestos (Jansson et al., 2005a). A 
study in the USA revealed a negative association with “engineers, architects 
and surveyors”, but a positive association with “ administrative support, 
financial, insurance and real estate workers, and among health service 
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providers”. However the association was weak and likely due to confounding 
(Engel et al., 2002). 
 
Identification of androgen receptors on oesophageal adenocarcinoma cells 
raises the possibility of a role for male sex hormones in the oncogenesis of 
OAC (Tihan et al., 2001). Stimulation of these receptors by androgens has 
been shown to alter protein expression that may be implicated in the 
development of OAC (Awan et al., 2007). Epidemiological investigation of a 
cohort of prostate cancer patients in Sweden, an androgen driven tumour, 
failed to reveal any association with male sex hormones and OAC (Lagergren 
and Nyren, 1998). 
 
A protective influence of oestrogens has been postulated, with oestrogen 
receptors discovered on OAC cells (oestrogen capable of inducing apoptosis) 
(Chandanos and Lagergren, 2009). Among a cohort of women with OAC, 
breast-feeding was proposed as a potential protective factor in the 
development of OAC, suggesting a hormonal role (Cheng et al., 2000). 
However, analysis of hormone-replacement therapy should no association 
with OAC (Lindblad et al., 2006). 
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Chapter 2 
 
Aims and Objectives 
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1. To examine the incidence of oesophageal cancer by morphology in the 
West Midlands over the last 30 years, and identify trends and 
associations with age, gender, socio-economic status and ethnicity 
 
2. To identify the role of androgens in the aetiology of oesophageal 
adenocarcinoma in the West Midlands 
 
3. To further examine the effect of androgens, including duration of 
androgen effect and ethnicity in the United States of America 
 
4. To determine potential risk factors for the progression of Barrett’s 
oesophagus to oesophageal adenocarcinoma, focusing on the effect of 
medication 
 
5. To identify the protective effect of medication in a case-control GP 
data-base study 
 
6. Prospectively examine aetiological factors in the development of 
oesophageal adenocarcinoma within the West Midlands 
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Chapter 3 
 
Materials and Methods 
  
 43 
3.1 West Midlands Cancer Intelligence Unit (www.wmciu.nhs.uk) 
 
The West Midlands Cancer Intelligence Unit (WMCIU) has collected 
radiotherapy data since 1936 for the central Birmingham area and been 
population based since 1957. The WMCIU records data from the ‘West 
Midlands Strategic Health Authority region’, a population of 5.3 million (2008), 
approximately 10% of the population of England and Wales.   
 
The 28 acute National Health Service (NHS) hospitals within the West 
Midlands are required to send details of cancer patients admitted as either in-
patients or day cases to the WMCIU. The WMCIU also receives information 
from hospices, pathology laboratories, community hospitals, screening 
centres, general practitioners and private hospitals. Death certificates with any 
record of cancer are also provided to the unit. Data completeness are 
estimated to be greater than 95%. 
 
The data includes patient demographics (name, date of birth, gender, and 
address), tumour details (cancer origin, morphology and stage), diagnostic 
and treatment methods, and date, place and cause of death. Internal and 
external data quality controls are in place, including cross-referencing with the 
Office for National Statistics (ONS).  “The International Statistical 
Classification of Diseases and Related Health Problems” 10th revision (ICD10) 
was used to identify oesophageal cancers (code c15). Cancer morphology 
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was identified using the “International Classification of Diseases for Oncology 
second edition” (ICD-O-2): adenocarcinoma (814*-838*, 848*-849*, 8550, 
8570), squamous cell carcinoma (805*-808*) or other/unknown morphology. 
 
3.1.1 Time period and case validations 
The time period used for the studies utilising WMCIU data in this body of work 
was 1977-2004, covering 28 years of data collection. This time period was 
selected due to the availability of oesophageal cancer data: all case notes 
during this time had been abstracted into the computer registry, or copies on 
microfilms were readily available for examination. In the first ten years of the 
time period examined there was a high proportion of incomplete abstraction of 
notes and registration of morphology being recorded as carcinoma or 
unknown, and those recorded as gastric cardia (an area where doubt arose as 
to definition employed in the registry at that time). Along with the low numbers 
of subsequently incompletely abstracted notes from the later years, case note 
reviews were undertaken and a member of the WMCIU verified randomly 
selected files. A total of 4252 patient records (1731 originally coded as cardia, 
and 2641 as oesophageal) were re-examined. 296 (17%) of the cardia 
cancers were re-classified as oesophageal. Of the 138 oesophageal cancer 
morphologies originally coded as carcinoma, 27 (20%) were re-classified 
OAC, and 26 (19%) as OSCC. Of the 2641 oesophageal cancers that were 
either not abstracted or of non-specific/unknown morphology, 972 were re-
classified as OAC, and 946 as OSCC. No other OAC or OSCC morphologies 
were newly identified in the remaining records examined. 
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3.1.2 Socio-economic status 
Two different measures were employed to analyze socio-economic status: 
“The Townsend Index (Townsend, 1979) and the Index of Multiple Deprivation 
(IMD) 2004 (Noble, 2004). The Townsend Index, derived from the postcode, is 
based on four variables based on census data from 1991: unemployment, 
overcrowding, non-car ownership and non-home ownership and is focused on 
material deprivation. The Townsend Index was produced at the Enumeration 
District level: small geographical areas used for the output of census data, of 
which there were 10,864 in the West Midlands in 1991. Five socio-economic 
quintiles from 1 (most affluent) to 5 (most deprived) were derived by assigning 
postcodes to equal percentages of the whole West Midlands population in 
each group. Each patient was then allocated to one of the five groups based 
on their postcode. EASRs were calculated for each Townsend quintile based 
on the 1991 census population data. These 1991 populations were then 
weighted to take account of the change in the size of the West Midlands 
population from 1977 to 2004. For the period 1999-2004, the income domain 
of the IMD 2004 was used as a second measure of deprivation. The IMD 
provides a measure of deprivation for each Lower Super Output Area (LSOA) 
in England (LSOAs are small geographical areas that are fairly homogenous 
and consist of approximately 1,500 people; there are 3,482 LSOAs in the 
West Midlands). The income domain consists of several variables, such as 
the percentage of population in that LSOA claiming various income-based 
benefits and tax credits, which are then weighted and a score assigned to 
each LSOA. Patients were again allocated to a quintile (calculated based on 
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the percentage of the English population in each group) and EASRs were 
calculated for each quintile using the 2001 census population data. This was 
to check whether use of West Midlands regional derived deprivation quintiles 
based on the 1991 Census (Townsend) gave similar results to national 
quintiles based on a range of measures generally recorded in 2001 and 
compiled in 2004.” (This explanation of methodologies and the analytical 
process was completed by Rosie Day at the WMCIU) 
 
3.1.3 Ethicity 
Ethnicity data were compiled via linkage of individual patients and their 
tumours from the cancer registration database with data from the Hospital 
Episode Statistics (HES). At the time of linkage, the WMCIU had access to 
HES data for financial years 1997/98 through to 2004/05. Ethnicity was 
classified as White, Asian (Indian sub-continent), or Black, and those 
individuals with multiple ethnicity recordings were classified as other/mixed 
(including Chinese/Oriental). The ethnic breakdown of the population was 
derived from 2001 census data (Large, 2006). (Linkage with HES and 
ethnicity was provided by Colin Brookes at the WMCIU) 
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3.1.4 Study design for examining the incidence of a second malignancy of the 
oesophagus following a first primary of the prostate (Chapters 5 and 6) 
A population based retrospective cohort of men with a first malignant primary 
(excluding non-melanoma skin cancers) of PC (International Classification of 
Diseases tenth edition (ICD10) code C61) diagnosed between 1977 and 
2004, was identified from the cancer registration database at the West 
Midlands Cancer Intelligence Unit (WMCIU). These patients were followed up 
until diagnosis of a second malignant primary (excluding non-melanoma skin), 
death, or the end of the follow-up period in the registry (31st December 2004). 
Patients with follow up of less than 3 months were excluded to prevent 
inclusion of concurrent or undiagnosed cancers. Ethnicity data were obtained 
using linkage between the cancer registration database and Hospital Episode 
Statistics (HES).  
 
3.1.4.1 Data analysis 
Age- and period-adjusted standardised incidence ratios (SIR) were calculated 
as an estimate of relative risk for a second malignant primary of the 
oesophagus (ICD10 code C15). These cases were further examined by 
morphology: coding classified as adenocarcinoma (ICD-O-2 codes: 814* - 
838*, 848* - 849*, 8550, 8570), squamous cell carcinoma (ICD-O-2 codes: 
805* - 808*) or other and unknown morphologies. The expected numbers of 
oesophageal cancers, overall and by morphology, were estimated by 
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multiplying the observed number of exact person-years by calendar year and 
quinary age specific incidence rates for the West Midlands (Breslow, 1987). 
The 95% confidence intervals were calculated assuming a Poisson 
distribution of second primary malignancies, and a two-tailed p-value 
calculated (Breslow, 1987). Latency intervals between a diagnosis of PC and 
oesophageal cancer (OC) were derived as a surrogate for length of potential 
exposure to anti-androgen therapy prior to the development of the OC. 
Statistical programming for STATA shown in appendix 1 
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3.2 Survival, Epidemiology, and End Results (http://seer.cancer.gov/) 
The USA National Cancer Act in 1971 led to the collection of cancer data in 
the USA commencing in 1973 (Hankey et al., 1999). The SEER (Survival 
Epidemiology and End Results) 9 Registries Database has been reliably 
collecting data since 1977, covering approximately 10% of the population of 
the United States of America, providing not only an exact duplicate of the time 
period analysed in the WMCIU studies, but also a similar proportion of the 
overall population. “The SEER 9 registries are Atlanta, Connecticut, Detroit, 
Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and 
Utah”.  While SEER has expanded from the initial 9 areas, to include SEER 
11, SEER 13, SEER 17 and SEER 18 registries, only SEER 9 registries 
database has recorded the selected population for the whole 28 years, thus 
providing comparable period of follow-up. The characteristics of the SEER 
populations is comparable to that of the whole of the USA, with 12.9% below 
the poverty line (vs 12.4% of US population), 20.4% not attaining High School 
diploma (vs 19.6%), urban based 88.2% (vs 79%), and 17.3% first generation 
immigrants (vs 11.1%) [http://seer.cancer.gov/registries/characteristics.html] 
 
SEER is a well-utilised database, with many publications (Hankey et al., 
1999), including evidence of its robustness. With 3,405,000 tumours recorded 
in the SEER 9 Registries database 1977-2004, we hypothesised that greater 
power could be generated for the anti-androgen theory by providing longer 
follow-up periods. Moreover, ethnicity data are available for the whole time 
frame.  
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Case ascertainment is reported as greater than 98%, with quality control 
procedures including “potentially case-finding, re-abstracting/recoding and 
reliability studies”. 
 
The same ICD10 and ICD-O-2 codes were utilised as for the WMCIU studies. 
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3.3 The Health Improvement Network (http://csdmruk.cedegim.com/) 
The Health Improvement Network (THIN) database utilised contains 
computerised and anonymised longitudinal records from 326 UK General 
Practice (GP) surgeries, covering 5 million patients that are regionally and 
demographically representative of the UK population. THIN commenced in 
2002, with full data collection occurring at each practice upon joining the 
network, enabling follow-up data availability prior to this date. Data are then 
collected during routine practice, and via the specialised “Vision software” it is 
uploaded to the central THIN database every month (incremental update). 
The database was originally under the management of EPIC, now CSD 
Research Medical Group (part of Cedegim).  
 
Data are provided in four files (medical, therapy, additional health data (AHD) 
and postcode variable indicators (PVI)) with a fifth linking file (patient file). 
Anonymised data are identified by practice identification and a patient 
identification, when combined forms a unique identifier. The patient file 
contains information including age, date of birth, gender, and dates of entering 
and leaving the practice (e.g. including transfer to another practice or death). 
The medical file holds data surrounding medical diagnoses coded using Read 
codes. The therapy file contains prescribing data gathered by each electronic 
prescription completed by the general practitioner and recorded by Multilex 
codes (and British National Formulary coding). The AHD file contains a 
number of items including height, weight, BMI, smoking and alcohol habits. 
Finally the PVI file contains postcode-linked data for socio-economic status, 
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ethnicity and environmental factors (e.g. air pollutants). Socio-economic status 
is derived at the post-code level (Townsend score, 2001 census data) and 
recorded in quintiles. 
 
The strength of the database lies in the computerised prescribing practices of 
GPs, ensuring that all drugs prescribed for subjects in this population will be 
recorded. Demographic and lifestyle information (e.g. sex, age, smoking 
status, height and weight) are subject to “QOF” (Quality and Outcomes 
Framework) criteria, and thus a very high level of data entries are ensured. 
QOF is active among all GP surgeries in England, rewarding and incentivising 
high levels of accurate data collection (http://www.qof.ic.nhs.uk). 
 
The quality of the data, while maintained by CSD, has been verified in several 
publications. The incidence of cancers within THIN is comparable to that of 
the cancer registry data: standardised incidence ratio (SIR) within 10% 
(Haynes et al., 2009). Prescribing data has also been verified against national 
dispensing data and comparing practices that do and do not report data for 
the General Practice Research Database (GPRD) (Langley et al., 2010, Lewis 
et al., 2007). 
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3.4 Midlands OeSophageal adenocarcinoma Epidemiology Study 
3.4.1 Study design 
A case-control study with subjects with OAC and three control groups, 
subjects with endoscopic proven LSBE (or SBE with intestinal metaplasia on 
histology), subjects with endoscopic proven RO and community subjects was 
designed: Midlands OeSophageal adenocarcinoma Epidemiology Study 
(MOSES). Ethical approval for the research study was obtained (MREC 
05/Q2803/93), and approval obtained from each hospital and primary care 
trust research and development department. The study was adopted by the 
National Cancer Research Network. Cases of type 1 oesophageal 
adenocarcinoma, defined as the centre of the tumour arising above the 
gastro-oesophageal junction (Siewert and Stein, 1998), were identified from 
12 West Midland hospital upper gastrointestinal cancer multidisciplinary 
meetings, where prior histology reports of the morphology of adenocarcinoma 
were then confirmed. OAC, RO and BO subjects were recruited from Sandwell 
General Hospital, City Hospital (Dudley Road, Birmingham), Dudley Group of 
Hospitals, New Cross Hospital (Wolverhampton), Walsall Manor Hospital, 
Queens Hospital (Burton-upon-Trent), Good Hope Hospital (Sutton Coldfield), 
Heartlands Hospital (Birmingham), University Hospital Coventry and 
Warwickshire, Warwick Hospital, Alexandra Hospital (Redditch) and University 
Hospital Birmingham. Type 2 and 3 adenocarcinomas of the gastro-
oesophageal junction/cardia/upper stomach were not included in the study as 
their aetiological factors have differences that would confound the study. 
Community subjects were recruited from general practice surgeries in the 
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catchment area of each hospital; three practices were recruited for each 
hospital to enable closer geographical matching (appendices 2 and 3). 
 
3.4.2 Sample size and statistical considerations 
Recruitment of 208 cases of OA and 224 controls subjects would provide 80% 
power to detect a relative risk of 2 for dichotomous risk factors at the 5% 
significance level, except where the prevalence among controls is very low 
(<10%) or very high (>80%). The prevalence of each risk factor for OA being 
studied is within the 10-80% range in both patients and controls. Examples of 
prevalence in OAC include (figure in brackets community prevalence) 19% 
H.pylori prevalence (40%), 17% aspirin or NSAID use (25%), smoking 24% 
(18%), excess alcohol 20%, GORD symptoms 54% (17%), low education 28% 
and highest quartile for BMI 52% (26%).  
 
The incidence of oesophageal cancer in the Midlands is 14 per 100000 at the 
planning stage of the research (personal communication, West Midlands 
Cancer Registry). Analysis of cases discussed at upper gastrointestinal 
cancer multi-disciplinary meetings over the past year in the Pan-Birmingham 
network, suggests 70% of all oesophageal cancers are adenocarcinomas 
(personal communication Mr M. Hallissey and Mr M. Richardson). The Pan-
Birmingham network covers 1.8 million people and there will therefore be at 
least 180 cases of oesophageal adenocarcinoma available per annum for the 
study. A study period of 30 months was planned. 
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All control subjects were matched by gender, age (within 5 years), ethnicity 
(where possible), and geographical location. Control subjects with both 
incident cases of BO and endoscopically proven RO (any grade) were 
identified from those attending the endoscopy unit closest to the index case 
home address. Endoscopic evidence for Barrett’s mucosa was accepted if the 
segment was greater than 3cm (LSBE), but necessitated histological evidence 
if the segment was only 1-3cm; subjects with ultra short-segment Barrett’s 
oesophagus (<1cm) were not included. Community subjects were recruited 
from local general practices: for each hospital, three general practices were 
invited to participate in MOSES. When recruiting community subjects, the GP 
staff initially selected all patients within the practice by matching as detailed 
above. A random number generator selected six to eight cases from the list to 
invite.  
 
Once inclusion criteria for OAC were met and confirmed with the Clinical 
Nurse Specialist (CNS), following the upper gastrointestinal cancer multi-
disciplinary meeting at the subjects hospital, the CNS would approach the 
patient with OAC to gain consent for the research team to approach them. 
Information sheets and consent forms were given to the patient by the CNS, 
and the research team would await the confirmation of consent to contact the 
patient either from a return of reply slip (pre-paid envelope), or via the CNS. 
Informed consent was taken at time of visit.  
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All control subjects were provided with information sheets and consent forms 
by post at invitation, sent by a pre-prepared approved letter from the patient’s 
general practitioner, confirming willingness to participate by postal return (pre-
paid envelope). In the event of insufficient responses to meet the matching 
process, a second invitation would be sent as a final request. 
 
One of three research staff (SCC, SP or LP) would visit the patient in order to 
interview the subjects (SP and LP trained by SCC in accordance with 
suggested technique (Jain, 1989), measure leg length (iliac crest to lateral 
malleolus), and take blood samples. 
 
3.4.3 Response rates 
During the study period of 30-months, 330 case of type-1 OAC were identified 
from the 12 recruiting hospitals across the West Midlands. 86 were not eligible 
for the study being incompetent to consent (n=8), having commenced 
treatment pathway already (eg surgery or chemotherapy) and thus likely to 
alter their recall and introduce confounding (n=50), ten had died before 
contact could be made, 17 were too poorly with WHO performance status of 
4, and one had already been enrolled in another epidemiological study 
(SOCS). Two hundred and forty-four subjects were therefore eligible, with 32 
either declining or not replying to the invitation, and four more agreeing to take 
part, but due to logistical difficulties could not be enrolled. Thus 208 cases 
were recruited, meeting the number required by the power calculation. The 
response rate was 86.9% of those eligible to be invited. 
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Among the control groups, response rates were higher among those with 
disease: subjects with BO 80.4%, subjects with RO 55.7% and community 
subjects 35.8%. 
 
3.4.4 Interview 
A twelve page questionnaire was created (appendix 4), collecting information 
in six sections: section A background information and demographics, section 
B dietary history, section C smoking and alcohol history, section D medical 
history including heartburn symptoms, body parameters (eg height, weight, 
waist measurement, finger and leg length as described above), and 
medication history, Section E educational history and section F family history. 
With respect to cancer patients all questions were asked in respect to one 
year prior to the interview date and 11 years prior, in order to avoid 
confounding from cancer symptoms or treatments.  
 
3.4.5 Nutrition section 
As dietary recall suffers from memory bias, the questions were kept to food 
groups rather than individual items. Food groups included: fresh vegetables 
(not potatoes), fresh fruit, fruit juice, potatoes, red meat (beef, pork and lamb), 
white meat/poultry, fish/seafood, tea, coffee and use of vitamin/mineral 
supplements. For portion size, a portion was determined as the amount of 
food each subject would place in the palm of their hand (or glass/mug as 
appropriate), thus keeping portion size proportional to each person. For each 
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food group, frequency of consumption (days of the week) and number of 
portions consumed on those days at the time of interview (or 1 year ago for 
cancer patients) and 10 years prior was requested. Alcohol consumption was 
recorded as current, ex or never, with duration and quantity drunk. Quantity of 
alcohol consumed was transcribed into units by the interviewer based on 
percentage and volume consumed (1litre of x% = x units) at time of interview 
(or 1-year prior for cancer patients), 10 years previously and at the heaviest 
regular period. Continuous variables were categorised into appropriate 
tertiles/quartiles/quintiles for logistic regression analysis to generate odds 
ratios with 95% confidence intervals. 
 
3.4.6 Blood sampling 
Venous blood sampling was performed by each interviewer, with 25ml of 
blood taken from each subject. Two EDTA tubes and three clotted/serum 
samples were obtained, and centrifuged for ten minutes upon return to the 
laboratory within 24 hours. Plasma, buffy coat and serum was pipetted 
manually and stored in “cryo vials” at -80 degrees Celsius in a laboratory 
maintained and monitored freezer. 
 
3.4.7 Blood analysis 
Serum samples were defrosted and analysed for IgG antibodies to H.pylori 
and cagA using ELISA kits from Genesis Diagnostics Ltd, London UK 
(Registered in England No. 02924988). ELISA kits were CE marked and the 
microbiology laboratory at City Hospital, Sandwell and West Birmingham NHS 
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Trust is CPA (Clinical Pathology Accreditation) approved. The ELISAs were 
performed by Rushana Hussain, a trained microbiology biomedical scientist.  
 
The H.pylori IgG ELISA has a sensitivity of 91%, specificity of 100%, positive 
predictive value of 100% and negative predictive value 95% when compared 
with urease breath testing and histology. The cagA IgG ELISA sensitivity is 
97% and specificity of 96% when compared with Western Blot techniques. 
Following recommendations from Genesis Diagnostics, the cagA ELISAs 
were run in duplicate for each subject, and reproducibility checked. H.pylori 
ELISA was run once for each subject. 
 
A number of H.pylori samples were processed at the Dudley Group NHS 
Foundation Trust microbiology laboratory (n=111)(CPA approved) due to 
processing later than the main batch and the Sandwell and West Birmingham 
NHS Trust converting from ELISA to stool antigen testing, and no longer being 
set up to provide this assay. These last samples were processed using 
H.pylori IgG ELISA kits (CE Marked) produced by Zeus Scientific, Zierikzee 
Netherlands. Concordance with other commercially available H.pylori  assays 
is 97.8% (tested within Zeus laboratory). 
 
3.4.8 Reproducibility of interview 
Prior to use, the reproducibility of the questionnaire was confirmed using 
kappa statistics by interviewing 100 non-study subjects (relatives of patients 
attending for out-patient clinics or day case procedures) twice, three to four 
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weeks apart. The reflux symptom section of the questionnaire had already 
been validated (Mohammed et al., 2005).  
 
Interpretation of kappa statistics is shown in table 3.1. Of the one hundred 
subjects interviewed, 63 underwent a second interview within 3-4 weeks, with 
the remainder declining or further contact not achieved, achieving a response 
rate of 63%. The agreement between continuous variables was performed 
after categorising data into tertiles, quartiles or quintiles where appropriate. 
 
 
Table 3.1 Interpretation of kappa statistics 
Kappa statistic Interpretation 
<0 No agreement 
0-0.2 Slight agreement 
0.21-0.4 Fair agreement 
0.41-0.6 Moderate agreement 
0.61-0.8 Substantial agreement 
0.81-1 Almost perfect agreement 
 
 
As the cagA ELISAs were run twice, agreement between results was 
measured as substantial agreement (kappa 0.76). Any definite result and a 
second equivocal result was reported as the definitive result. There were no 
disagreements between a negative and positive result.  
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Smoking status (current, previous or never) was in perfect agreement (kappa 
1), with quantity smoked 10 years ago in almost perfect agreement (kappa 
0.87). Alcohol status was in substantial agreement (kappa 0.79). While the 
gastro-oesophageal reflux section had previously been validated, 
reproducibility was examined with substantial agreement with both having 
ever or never experience heartburn or acid regurgitation (kappa 0.77 and 0.8 
respectively). Being woken by GORD symptoms also showed substantial 
agreement both at time of interview and 10-years prior (kappa 0.74 and 0.76 
respectively). 
 
The dietary section of the interview illustrated moderate to substantial 
agreement overall. Selected kappa statistics are provided: current frequency 
of fruit consumption kappa 0.75 (substantial agreement), frequency of fruit 
consumption 10 years ago: kappa 0.55 (moderate agreement); portions of fruit 
per day now: kappa 0.57 (moderate agreement); portions of fruit consumption 
10 years ago: kappa 0.6 (moderate agreement); red meat portions per day: 
kappa 0.61 (substantial agreement); red meat portions per day 10 years ago: 
kappa 0.52 (moderate agreement); frequency of fish consumption currently 
0.52 (moderate agreement); frequency of fish consumption 10 years ago: 
kappa 0.39 (fair agreement); portions of fish consumed per day currently and 
10 years ago: kappa 0.33 and 0.32 respectively (fair agreement); cups of tea 
per day drunk currently and 10 years ago: kappa 0.58 and 0.56 respectively 
(moderate agreement). 
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Chapter 4 
 
Examination of the trends in incidence of oesophageal 
adenocarcinoma, and the influence of ethnicity and socioeconomic 
status in the West Midlands 
 
(Data from this chapter have been published: see appendix 5 for reference) 
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4.1 Introduction 
Over the last 30 years, the incidence of oesophageal cancer (OC) has been 
reported to be increasing in Europe and the USA (Botterweck et al., 2000, 
Hesketh et al., 1989, Powell and McConkey, 1992, Wayman et al., 2001, 
Kocher et al., 2001, Powell et al., 2002, Devesa et al., 1998, Pera et al., 1993, 
Bytzer et al., 1999, Hansson et al., 1993). Oesophageal squamous cell 
carcinoma (OSCC) rates have been stable, or declining, while the incidence of 
OAC has been rising rapidly. This rapid change in incidence has been noted 
to be greater than for any other cancer among males in the USA (Blot et al., 
1991). Examination of cancer registry data across Europe reveals that the 
highest incidence of OAC is in the United Kingdom (Botterweck et al., 2000). 
An association between ethnic origin and the different morphologies of OC 
has been described in the USA, with OSCC being more common among the 
black population while OAC is seen most frequently among white males 
(Hesketh et al., 1989, Yang and Davis, 1988). The influence of ethnicity has 
not been examined in the UK. 
OSCC has been reported to be associated with deprivation (Brown et al., 
2001), however reports of the influence of socio-economic status on OAC are 
inconsistent, some describing an association with deprivation (Jansson et al., 
2005b, Brown et al., 1994) and no association was found in Scotland 
(Brewster et al., 2000). A direct comparison of OSCC and OAC in Australia 
suggests OSCC is more clearly associated with deprivation(Nguyen et al., 
2003). The influence of socio-economic status upon the incidence of OAC has 
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yet to be examined in England. 
We have examined the incidence of OC in the West Midlands, England 
between 1977 and 2004 to identify changes in the incidence of its 
morphological subtypes and to examine the role of sex, ethnicity and 
affluence and deprivation. 
 
4.2 Materials and Methods 
Oesophageal cancers diagnosed in residents of the West Midlands were 
included in the study, and grouped by morphology code (ICD-O-2) classified 
as adenocarcinoma codes, squamous cell carcinoma or other and unknown 
morphologies.  
Incidence rates were calculated and cancers were grouped into five-year 
diagnosis periods and directly age standardised incidence rates per 100,000 
population, using the European Standard Population (EASRs), were 
calculated for each morphological group by sex for the years 1977-2004. A 
Mann Whitney U test (SPSS 12.0.1, Apache Software Foundation, USA) was 
employed to detect if any difference in age at diagnosis was significant 
between men and women in the two time-periods 1977-81 and 2000-4. 
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4.3 Results   
4.3.1 Incidence 
During the 28-year period 1977-2004, 15,138 OC cases were registered with 
the WMCIU, including 5517 cases of OAC, and 6314 OSCC. In 1977, 20% 
were OAC (n=78), and 48% OSCC (n=185), with 32% (n=124) either another 
morphology or unclassified. By 2004 the majority of OC was OAC (53%, 
n=366), with OSCC 31% (n=213) and other morphology/unclassified 17% 
(n=116). Changes in five year EASRs, with 95% confidence intervals (CI) for 
the different morphologies are shown in table 4.1 and figure 4.1. The 
significant rise observed for all OC in males was due to the marked increase 
in OAC (greater than four-fold), while there was no significant change for 
OSCC and a fall in those with other morphology/unclassified. In females, the 
picture was different, with significant increases being seen for both OAC 
(greater than three-fold) and a smaller but significant rise in OSCC. A small 
fall in unclassified/other morphology was also observed in women. 
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Table 4.1 Five year EASRs (95% CI) for oesophageal cancer by morphology 
and sex  
 
Cancer 
Morphology 
Males Females 
1977-1981 2000-2004 1977-1981 2000-2004 
EASR 95% CI EASR 95% CI EASR 95% CI EASR 95% CI 
All  8.57  8.03 - 9.10   13.73  13.13 - 14.32 5.04  4.69 - 5.39 6.28  5.92 - 6.64 
OAC 2.14 1.87 - 2.40 8.53  8.06 - 9.00 0.52  0.41 - 0.64 1.72  1.53 - 1.90 
OSCC 3.65  3.30 - 3.99 3.37  3.08 - 3.67 2.91  2.64 - 3.19 3.50  3.22 - 3.77 
Other/unclassified 2.78 2.46 - 3.11 1.83 1.61 - 2.04 1.60  1.42 - 1.79 1.07  0.93 - 1.21 
 
  
 67 
 
Figures 4.1a and 4.1b: Incidence of oesophageal adenocarcinoma and 
oesophageal squamous cell carcinoma in England (West Midlands) 1977-
2004 - Five year EASRs (95% CI) for oesophageal cancer for males (figure 
4.1a) and females (figure 4.1b) 
 
Figure 4.1a 
 
 
 
Figure 4.1b 
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The age at diagnosis of OAC was older in females during 1977-81 median 
72.5 (IQR 63.3-78) than in males 65 (51-71.8), and also in 2000-4 (78 (69-83) 
vs 70 (61-77)) (p<0.0001 both time periods), and has increased in both men 
and women during the time period examined. 
 
4.3.2 Socio-economic status 
Figures 4.2 and 4.3 illustrate the effect of socioeconomic status on the 
incidence of OAC and OSCC respectively, over the time-period 1977-2004 for 
both sexes, giving the least and most deprived quintiles. It can be seen that 
there was no consistent relationship between socioeconomic status and the 
incidence of OAC in men (figure 4.2a) or women (figure 4.2b) during the 28-
year period. In contrast, figure 3a illustrates clearly that while OSCC was 
significantly more common in the most deprived (EASR (95%CI) 6.19 (5.05-
7.33)) than the affluent (1.85 (1.31-2.4)) for men in the earlier years, this 
association with deprivation was no longer evident in the latter years of the 
study period, with both affluent and deprived males having rates of about 4 
per 100,000 population. A similar pattern was found for women with OSCC 
(most deprived 3.67 (2.88-4.45), most affluent 2.03 (1.52-2.54) in the early 
years of the study period (figure 4.3b). However, the difference by socio-
economic status was less marked, and was not apparent after the 1992-6 
period. 
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Figures 4.2a and 4.2b: Incidence of oesophageal adenocarcinoma in most 
affluent and most deprived Townsend quintiles in males (figure 4.2a) and 
females (figure 4.2b) in England (West Midlands) 
 
Figure 4.2a 
 
 
 
Figure 4.2b 
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Figures 4.3a and 4.3b: Incidence of oesophageal squamous cell carcinoma in 
most affluent and most deprived Townsend quintiles in males (figure 4.3a) 
and females (figure 4.3b) in England (West Midlands) 
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When the analyses were repeated using the IMD 2004 for cancers diagnosed 
in 2000 to 2004, the results agreed with the Townsend Index for OAC, with no 
association between socio-economic status and incidence of OAC. However, 
the incidence of OSCC was positively associated with deprivation, with the 
most deprived quintile having EASRs of 4.73 (3.96-5.5) in males and 4.96 
(4.22-5.69) in females. In contrast the rates of OSCC in the most affluent 
quintile were 2.55 (1.93-3.17) in males and 2.53 (1.97-3.1) in females, 
respectively. 
 
4.3.3 Ethnicity 
Figures 4.4a and 4.4b shows the EASRs of OAC and OSCC by ethnic group 
for the period 1998- 2004. OAC was significantly more common among the 
white population than other ethnic groups for both sexes. Indeed, no cases of 
OAC were observed among women in any ethnic groups other than white 
during the seven years examined. In contrast, OSCC was significantly more 
common than OAC among black men. OSCC was more common among 
black men than in white men, although this difference was not statistically 
significant. 
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Figures 4.4a and 4.4b: EASRs for oesophageal adenocarcinoma and oesophageal 
squamous cell carcinoma diagnosed in males (figure 4.4a) and females (figure 4.4b) 
in England (West Midlands) between 1998 and 2004 by ethnicity 
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4.4 Discussion 
The rising incidence of OC, specifically OAC, observed in the UK ten years 
ago (Botterweck et al., 2000, Powell and McConkey, 1992, Wayman et al., 
2001, Kocher et al., 2001, Powell et al., 2002) continues unabated during the 
past decade. In comparison, the incidence of OSCC has altered little in 
England, confirming that the rise in OAC is very unlikely to be a result of 
improved diagnostic or reporting methods, despite there being a fall in the 
rates of the unclassified cases. Re-examination of 4252 of the records for this 
study further strengthens this conclusion with similar percentages reclassified 
as OAC and OSCC from cases previously unclassified. 
 
The development of OAC is positively associated with gastro-oesophageal 
reflux (Lagergren et al., 1999a, Wu et al., 2003), obesity (Wu et al., 2003, 
Lagergren et al., 1999b, Vaughan et al., 1995) and being male (Blot et al., 
1991). Limited data suggest an increase in recent years in the endoscopic 
incidence of the pre-malignant complication of chronic gastro-oesophageal 
reflux BO (Prach et al., 1997). This change may in part be due to increasing 
use of endoscopy but also due to greater awareness of BO among 
endoscopists (Conio et al., 2001). Obesity in the US has been increasing for 
50 years(Parikh et al., 2007), with the incidence of obesity within the UK 
doubling from 1985-1992 (Prentice and Jebb, 1995). This rapid change, with 
obesity also associated with an increased incidence of gastro-oesophageal 
reflux symptoms (Mohammed et al., 2005), may well have contributed to the 
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rise in OAC seen. The rise in incidence of OAC was greatest in men, although 
a significant but smaller rise was also seen among women. Male pattern 
obesity with increased abdominal or visceral fat is particularly associated OAC 
(Vaughan et al., 2002). Occupational exposure to cement dust and asbestos 
(Jansson et al., 2005a) has been associated with development of OAC. Males 
develop OAC on average 8 years younger than females and cases of OAC 
before the menopause are very unusual. This raises the possibility that female 
sex hormones may protect against the development of OAC, or OAC 
oncogenesis may be, in part, driven by androgens. 
 
It has also been shown that the development of OAC is negatively associated 
with Helicobacter pylori (de Martel et al., 2005) and increasing consumption of 
fruit, vegetables and fibre (Brown et al., 1995). The incidence of Helicobacter 
pylori has fallen by 25% between the 1970s and 1990s (Haruma et al., 1997, 
Kosunen et al., 1997). A significant minority of patients with Helicobacter 
pylori develop atrophic gastritis and are rendered achlorhydric (Kuipers et al., 
1995, Harford et al., 2000) and therefore not at risk of acid gastro-
oesophageal reflux and its complications BO (Vicari et al., 1998, Vaezi et al., 
2000) and OAC (Vicari et al., 1998). The fall in incidence of Helicobacter pylori 
may have therefore increased the numbers of individuals in the population at 
risk of OAC. The consumption of fruit has changed little, whilst that of green 
vegetables has fallen in the UK during the study time-period (Statistics). 
However, it has been hypothesised that the use of nitrogenous fertilizers on 
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vegetables may have contributed to the rise in incidence of OAC (Iijima et al., 
2003b, Suzuki et al., 2005). 
 
The present study used two measures of socio-economic status, the 
Townsend score based on the 1991 Census using regional quintiles and the 
IMD 2004 using national quintiles based on 2001 data, with almost identical 
results, showing there was no association between socio-economic status and 
OAC. Thus it is unlikely that deprivation or affluence contribute to the 
development of OAC in England, in keeping with findings in Scotland from 
1987-1996 (Brewster et al., 2000). 
 
In contrast, deprivation was strongly associated with OSCC as has been 
previously noted (Brown et al., 2001). Unexpectedly, this association 
appeared to become weaker in the 1990’s using the Townsend index, due to 
a declining incidence in the deprived in addition to an increasing incidence in 
the affluent. However, the IMD 2004 measure showed that the association 
between deprivation and OSCC remained strong at the end of the study 
period, with a higher incidence in the deprived group than in the affluent 
group. It is not clear why the two measures of socio-economic status are 
discordant. The Townsend index focuses more on material deprivation rather 
than income and benefit allowances identified by the IMD, potentially leading 
to discrepancies between the scoring systems. The deprivation level of an 
area can change considerably, for example with the introduction of new 
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housing and redevelopment schemes, which may have altered over the study 
period. It is possible that since the Townsend index utilised was based on the 
1991 census, that for cases diagnosed in the late 1990s and 2000s this is a 
less reliable measure than the IMD. In our study, the Townsend Index was 
preferred, as the data used to construct this index were taken from around the 
mid-point of the study period 1991. It is known that OSCC is associated with a 
diet poor in fruit and vegetables (Bosetti et al., 2000), smoking and excess 
alcohol (Vaughan et al., 1995), all of which are more common among those 
from deprived backgrounds (Lallukka et al., 2007, Roos et al., 2008, Casswell 
et al., 2003, Jefferis et al., 2004). 
 
The higher rates of OAC in both men and women with white ethnicity than in 
other ethnic groups, confirms the findings of studies in other countries 
(Hesketh et al., 1989, Roos et al., 2008). Although GORD symptoms appear 
equally common among non-white subjects, endoscopic oesophagitis and 
Barrett’s oesophagus are much less common in these groups (Ford et al., 
2005). The higher incidence of Helicobacter pylori among non-white subjects 
(Everhart et al., 2000) may partly explain these differences but further 
research into this striking difference in incidence is clearly needed. It must be 
noted that this analysis is limited by the fact that 13.3% of the population (523 
out of 3909) were either unknown or not HES matched. However, as HES 
data are derived directly from the patient, interpretation of ethnicity by data 
collectors will not have been an issue. The creation of the National 
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Cancer Intelligence Network should serve to improve the quality of ethnicity 
data, enabling application to the whole of the population of England. 
 
Through examination of those cases incompletely abstracted with unknown 
morphology and those coded as gastric cardia between 1977 and 1986, the 
validity of the data has been strengthened. The proportionally high number of 
other or unknown cancer morphologies, particularly early in the time period 
examined, may mean an under representation of the incidence of OAC or 
OSCC, but there is no reason to suspect that this would be preferential for 
either morphology. During the time period examined, while the number of 
unknown/other morphologies did not change as an absolute figure (124 
cancers in 1977 to 116 in 2004), there was a significant fall in the rates of 
cancers without a specific known morphology. Thus, there has been an 
improvement in either reporting trends, or classification by histopathologists, 
but this is similar for both OAC and OSCC. The data presented here are only 
for patients who live within the unchanging boundaries of the WMCIU, and do 
not include individuals referred from outside the region. Thus referral patterns 
for treatment do not explain any of the incidence patterns. 
 
This analysis of the incidence of oesophageal cancer covers one of the 
longest periods examined in the literature (28 years), includes a novel 
examination of the influence of socioeconomic status in a representative 
population of England, and is the first to report on the influence of ethnicity in 
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the UK. The incidence of oesophageal cancer continues to rise in England 
due to a marked rise in OAC, which is strongly associated with male gender 
and white ethnicity. Socio-economic status does not appear to influence the 
incidence of OAC. The incidence of OSCC has not changed, and is the most 
common tumour morphology in black men and white women. OSCC is 
strongly associated with measures of deprivation.  
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Chapter 5 
 
Patients with prostate cancer are less likely to develop oesophageal 
adenocarcinoma - could androgens have a role in the aetiology of 
oesophageal adenocarcinoma? 
(Data from this chapter have been published: see appendix 5 for reference) 
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5.1 Introduction 
Men have a five-fold increased incidence of oesophageal adenocarcinoma 
(OAC), as compared with women (Blot et al., 1991). Epidemiological studies 
of the aetiology of OAC have identified a number of consistent associations, 
but only male pattern obesity is of relevance to gender. Occupational 
exposures have been examined, with positive associations with the 
development of OAC reported for exposure to cement dust and asbestos 
(Jansson et al., 2005a). However none of these associations can fully provide 
an explanation for the five-fold increased incidence of OAC in men (Blot et al., 
1991). 
 
Differences in sex hormones such as higher concentrations of androgens in 
men may provide a potential explanation for the difference in OAC incidence 
by sex. Prostate cancer (PC), an androgen sensitive tumour with a long 
natural history (five-year relative survival of over 70% for non-metastatic 
tumours at presentation (Cancer Research, 2008)), should allow insight into 
this putative explanation. We have therefore examined the incidence of a 
second primary of OAC in those with a first primary of PC in the West 
Midlands, UK, to examine whether androgens may potentially contribute to the 
higher incidence of OAC among men. 
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5.2 Materials and Methods 
5.2.1 Study design 
A population based retrospective cohort of men with a first malignant primary 
of PC diagnosed between 1977 and 2004, was identified from the cancer 
registration database at the West Midlands Cancer Intelligence Unit (WMCIU) 
as described in Chapter 3. Inclusion in the WMCIU database requires 
histology, clinician evaluation or on the basis of a death certificate, and is 
never purely from a raised serum marker such as “Prostate Specific Antigen” 
(PSA). These patients were followed up until diagnosis of a second malignant 
primary, death, or the end of the follow-up period in the registry (31st 
December 2004). Ethnicity data were obtained using linkage between the 
cancer registration database and Hospital Episode Statistics (HES).  
 
Statistical analysis was performed (by Stacey Croft, WMCIU) using STATA 
version 9 (StataCorp, 2005). 
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5.3 Results 
5.3.1 Study subjects 
From 1977-2004, 44 189 patients developed PC as a first primary malignant 
tumour within the West Midlands. Following exclusion for follow-up of less 
than three months, 38 627 were eligible for study, providing 143 526 patient 
years of follow-up (mean 4.0 years, range 3 months to 27.8 years). Figure 5.1 
shows an increasing incidence of PC in the West Midlands over this time 
period, initially quite gradual until the early 1990s, when the rise becomes 
more rapid following the introduction of PSA testing in the UK. 
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Figure 5.1 The incidence of prostate cancer in the West Midlands 1977-2004 
directly standardised to the European Standard Population 
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5.3.2 Ethnicity 
Examination of ethnicity for the 19 071 patients diagnosed with OC during 
1998-2004 revealed that the vast majority (83%) of PC patients included in the 
study from this period were white (n=15 751), with only 7 black individuals, 
and one South Asian subject (table 5.1). However, there were 3 312 cases for 
whom ethnicity could not be determined. 
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Table 5.1 Ethnicity of patients with a first primary of prostate cancer 1998-
2004 (HES data availability) with end of follow-up reason stated 
 
 
End of follow-up 
reason Ethnicity  
 
Mixed, 
other,  
Unknown Black White 
South 
Asian Total 
Developed oesophageal 
cancer 4 1 34  0 39 
Developed other 
malignant tumour  64 6 639  0 709 
Died 707  0 4635  0 5342 
Alive and free from 
second cancer at end of 
follow-up 2537  0 10443 1 12981 
Total 3312 7 15751 1 19071 
 
 
 
 
 
  
 86 
5.3.3 Risk of second oesophageal malignancy 
Table 5.2 and figure 5.2 show the observed incidence of a second malignancy 
of OC following a primary of PC, with the expected incidence of OC among an 
age- and period-adjusted general population, and the SIR as an estimate of 
relative risk. The SIR (95% CI) of developing OC following PC is significantly 
lower than expected at 0.78 (0.62-0.96). Examination of morphologies reveals 
that this overall decreased SIR is due to the reduced SIR of OAC at 0.70 
(0.50-0.95), with the SIR of developing OSCC being no different from that that 
would be expected in the general population, 1.03 (0.69-1.47). 
 
5.3.4 Time between diagnosis of prostate cancer and the diagnosis of 
oesophageal cancer (latency intervals)  
Examination of latency (table 5.2 and figure 5.2) shows that no time period 
was individually associated with a reduced risk of OC, overall or when 
examined by individual morphology. Furthermore, there was no evidence of a 
declining risk over the entire time period. 
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Table 5.2 Observed and expected incidence of oesophageal cancer by 
morphology with SIR and 95% confidence intervals 
 
 
 All cases 3mths - 1yr 1yr - 5yrs 5yrs - 10yrs >10yrs 
Person years 143525.9 26446.24 76848.13 28864.81 11366.69 
Patients 38627 38627 31760 10391 2699 
All Oesophageal cancer 
Observed 86 18 43 21 4 
Expected 110.1 18 56.4 24.2 11.5 
SIR (95% CI) 
0.78  
(0.62-0.96) 
1.00  
(0.59-1.58) 
0.76  
(0.55-1.03) 
0.87 
(0.54-1.35) 
0.35 
(0.1-0.89) 
Oesophageal Adenocarcinoma 
Observed 40 7 20 10 3 
Expected 57.3 9.1 29.3 12.8 6.2 
SIR (95% CI) 
0.70 
(0.5-0.95) 
0.77 
(0.31-1.58) 
0.68 
(0.42-1.06) 
0.78 
(0.37-1.44) 
0.49 
(0.18-1.66) 
Oesophageal Squamous Cell Carcinoma 
Observed 30 8 12 10 0 
Expected 29.2 5 15.2 6.2 2.7 
SIR (95% CI) 
1.03 
(0.69-1.47) 
1.59 
(0.69-3.13) 
0.79 
(0.41-1.38) 
1.60 
(0.77-2.95) 
0 
 
 
 
  
 88 
Figure 5.2 SIR (95% confidence intervals) for oesophageal cancer by 
morphology following a first primary of prostate cancer compared to the 
general population 
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5.4 Discussion 
The strikingly increased incidence of OAC in men relative to women remains 
largely unexplained. Although male pattern obesity has been reported to be 
associated with the pre-malignant condition Barrett’s oesophagus (Vaughan et 
al., 2002) and industrial exposure to potential carcinogens (Jansson et al., 
2005a) have been hypothesised to play a role, it seems unlikely that either are 
a plausible explanation for all of the difference in incidence observed between 
the sexes. OAC cells express greater concentrations of androgen receptors 
than non-malignant oesophageal cells in animal models and in human 
oesophageal resection specimens (Awan et al., 2007, Tihan et al., 2001, 
Waraich, 2008), providing a molecular basis for the hypothesis that OAC 
oncogenesis may be, at least in part, androgen driven. 
 
PC, as an androgen sensitive tumour (Balk and Knudsen, 2008), is typically 
treated with anti-androgen therapy, either surgically by orchidectomy, or 
medically with cyproterone or gonaderalin analogues (Jones, 1983). We have 
demonstrated that there is a significantly reduced risk of developing OAC 
following a first primary malignancy of the prostate, but not OSCC. To 
establish whether this could be as a result of anti-androgen therapy we have 
examined for a latency effect during follow-up following the initial diagnosis of 
PC, as a surrogate marker for exposure to anti-androgen therapy. It would be 
expected that there would be a progressive fall in the incidence of OAC, 
following commencing anti-androgen therapy if androgens had an important 
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role in the pathogenesis of OAC. No effect of latency was observed, 
suggesting that either increased exposure to anti-androgen therapy may not 
be associated with the reduced risk observed in developing OAC after PC or 
that there may be a latency effect but that the study lacks sufficient power to 
detect it, as it is important to recognise that the numbers of observed and 
expected cases of OAC in the longer time periods are small. 
 
An examination of the SEER-9 registries database 1973-2003 revealed that 
OC was significantly less common among PC patients than the general 
population, SIR 0.83, but did not examine the different morphologies of OC 
separately (Hayat et al., 2007). An earlier study examining the combined 
incidence of OAC and gastric cardia adenocarcinoma following PC failed to 
reveal any association(Ahsan et al., 1997). However, although OAC and 
gastric cardia tumours share some aetiological factors, others differ (e.g. 
Helicobacter pylori) (El-Serag et al., 2002). A study among Swedish men 
between 1958 and 1992 reported no significant difference between observed 
and expected numbers of new cases of OAC following PC (Lagergren and 
Nyren, 1998). However, despite 400 000 patient years of follow-up, it is 
possible that this study lacked statistical power due to the low incidence of 
OAC in Sweden during this time period (Lagergren and Nyren, 1998). OAC is 
5-fold more common in the United Kingdom than in Sweden (el-Serag, 2002). 
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PC and OAC share a number of aetiological risk factors. Obesity is associated 
with OAC and PC, although the association with the latter is with a more 
aggressive form of the disease (Hsing et al., 2007). This may potentially mean 
that some longer-term survivors of PC would be less obese, and thus at less 
risk of developing OAC. Greater levels of IGF-I (insulin-like growth factor-I), a 
“noted mitogen”, are seen in both PC (Stattin et al., 2000) and OAC (Siahpush 
et al., 2007). 
 
While PC is more common among the affluent (Rowan, 2007) and OSCC is 
more common among the deprived (Brown et al., 2001, Nguyen et al., 2003), 
there is no association between socio-economic status and the incidence of 
OAC (Brewster et al., 2000). This would suggest that affluence should not 
influence the risk of OAC among PC patients, but would perhaps lower the 
risk of OSCC among PC patients. It is therefore likely that the socio-economic 
status of the PC patients is not influencing the development of either OAC or 
OSCC. Black ethnicity is associated with PC (Yanke et al., 2006), and white 
ethnicity with OAC (Chapter 4). Thus, if a significant number of the PC 
patients were of black ethnic origin, and therefore at lower risk of OAC, this 
could provide a plausible explanation for the effect observed. However, 
examination of HES data from 1997/8-2004/5 revealed that the number of 
black subjects developing PC in this cohort was extremely small, and thus 
unlikely to influence the results, although there were a large number of 
patients with unknown ethnicity and so we cannot entirely rule out this 
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explanation. 
 
The incidence of PC has been rising over the past 30 years (figure 5.1), the 
more rapid growth since the early 1990s being largely due to an increased 
public awareness and “screening” with serum markers such as PSA (Cancer 
Research, 2008). Such patients identified through screening may have 
“healthier lifestyles” than patients who do not undergo screening (Sutton et al., 
2000). Such patients may therefore be at a lower risk of OAC. A diagnosis of 
PC may also induce patients to alter their lifestyle, becoming a “healthy 
cohort” (akin to the “healthy worker effect”) (Li and Sung, 1999), thus reducing 
their risk of developing a subsequent malignancy. However, as the risk of 
OSCC, in contrast to OAC, remains broadly similar to that of the age- and 
time-period adjusted male population, these potential explanations for the 
study findings would appear unlikely. 
 
In summary, we have demonstrated that a first primary cancer of the prostate 
is associated with a reduced risk of developing a second primary of 
oesophageal cancer, specifically adenocarcinoma rather than squamous cell 
carcinoma. Prostate cancer may be associated with unrecognised risk factors 
that are negatively associated with oesophageal adenocarcinoma. While it 
was not possible to demonstrate a latency effect to support the hypothesis 
that cumulative use of anti-androgen therapy is the mechanism reducing OAC 
incidence in this cohort, this remains a plausible explanation. 
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Chapter 6 
 
 
Subjects with prostate cancer are less likely to develop oesophageal 
cancer – analysis of SEER 9 Registries Database 
 
(Data from this chapter have been published: see appendix 5 for reference) 
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6.1 Introduction 
Oesophageal adenocarcinoma is five times more common among men than 
women in both the UK (Chapter 4) and the US (Blot et al., 1991). Examination 
of animal-model and human OAC pathology specimens has revealed 
increased androgen receptor expression on OAC as compared with normal 
oesophageal cells(Waraich, 2008, Awan et al., 2007, Tihan et al., 2001). 
We have previously investigated the hypothesis that androgens may 
contribute to the aetiology OAC by identifying subjects with a first primary of 
prostate cancer, an androgen sensitive tumour (Balk and Knudsen, 2008) with 
a long natural history (five year survival of over 70% for those presenting 
without metastases (Cancer Research, 2008)) in the West Midlands Cancer 
Intelligence Unit registry (UK) and examining the risk of developing a second 
cancer of the oesophagus, compared with the general population (Chapter 5). 
The study identified a reduced risk of developing OAC following PC, but not 
OSCC. We hypothesised that anti-androgen therapy (surgical or medical), 
often employed in the management of PC (Jones, 1983), may reduce the risk 
of developing OAC after PC. However, we were unable to identify the 
increasing reduction in OAC incidence with time that would be expected if this 
hypothesis was correct. 
 
We have therefore re-examined the association between PC and subsequent 
oesophageal cancer in the SEER 9 Registries Database (Hankey et al., 
1999). The SEER database includes ethnicity data, enabling us to control for 
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the potential confounding effect of PC being more common in black subjects 
(Yanke et al., 2006), while OAC is more common in whites. 
 
6.2 Materials and Methods 
The study design and data analysis (chapter 3) are identical to the study in 
chapter 5, but uses the SEER 9 registries database, providing an almost ten-
fold greater patient year of follow-up, aiming to improve the power to identify a 
latency effect. Moreover, the SEER dataset contains ethnicity dataset for the 
whole time-period. Enabling thorough examination of the impact of ethnicity. 
 
Statistical analysis was performed personally using STATA version 10 
(StataCorp, 2005). 
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6.3 Results 
6.3.1 Study subjects 
Between 1977 and 2004, 362 553 subjects (301 576 white and 41 141 black) 
developed PC as a first primary malignant tumour within the SEER 9 
registries. Following exclusion criteria, 343 538 were eligible for study, 
providing 2 014 337 years of follow-up. The incidence of PC was highest 
among black individuals, but has been rising steadily among both black and 
white ethnicities, with a sharp rise seen from the late 1980s (figure 6.1). 
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Figure 6.1 The incidence of prostate cancer by ethnicity using five year rolling 
directly age-standardised rates per 100 000.
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There has been a steady rise in the incidence of OAC during the study period, 
predominantly among white men (figure 6.2). OSCC is more common among 
black men, however, there has been a sharp decline in OSCC incidence 
among this ethnic group in the last two decades (figure 6.3). 
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Figure 6.2 The incidence of oesophageal adenocarcinoma by gender and 
ethnicity using five year rolling directly age standardised rates per 100,000.  
 
 
 
 
 
 
 
0 
2 
4 
6 
8 
10 
12 
14 
16 
19
77
-1
98
1 
19
78
-1
98
2 
19
79
-1
98
3 
19
80
-1
98
4 
19
81
-1
98
5 
19
82
-1
98
6 
19
83
-1
98
7 
19
84
-1
98
8 
19
85
-1
98
9 
19
86
-1
99
0 
19
87
-1
99
1 
19
88
-1
99
2 
19
89
-1
99
3 
19
90
-1
99
4 
19
91
-1
99
5 
19
92
-1
99
6 
19
93
-1
99
7 
19
94
-1
99
8 
19
95
-1
99
9 
19
96
-2
00
0 
19
97
-2
00
1 
19
98
-2
00
2 
19
99
-2
00
3 
20
00
-2
00
4 
Incidence Years 
White Males 
White Females 
Black Males 
Black Females 
 100 
Figure 6.3 The incidence of oesophageal squamous cell carcinoma by gender 
and ethnicity using five year rolling directly age standardised rates per 100 
000. 
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172 990 312 436 343 538 343 538 PC patients 
All OSCC 
All OAC 
815 578 952 243 246 515 2 104 337 Patient years follow-up 
0.71 (0.57-0.88) 0.79 (0.66-0.95) 1.01 (0.72-1.39) 0.79 (0.69-0.89) SIR (95% CI) 
122 145 38 305 Expected 
87 115 38 240 Observed 
0.75 (0.62-0.89) 0.85 (0.71-1.01) 1.1 (0.79-1.5) 0.83 (0.74-0.93) SIR (95% CI) 
174 159 36 369 Expected 
130 135 40 305 Observed 
> 5 years 1 – 5 years 3 months - 1 year 3 months >  
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6.3.2 Risk of a second malignant primary of oesophageal cancer 
The observed standardised incidence ratios (SIR) of both OAC (0.83(95% CI 
0.74-0.93) and OSCC (0.79(0.69-0.89) following a first primary of PC were 
significantly less common than would be expected for an age and time-period 
adjusted population (table 6.1). 
 
Moreover, the SIR fall with increasing time interval from the date of diagnosis 
of PC for both OC morphologies, suggesting a latency effect. 
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Table 6.1. Observed and expected incidence and standardised incidence 
ratios of oesophageal adenocarcinoma and squamous cell carcinoma among 
men of all races following a first primary cancer of the prostate. 
 >3 months 3 months-1 
year 
1-5 years >5 years 
PC  years of 
follow-up 
2 104 337 246 515 952 243 815 578 
Subjects 343 538 343 538 312 436 172 990 
Oesophageal adenocarcinoma 
Observed 305 40 135 130 
Expected 369 36 159 174 
SIR (95% CI) 0.83 (0.74-
0.93) 
1.1 (0.79-1.5) 0.85 (0.71-
1.01) 
0.75 (0.62-
0.89) 
Oesophageal squamous cell carcinoma 
Observed 240 38 115 87 
Expected 305 38 145 122 
SIR (95% CI) 0.79 (0.69-
0.89) 
1.01 (0.72-
1.39) 
0.79 (0.66-
0.95) 
0.71 (0.57-
0.88) 
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6.3.3 Ethnicity 
The SIR of OC, OAC and OSCC following a first primary of PC by ethnicity are 
shown in table 6.2. The SIR for all OC and OSCC following a diagnosis of PC 
is reduced in both whites and blacks. The SIR for OAC is also reduced in 
white men following a diagnosis of PC (0.83(0.73-0.92), but not among black 
men (0.95(0.35-2.07)), although very few black subjects developed OAC 
during the study period. 
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Table 6.2 Observed and expected incidence and standardised incidence 
ratios for oesophageal cancer by morphology and ethnicity following a first 
primary cancer of the prostate. 
 All races White Black 
PC subjects 343 538 286 162 38 837 
Years follow-up 2 014 337 1 711 512 202 910 
All oesophageal cancers 
Observed 604 501 81 
Expected 758 639 108 
SIR (95% CI) 0.8 (0.73-0.86) 0.78 (0.72-0.86) 0.75 (0.6-0.93) 
Oesophageal adenocarcinoma 
Observed 305 297 6 
Expected 369 360 6 
SIR (95% CI) 0.83 (0.74-0.93) 0.83 (0.73-0.92) 0.95 (0.35-2.07) 
Oesophageal squamous cell carcinoma 
Observed 240 155 68 
Expected 305 208 90 
SIR (95% CI) 0.79 (0.69-0.89) 0.75 (0.63-0.87) 0.76 (0.59-0.96) 
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6.4 Discussion 
The higher incidence of OAC among males has not been satisfactorily 
explained by differential exposure to potential risk factors for OAC. However, 
a putative molecular basis for androgens contributing to the oncogenesis of 
OAC has been reported (Waraich, 2008, Awan et al., 2007, Tihan et al., 2001) 
and epidemiological evidence of a reduced incidence of OAC following PC 
(Chapter 5). In chapter 5, we could not identify a latency effect that would 
support the hypothesis that androgens play a role in the aetiology of OAC but 
postulated that the lack of an effect was likely to be due to a relative lack of 
power to demonstrate it. 
 
By examining the SEER dataset, we have been able to include nearly ten 
times as many patients and over 14 times more patient years of follow up, 
over the same time-period and in the same percentage of the country’s 
population, using the same methodology, thus providing greater power to 
identify a possible latency effect. The use of more accurate and extensive 
ethnicity data within SEER has enabled the examination of potential 
confounding due the greater incidence of OAC among white males, but 
greater incidence of PC among blacks (Yanke et al., 2006) 
 
Previous studies of this subject have revealed conflicting results. A Swedish 
study reported no change in the incidence of OAC following PC with a SIR of 
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0.9 (95% CI 0.5-1.5) but was hampered by the rarity of OAC during the study 
period in Sweden (Lagergren and Nyren, 1998). A previous examination of the 
SEER dataset from 1973-2003 revealed a reduced incidence of OC following 
PC with a SIR of 0.83 (p<0.05), in keeping with the findings of the present 
study, despite a slightly earlier time period (Hayat et al., 2007). OC 
morphology (OAC and OSCC) was not examined in that study. However, a 
study that did examine the combined the incidence of OAC and 
adenocarcinoma of the gastric cardia reported finding an increased incidence 
following a diagnosis of PC (Ahsan et al., 1997). Although OAC and gastric 
cardia adenocarcinoma share some aetiological factors, others are completely 
divergent in their influence (e.g. Helicobacter pylori)(El-Serag et al., 2002). 
 
In the present study, a reduced incidence of OAC following PC was again 
observed of a similar order of magnitude to that seen in the UK (0.83 versus 
0.7 in the UK). Furthermore, a latency effect has been demonstrated, with a 
lower SIR the longer the time period since developing PC. This is compatible 
with our original hypothesis that since a greater time period following 
development of PC is plausibly a surrogate for cumulative anti-androgen 
treatment, androgens may contribute to the increased incidence of OAC in 
men. 
 
In contrast to the previous study from the UK, there was also a reduced risk of 
developing OSCC following a diagnosis of PC, an observation identified in 
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both ethnic groups studied. Moreover, an apparent latency effect was also 
observed for OSCC with a lower SIR with longer follow up. Whilst OSCC is 
more common among males, the incidence is falling in all genders and 
ethnicities, although this appears greatest among black men (figure 6.3). 
Androgen receptor expression was reported in 3 out of 14 OSCC resections 
compared with 5 out of 11 OAC (Tihan et al., 2001). It is therefore possible 
that anti-androgen therapy is responsible for the latency effect observed. 
However, a plausible alternative explanation is the fact that PC is associated 
with affluence (Rowan, 2007), while OSCC is more common among deprived 
populations (Brown et al., 2001, Nguyen et al., 2003). OSCC may therefore be 
less common in subjects with PC than among the general population as the 
PC subjects come from more affluent backgrounds. However, this is unlikely 
to be the explanation either for the latency effect demonstrated of decreased 
incidence of OSCC following PC or for the lower incidence of OAC after PC. 
 
Figure 6.1 clearly shows the rising incidence of prostate cancer, with a 
sharper increase seen in the middle of the time period examined. This was 
also seen in the UK and is a reflection of increased public awareness of PC 
and the presence of acceptable screening tests, such as the serum marker 
prostate-specific antigen. This has resulted in more than one million additional 
diagnoses of PC in the US since the advent of screening (Welch and 
Albertsen, 2009). Particular reference must be made to the changing 
demographics of those diagnosed with PC with the average age of diagnosis 
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dropping from 72 to 67 years and the black population in particular were more 
likely to be diagnosed at a younger age in 2004/5 compared with 1988/9. 
Furthermore, screening has led to much improved or earlier staging at 
diagnosis, with the incidence of T3/4 disease dropping from 52.7 to 7.9 per 
100 000 among whites and 90.9 to 13.3 per 100 000 among blacks (Shao et 
al., 2009). Not only will younger age at diagnosis affect the subsequent risk of 
developing a second malignancy in subsequent years, but earlier disease may 
reflect survival advantage and less reliance on longer term anti-androgen 
treatment, with much debate surrounding long- or short-term hormone therapy 
for locally advanced prostate cancer (Brower, 2009), thus impacting upon the 
latency effects observed. The use of anti-androgens in the therapy for PC has 
increased in the US, most notably among those in whom it is prescribed as 
neo- adjuvant therapy prior to radiotherapy (from 9.8% to 74.6%), thus 
suggesting that the overall duration of anti-androgen therapy has been 
reduced in recent years (Cooperberg et al., 2003). This casts some doubt on 
the potential role of anti-androgen therapy in the latency effect noted in the 
present study. 
 
Patients who attend screening are more likely to be affluent, to have better 
access healthcare and a healthier lifestyle (Sutton et al., 2000, Thomas et al., 
2002) and thus may be at a lower risk of developing subsequent cancers 
including OC. Moreover, developing PC may encourage patients to attend to 
unhealthy aspects to their lifestyle, thus reducing their risk of subsequent 
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cancer. For example, it has been identified that cancer survivors are more 
likely to take vitamin and mineral supplements than the cancer-free general 
population (Velicer and Ulrich, 2008). A reduction in the incidence of a variety 
of second malignancies following PC have been identified in the SEER 
dataset, including colon, stomach and interestingly also cancers often 
associated with tobacco usage such as lung, oral cavity/pharynx (Hayat et al., 
2007). The effect of adopting a healthier lifestyle is a plausible explanation for 
this widespread reduction in second malignancy incidence. It must be 
acknowledged that since PC has one of the better prognoses (Cancer 
Research, 2008), there is often an opportunity to alter lifestyle that may not be 
available with malignancies with a worse prognosis. However, since OSCC is 
strongly associated with smoking and subjects were excluded following 
developing a second malignancy, the development of other smoking related 
malignancies may also partly explain the latency effect observed for a 
reduced incidence of OSCC following PC in the present study. 
 
The rapidly decreasing incidence of OSCC during the time-period examined, 
especially among black males in whom the incidence of PC is greatest, may 
contribute to the reduced risk of developing OSCC following a diagnosis of 
PC. The age and staging of PC at diagnosis has fallen markedly among black 
males (1988/9 compared with 2004/5) (Shao et al., 2009), allowing for 
potential greater longevity in this ethnic group in whom OSCC is more 
prevalent. Indeed, examining the incidence of OSCC following PC in the 
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SEER 1973-1990 dataset, a time period before the sharp decline in the 
incidence of OSCC, revealed no difference in the incidence of OSCC 
compared with the PC free matched general population (Ahsan et al., 1997). 
This is in keeping with the UK study, where the incidence of OSCC has 
remained relatively stable between 1977-2004 (Chapter 4). Although we have 
attempted to correct for time- period in the analysis, this may explain at least 
part of the difference between the reduced SIR for OSCC after PC in the 
SEER dataset and the lack of an effect in the UK study. However, differences 
in ethnicity between patients with PC and OAC are clearly not the explanation 
for the lower incidence of OC following PC. 
 
Interestingly, although colorectal cancer is less common following PC (SIR 
0.95(p<0.05)) (Hayat et al., 2007), its incidence is increased among men who 
have undergone orchidectomy (hazard ratio 1.37) or medical anti-androgen 
therapy (HR 1.31) (Gillessen et al., 2010). A study utilising a similar combined 
healthcare and cancer registry database would allow clarification of the effect 
of anti- androgen therapy on the development of OAC and OSCC. 
 
In summary, using the SEER 9 registries dataset we found that the incidence 
of both OAC and OSCC was reduced following PC. Furthermore, there was 
evidence of a latency effect suggesting that changes following a PC diagnosis 
progressively reduced the incidence of OAC and OSCC. The influence of anti-
androgen therapy, the healthier lifestyle that subjects may adopt following a 
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diagnosis of PC and the rapidly falling incidence of OSCC in the USA are all 
potential explanations for the study findings. 
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Chapter 7 
 
Risk factors for the development of oesophageal adenocarcinoma in 
Barrett’s oesophagus: a UK primary care nested case-control study 
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7.1 Introduction 
The incidence of OAC is rapidly rising across the Western world, particularly 
in the UK (Chapter 4). The five-year survival of patients developing OAC 
remains dismal (Rachet et al., 2009). BO, a sequela of chronic GORD, is a 
pre-malignant pre-cursor of OAC. The annual risk of progression from BO to 
OAC has been reported to be between 0.2-2% (Spechler, 1992, Eckardt et al., 
2001, Drewitz et al., 1997, de Jonge et al., 2010). However a recent large-
scale population cohort study based on pathology records suggested this was 
an over estimate, with the annual progression rate among 11 028 Danish BO 
patients reported to be 0.12% (Hvid-Jensen et al., 2011). Since the annual 
OAC progression rate is a big predictor of the cost effectiveness of BO 
endoscopic surveillance in mathematical model, the value of surveillance has 
been questioned (Barbiere and Lyratzopoulos, 2009). 
 
Studies of the risk factors associated with the progression of BO to OAC are 
often limited by the inherent selection bias in studying those undergoing 
endoscopic surveillance rather than an unselected cohort (El-Serag et al., 
2004, Nguyen et al., 2009). An unselected study of risk factors for progression 
to OAC among BO patients has not been previously performed in the UK 
despite the availability of primary care databases with substantial longitudinal 
data.  
 
We have therefore examined a retrospective cohort of BO subjects, from a UK 
primary care database, and examined risk factors for the development of 
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oesophageal cancer (OC) to guide surveillance efforts and suggest other 
interventions to lower the risk of OAC in BO.  
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7.2 Methods 
 
7.2.1 Subjects 
BO subjects were identified from The Health Improvement Network (THIN) 
database. Only BO subjects with a minimum of one year of follow-up, and, 
when applicable, a minimum of one year between a diagnosis of BO and 
oesophageal cancer (OC) were included in the study. Study subjects were 
followed from the first coded entry of BO or Barrett’s ulcer until either end of 
registration with the database, death, end of data capture period or diagnosis 
of OC. 
 
7.2.2 Data extracted 
Patient demographics (sex, age, period of follow-up with BO, proportion 
developing OC, socioeconomic status by Townsend quintile, BMI and 
smoking status (never versus ever)) were extracted. Both smoking status and 
BMI data were extracted from closest to the first recorded entry code for BO. 
To avoid confounding from subjects’ smoking status changing as a result of a 
diagnosis of a potential pre-malignant condition (BO), smoking status was 
established as never or ever having smoked. If there was no entry for BMI, it 
was calculated (mass(kg)/height(m)2) using an entry for height from age 18 
onwards, and a weight closest to the first recorded code for BO. 
 
7.2.3 Oesophageal cancer morphology 
As the database does not record the morphology of OC, verification of OC 
diagnosis and subtype was sought. The “free text entry” of the THIN database 
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was examined for each OC patient, and enquiries were made of the subjects’ 
GPs or by death certification (via an anonymised process through EPIC-UK 
(now Cedegim), the company administering THIN) to verify the morphology as 
OAC or other morphology. Cases proven to be squamous cell carcinoma of 
the oesophagus were excluded. 
 
Study subjects were followed from the first coded entry of BO or Barrett’s 
ulcer until either end of registration with the database, death, end of data 
capture within the database, or diagnosis of OC, whichever the former is. Use 
of drugs, by class, was initially examined as having ever, or never, been 
prescribed. In subjects developing OC, drug prescription was censored from 
examination 1 year before first coding of OC to prevent confounding from 
drugs that may have been prescribed for cancer symptoms. Drug classes 
examined include those believed to be negatively associated with OAC: 
aspirin, NSAIDs, proton-pump inhibitors (PPI), statins, and angiotensin 
converting enzyme inhibitors (ACE-I), and those potentially implicated in the 
aetiology of OAC by their side-effect of relaxation of the lower oesophageal 
sphincter (LOS): tri-cyclic antidepressants (TCAs)/anti-cholinergics, 
benzodiazepines, calcium channel antagonists, b-agonists, nitrates, and 
theophyllines, and those used for asthma including inhaled steroids.  
 
Ethical approval (MREC) was obtained for use of THIN data (London MREC: 
06/MRE02/93). 
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7.3.4 Statistical methods 
SPSS version 19.0.0 (IBM, USA) was used to perform Cox regression 
analysis to produce hazard-ratios (HR) with 95% confidence intervals, 
adjusting for age and gender, to evaluate the association of risk factors with 
the development of OAC. For drugs associated with smoking related COPD 
management, correction for smoking status was also employed, to control for 
potential confounding from smoking.  
 
To establish if dose-response relationships existed for the drugs examined, 
the number of scripts prescribed during the time period on the database was 
extracted, providing prescription density. Prescription density data were 
separated into quintiles and further Cox regression analysis performed as 
detailed above. Cumulative use of drugs associated with LOS relaxation and 
also cumulative use of drugs used to treat asthma/COPD including inhaled b-
agonists, inhaled steroids (and combined steroid and beta-agonist inhalers), 
and oral theophyllines were also examined using Cox regression analysis.  
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7.3 Results 
7.3.1 Subjects and validation 
3 752 subjects with BO were eligible for inclusion in the study, following 
exclusion for those with less than one year of follow-up within the database, 
and those subjects developing OC within one year of the first recorded 
diagnosis of BO (n=34). 
 
Fifty-three of the 58 identified OC subjects were successfully verified as 
having cancer of the oesophagus by the methods described. Three subjects 
had no free-text or death certification and did not belong to a registering 
practice that was signed up to respond to queries; two subjects had no useful 
information in their free text or death certificate and their GP was not available 
to respond or failed to respond to a query. 38 free text entries revealed the 
morphology for 31 subjects was OAC, two cancers required chemotherapy 
consistent with treatment of OAC, one was recorded as poorly differentiated 
(no morphology entered), one small cell cancer (an acknowledged 
complication of BO, thus remaining in the study), and three were oesophageal 
squamous cell carcinoma (one in a Barrett’s segment), subsequently excluded 
from the study. Examination of 16 death certificates confirmed the presence of 
oesophageal cancer in 15 (only one revealing morphology as OAC) and one 
having no mention of OC, but the death was certified over 3 years from the 
initial OC code entry, and there was an acute unrelated diagnosis on the 
certificate (subject not excluded). Six subjects with ‘free text comments’ were 
also assessed by viewing of death certification with no contradicting 
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comments discovered. Fifteen enquiries were made to general practitioners 
via EPIC-UK (thus remained anonymised): nine were confirmed as 
adenocarcinoma, five as cancer/carcinoma and one none response. 
 
7.3.2 Oesophageal cancer risk 
With exclusion of three cases of squamous call carcinoma after the 
verification process, 3 749 subjects with BO were included in the study, 
providing 17 743 subject years of follow-up (median 4 (interquartile range 
(IQR) 3-6) years). Median age was 63 (IQR 52-72) years, and 2731 were 
male (63%). Fifty-five subjects developed OC, a progression rate of 0.3% per 
annum.  
 
7.3.3 Risk factors for oesophageal cancer 
Table 7.1 shows the influence of age, gender, smoking status, BMI, and 
having ever been prescribed specified drugs within the study period among 
BO subjects who did and did not progress to OC. Male gender was associated 
with progression to OC HR 3.1 (1.5-6.2), p=0.002, as was increasing age HR 
(for each year) 1.03 (95% CI 1.01-1.05), p=0.005. BMI data were not 
entered/calculable from the database in 744 subjects (19.8%): 733 of the BO 
only group (19.8%) and 11 of the OC group (20%). Once corrected for age 
and gender there was no association between increasing BMI and 
progression to OC (0.99 (0.92-1.06)). Furthermore, no association was seen 
when analysed by categorising BMI up to 25, overweight (BMI 25.1-30) and 
obese (BMI >30) (data not shown). Smoking status was not recorded in 333 
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subjects (8.8%): 320 of the BO only group (8.7%) and 13 of the OC group 
(23.6%). 2037 (55%) of the BO only group and 33 (60%) of the OC group had 
ever smoked. Having smoked doubled the risk for progression to OC (2.36 
(1.13-4.93), p=0.023). 
 
Use of the following prescribed drugs (by class) was not associated with 
progression to OC after correction for age and gender (and smoking for 
inhaled b-agonists and theophyllines): PPI (130,021 (0.0-5.6E232), aspirin 
(0.81 (0.46-1.43)), NSAIDs (1.12 (0.65-1.91)), COX-2 inhibitors (0.49 (0.15-
1.56)), statins (0.94 (0.53-1.65)), oral iron preparations (1.38 (0.77-2.48)), oral 
anticholinergic drugs (1.67 (0.6-4.65))(including TCAs [1.18 (0.64-2.17)] and 
antispasmodics [1.35 (0.65-2.76)]), ACE-inhibitors (0.94 (0.53-1.66)), calcium 
channel blockers (1.04 (0.59-1.82)), hypnotics (including benzodiazepines 
[1.37 (0.79-2.36)]), inhaled β-agonists (1.27 (0.68-2.38)), nitrates (1.47 (0.84-
2.57)) and nicorandil (0.72 (0.17-2.95)). There was also no association with 
socio-economic status as determined by Townsend quintile (p=0.49 for trend). 
 
The use of inhaled steroids was associated with progression to OC (2.11 
(1.12-3.97) p=0.021), as was the use of inhaled steroid and b-agonists 
combination inhalers 2.54 (1.17-5.51) p=0.018 (both corrected for age, gender 
and smoking). Theophylline use failed to reach a significant association with 
progression to OC 2.31 (0.9-5.93) p=0.082 (corrected for age, gender and 
smoking). 
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When examined by prescription density, the fourth quintile of increasing 
inhaled steroid use was associated with developing OC corrected for age, 
gender and smoking status (2.78 (1.15-6.77) p=0.024) and also for trend 
through the quintiles (p=0.028) (figure 7.1). Examining prescription density for 
combined inhaled steroid and b-agonists (corrected for age, gender and 
smoking) revealed an association with developing OC (figure 7.2), reaching 
significance in the fourth and fifth quintiles (3.79 (1.16-12.39) p=0.027 and 
3.58 (1.09-11.8) p=0.036 respectively) with an increasing association across 
the quintiles (p=0.005). While theophyllines on an ever/never basis were not 
associated with progression to OC, the fourth quintile, after correction for age, 
gender and smoking status, exhibits a HR of 4.89 (1.17-20.37), p=0.029. 
 
Cumulative use of drugs used for asthma/COPD showed an increasing 
association with progression to (OC p=0.027 for trend), with HR 2.75 (1.14-
6.64) (p= 0.024) for the use of all three examined drugs (figure 7.3). This did 
not alter greatly when corrected for smoking (in addition to age and gender) 
with a HR 2.91 (1.1-7.68) p=0.031 for the use of all three drugs. 
 
The cumulative use of drugs that are known to have a side-effect of reducing 
LOS pressure was also associated with progression to OC. Figure 7.4 
illustrates an increasing risk with the use of one, two and three or more drugs 
within this category, with HR increasing from 0.86 (p=ns) for 1 drug, 1.71 
(p=ns) for any 2 drugs, reaching significance with 3 or more drugs HR 2.31 
(1.09-4.88) p=0.029 and p=0.009 for the trend seen. Given the associations 
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seen with cumulative asthma/COPD drugs, beta-agonists and theophylllines 
were subsequently removed from the cumulative LOS analysis, with loss of 
association, although there was still an increasing trend (non-significant 
p=0.283): 1 drug 1.15 (0.56-2.35), 2 drugs 1.38 (0.64-3), and 3 or more drugs 
1.46 (0.68-3.12). 
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Table 7.1 Risk factors implicated in the progression from Barrett’s 
oesophagus to oesophageal cancer 
 
 Median age 
(IQR) 
Gender Median BMI 
(IQR) * 
Smoking status Aspirin * Inhaled 
steroids # 
Inhaled 
steroids/b-
agonist # 
Theophylline # 
BO only 
(n=3694) 
63  
(52-72) 
63% male  
(n=2 325) 
25.9  
(23.7-28.3) 
55% ever smoked 
(n=2 037) 
32% 
(n=1194) 
19% 
(n=702) 
7% 
(n=259) 
4% 
(n=161) 
OC 
(n=55) 
67  
(59-73) 
84% male  
(n=46) 
25.8  
(23.7-28.5) 
60% ever smoked 
(n=33) 
35% 
(n=19) 
33% 
(n=18) 
15% 
(n=8) 
11% 
(n=6) 
Hazard 
ratio  
(95% CI) 
1.03 
(1.01-1.05) 
p=0.005 
 
3.06 
(1.5-6.24) 
p=0.002 
0.99 
(0.92-1.06) 
p=NS 
2.36 
(1.13-4.93) 
p=0.023 
0.81 
(0.46-
1.43) 
p=NS 
2.11  
(1.12-
3.97) 
p=0.021 
2.54 
(1.17-5.51) 
p=0.018 
2.31 (0.9-5.93) 
p=NS 
 
* corrected for age and gender 
# corrected for age, gender and smoking 
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Figure 7.1 Hazard ratios (95% confidence intervals) for the risk of developing 
oesophageal cancer from Barrett’s oesophagus by prescription density of 
inhaled steroids in quintiles 
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Figure 7.2 Hazard ratios (95% confidence intervals) for the estimation of risk 
of developing oesophageal cancer from Barrett’s oesophagus by prescription 
density of inhaled combined steroids/beta-agonist in quintiles 
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Figure 7.3 Risk of developing oesophageal cancer from Barrett’s oesophagus 
shown as hazard ratio (95% CI) by cumulative number of drugs prescribed for 
the treatment of asthma or chronic obstructive pulmonary disease 
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Figure 7.4 Risk of developing oesophageal cancer from Barrett’s oesophagus 
shown as hazard ratios (95% CI) by cumulative number of drugs with a side-
effect profile of relaxation of the lower oesophageal sphincter 
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7.4 Discussion 
Previous studies of BO and its progression to OAC often have inherent 
limitations with small numbers of subjects, often restricted to endoscopic 
surveillance patients with their inherent biases, and relatively short follow-up 
periods. This study aimed to overcome some of these issues by following 
subjects from a long-standing population based general practice database 
rather than a BO surveillance programme. The 0.3% per annum conversion 
rate from BO to OAC is at the lower end of previously published rates and is in 
keeping with more recent large Dutch and Danish studies (Hvid-Jensen et al., 
2011, de Jonge et al., 2010). The THIN database will rarely record the 
histological confirmation of BO with intestinal metaplasia, nor the degree of 
dysplasia present. Moreover, the length of Barrett’s segment will not usually 
be recorded either. The cohort would be expected to include many subjects 
with short segments of BO, since these are much more common than longer 
segments (Westhoff et al., 2005). Despite these inherent weaknesses of a 
general practice database study of BO, it is extremely unlikely that a diagnosis 
of BO would be coded for by a GP unless prompted by an endoscopic report 
of BO. The length of follow-up generated, with almost 18 000 subject years 
and a median follow-up per subject of 4 years, are strengths compared with 
many other studies of BO progression.  
 
OAC is more common in men and a number of potential explanations have 
been suggested including work-place exposure to potential carcinogens 
(Jansson et al., 2005a), the influence of sex hormones (Chandanos and 
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Lagergren, 2009, Yang et al., 2012) and the influence of increasing BMI 
(Anderson et al., 2007, Merry et al., 2007). In the present study there was a 
greater than three-fold increased risk of men developing OC. However no 
association was found between increasing BMI and progression to OC 
suggesting that the effect of gender at this stage of oncogenesis is unlikely to 
be related to visceral obesity. BMI may therefore be associated with OAC in 
other studies through influencing the frequency and severity of gastro-
oesophageal reflux disease and in turn the development of reflux oesophagitis 
and BO, rather than the development of OAC in BO subjects.  
 
Of the common OC morphologies, squamous cell carcinoma has been 
considered to be most influenced by smoking (Vaughan et al., 1995) and 
lower socio-economic status (Chapter 4). Our simplified analysis of smoking 
status (never versus ever) was designed to overcome some of the limitations 
of the database in the recording of smoking status at random rather than set 
intervals (an inherent weakness in a retrospective database study). Having 
ever smoked more than doubled the risk of developing OC from BO. Similar 
findings were reported in work from the Northern Ireland Barrett’s 
Oesophagus Registry (Coleman et al., 2012). On a practical note, the results 
of the present study and others on the influence of smoking in OAC strongly 
suggests that strenuous efforts should be made to encourage BO patients to 
stop smoking as a readily modifiable risk factor for OAC. There was no 
association between OAC progression and socio-economic status as 
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determined by Townsend quintile in the present study, a finding in keeping 
with an observational UK study of OAC (Chapter 4). 
 
Aspirin use was associated with a slightly reduced hazard ratio and NSAIDs a 
slightly increased hazard ratio for development of OC in this study but these 
both failed to reach statistical significance when examined ever versus never 
use, and also in prescription density analysis (data not shown). Previous 
case-control studies have shown a reduced risk of OAC with aspirin and /or 
NSAIDs (Sadeghi et al., 2008, Duan et al., 2008, Fortuny et al., 2007, 
Jayaprakash et al., 2006, Anderson et al., 2006), including a meta-analysis 
(Corley et al., 2003, Liao et al., 2012), and further modelling suggested that 
those who benefited most from aspirin/NSAIDs were those with frequent reflux 
symptoms (Pandeya et al., 2010). While several studies of aspirin/NSAIDs 
have shown a reduced risk of neoplastic progression from BO both 
retrospectively (Tsibouris et al., 2004) and prospectively (Vaughan et al., 
2005), including a reduction in aneuploidy and tetrapoidy (Vaughan et al., 
2005), analysis of the UK National Barrett’s Oesophagus Registry also failed 
to show an impact of aspirin use on not only on the development of OAC, but 
also on dysplasia (Gatenby et al., 2009). NSAID and aspirin use is not solely 
by prescription, with widespread over the counter (OTC) use. OTC aspirin and 
NSAID consumption will not be recorded in THIN, and the use of NSAIDs and 
aspirin is therefore likely to be an underestimate, potentially explaining the 
lack of a significant association in the present study. The results of the 
AspECT randomised control trial examining aspirin among BO patients, will 
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shed further light on the role of aspirin in progression of BO (Jankowski and 
Moayyedi, 2004).  
 
None of the medications that have a side-effect of reducing LOS pressure 
were individually associated with neoplastic progression. When analysed by 
increasing number of drugs (one, two and three or more) there was a 
significant trend for increasing relative risk of neoplastic progression seen. 
This finding is in keeping with previous case-control studies (Lagergren et al., 
2000, Corley et al., 2006), with the underlying mechanism of promoting 
gastro-oesophageal reflux. However, when beta-agonists and theophyllines 
were removed from the analysis of LOS relaxing drugs in order to further 
remove any confounding from asthma/COPD, the significant finding was lost. 
An increasing hazard ratio was still seen with increasing number of LOS 
relaxing drugs taken, although this failed to reach significance. It is likely that 
the failure to reach significance is due to reduction in power rather than 
confounding, especially as both theophyllines and beta-agonists failed to 
show significant association with progression to OC on an individual basis. An 
alternative and plausible explanation is that both beta-agonists and 
theophyllines may be implicated as they treat asthma/COPD, and these 
respiratory diseases are implicated in the progression form BO to OAC, rather 
than their LOS relaxation side effect. 
 
Some medications that may lead to reduced LOS pressure are also used for 
asthma, for example beta-agonists and theophyllines (Corley et al., 2006, 
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Vaughan et al., 1998). There is potential for confounding to occur between the 
association of asthma medication use, gastro-oesophageal reflux symptoms 
and Barrett’s oesophagus (Ladanchuk et al., 2010). Asthma/COPD drugs may 
be associated with developing OAC through GORD causing asthma and this 
combination being associated with an increased risk of COPD. Alternatively 
asthma/COPD drugs, through their effect on LOS pressure, may worsen 
gastro-oesophageal reflux and thereby increase OAC risk. Theophyllines have 
been shown to be associated with OAC in a meta-analysis (Alexandre et al., 
2012), but in the present study although there was an increased hazard ratio 
this failed to reach statistical significance, and in prescription density analysis 
the fourth quintile did reach significance (4.89 (1.17-20.37)), but there was no 
significant association was seen across the quintiles (data not shown). 
Inhaled steroids have not been shown to affect LOS pressure, but in the 
present study a doubling of the risk of progression to OC was seen not only 
comparing ever versus never use, but also with increasing prescription density 
suggesting a dose effect response, or more likely an association with 
increasing disease severity. The 5th quintile of prescription density was not 
significantly associated with OC, both with inhaled steroids and theophyllines, 
but this may be due to those with a greater severity of asthma or COPD 
developing complications of pulmonary disease, rather than OC, shortening 
their time on the database. Furthermore, combined inhalers containing both 
inhaled steroid and beta-agonist doubled the risk of neoplastic progression 
from BO with not only ever versus never use but also increasing across all 
quintiles, reaching significance in both 4th and 5th quintiles. There was 
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association between cumulative use of increasing numbers of different drugs 
used for asthma/COPD ad OC development, reaching significance with three 
drugs used.  
 
We were unable to definitively distinguish whether the association between 
asthma/COPD drugs and progression to OC relates to the side effects of the 
drugs on LOS pressure promoting reflux, or asthma/COPD in BO patients 
being associated with a higher risk of OC. However, the latter seems the more 
plausible explanation given the association of inhaled steroids with 
progression to OC. Controlling for smoking during the analysis removes one 
potential source of confounding in this association. 
 
There are inherent limitations in performing a nested case-control study from 
GP entered data such as the THIN database. While all prescriptions issued 
are accurately recorded as they are generally computer generated scripts, it 
cannot be guaranteed that the script is either dispensed, or that the prescribed 
medication is taken by the patient. In some cases, for example with beta-
agonist inhalers, multiple devices may be obtained by the patient, but not 
taken. Developing prescription density data (number of scripts issued per 
year) not only enables identification of any dose-response effects, but also 
reduces confounding from infrequent users of medication. Furthermore, OTC 
medication and drugs prescribed at other institutions will not be recorded. 
While these limitations exist, their impact is likely to be uniform among all 
patients, so bias is unlikely to affect the analysis. 
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The present study is reliant on correct data entry of the diagnosis of both OC 
and BO in the database. While we have undertaken a verification process 
concerning the OC entries, finding that cancer entries are accurate, although 
a few cases of squamous cell carcinoma were identified and excluded. We 
were unable to undertake a similar verification process for the diagnosis of BO 
as we did not have access to endoscopy or histology reports, but as this is an 
endoscopic and histological diagnosis as noted above, it is not one that 
general practitioners will make without a secondary care report based on 
endoscopy. Finally, we were unable to derive data on symptom patterns of 
GORD or dietary data, the prevalence of Helicobacter pylori, all of which may 
contribute to the development of OAC. 
 
We have shown that progression to OC from BO is more common among 
men, smokers and as age increases. Our study is in keeping with previous 
papers reporting the association between increasing numbers of LOS relaxing 
drugs and OC, although removal of beta-agonists and theophyllines from this 
analysis removes this association, illustrating their important role in this 
finding. We have examined the hypothesis that drugs used for asthma or 
COPD are implicated in the progression to OC from BO. The association of 
inhaled steroids with OC development strongly suggests that it is the 
pathophysiolology of asthma/COPD or the severity of gastro-oesophageal 
reflux necessary to cause asthma rather the drugs themselves that are 
associated with progression to OC.   
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Chapter 8 
 
 
The influence of aspirin, non-steroidal anti-inflammatory drugs and 
statins on oesophageal adenocarcinoma: a UK primary care case-
control study 
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8.1 Introduction 
With the rising incidence of OAC and continued poor prognosis, the search for 
modifiable aetiological factors is a subject of interest. Increasing body-mass 
index (BMI) (Anderson et al., 2007, Merry et al., 2007), smoking (Anderson et 
al., 2007, Solaymani-Dodaran et al., 2004), are positively associated with 
OAC, and aspirin and NSAIDs use have been reported to be negatively 
associated with OAC, but inconsistent results have been reported with statins 
(Shureiqi et al., 2001, Nguyen et al., 2009, Kantor et al., 2012, Kastelein et al., 
2011).  
 
Prospective case-control studies are often limited by the relatively low 
incidence of this cancer, restricting the study population size. We have 
therefore undertaken a case-control study of subjects with OAC in a UK 
primary care database with computerised prescribing data in comparison with 
subjects with BO, GORD and unselected control subjects.  
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8.2 Methods 
8.2.1 Subjects 
Oesophageal cancer patients were identified from The Health Improvement 
Network (THIN) database and those with a free text entry at this time period 
examined in order to select those with a confirmed diagnosis of OAC 
(anonymised by Cegedim the organisation managing the dataset). Cases 
were subjects with oesophageal cancer were identified by “Read” codes and 
adenocarcinoma morphology confirmed from the “free text” in-put by the 
General Practitioner. Three control groups were then identified: Barrett’s 
oesophagus (ratio of OAC:BO of 1:4), reflux oesophagitis (1:4) and 
unselected controls (1:10). All control subjects were matched by age (within 5 
years), gender, geographical location (by GP practice) and time of diagnosis 
of OAC (within 5 years). 
 
Ethics approval was obtained for use of THIN data (REC reference number 
06/MRE02/92).  
 
8.2.2 Variables examined 
The influence of socio-economic status (Townsend quintile based on 
postcode), height, weight, body mass index (BMI), smoking status (never, ex 
or current) and drugs potentially negatively associated with the development 
of OAC (proton-pump inhibitors (PPI), aspirin, NSAIDs, statins, and COX-2 
inhibitors), were assessed in the ten years prior to the year before a diagnosis 
of OAC, or 10 years prior to the matching date for control subjects. The data 
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within 1 year of diagnosis of OAC were censored to avoid confounding from a 
diagnosis of cancer or from drugs that may have been prescribed for cancer 
symptoms. Both smoking status and BMI data were extracted from during the 
study period, closest to the first recorded entry code for the period studied. If 
there was no entry for BMI, it was calculated (mass(kg)/height(m)2) using an 
entry of height from age 18 onwards, and a weight closest to the first recorded 
code within the study period.  
 
8.2.3 Statistical analysis 
Odds ratios (OR) with 95% confidence intervals (CI), correcting for age and 
gender, were generated by performing logistic regression analysis, using 
SPSS version 19.0.0 (IBM, USA).  
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8.3 Results 
8.3.1 Subjects 
From 1825 subjects with Read codes for oesophageal cancer in THIN, 468 
cases with a free text confirmation of adenocarcinoma were identified and 
eligible for the study, with at least one year of follow-up. 4652 unselected 
control subjects, 1636 BO subjects and 1644 RO subjects were matched 
according to the criteria described. The desired matching frequency was not 
always achievable (1:10, 1:4 and 1:4 respectively) due to limitations of case-
matching to geographical area, then age, gender and time-period: two OAC 
subjects were not matched to any control subjects; two different OAC subjects 
were not matched to RO subjects; and two further different OAC subjects 
were not matched to any BO patients. All other cases had at least one control 
in the three control groups successfully matched. Table 8.1 demonstrates the 
subject demographics. While age, gender, Townsend score (quintile) and drug 
data were all complete, table 8.2 shows the proportion of missing data for 
other variables.  
 
8.3.2 Logistic regression analysis 
Increasing height (analysed by deci-meter), weight and BMI were significantly 
associated with OAC when compared with all control groups (table 8.3).  
 
Current smoking was associated with OAC when compared to BO and 
unselected subjects but not with RO. No association was seen with being an 
ex-smoker with OAC, but a significant trend of smoking status from never, ex- 
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to current smoker was seen in the comparison of OAC with BO p=0.006, but 
fell just short of significance with OAC compared with RO (p=0.056) or with 
unselected controls (p=0.061). 
 
There was no consistent association between OAC and socio-economic 
status by Townsend quintile (table 8.4). 
 
The use of PPI was negatively associated with OAC as compared with BO 
and RO subjects, but positively when compared with community subjects. 
Aspirin and NSAIDs were negatively associated with OAC compared with RO 
and NSAIDs negatively associated with OAC compared with BO. The 
negative association between OAC and aspirin compared with BO fell just 
short of significance (table 8.3). There was no significant association with 
COX-2 inhibitor use. Statin use among unselected and RO subjects were 
negatively associated with OAC. The negative association seen with statins 
and OAC remained after correction for use of aspirin: unselected subjects 
(0.66 (0.46-0.97) p=0.032), RO subjects (0.6 (0.41-0.89) p=0.011), but not BO 
(0.81 (0.54-1.2) p=0.283). 
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Table 8.1 Demographics of the oesophageal adenocarcinoma subjects and 
the Barrett’s oesophagus, reflux oesophagitis and unselected control subjects 
 Oesophageal 
adenocarcinoma 
Barrett’s 
oesophagus 
Reflux 
oesophagitis 
Unselected 
control 
subjects 
Number of 
subjects 
468 1636 1644 4652 
Gender 
(male) 
384 (82.1%)  
 
1326 
(81.1%)  
1332 (81%) 3812 (81.9%)  
Median age 
(IQR) (years) 
69 (59-77) 69 (59-77) 69.4  
(59.5-76.6) 
69.5  
(59.5-77.5) 
Townsend 
quintile (IQR) 
3 (2-4) 3 (1-4) 3 (1-4) 3 (1-4) 
Median 
weight (IQR) 
(kg) 
80.2 (72.2-90) 76.2  
(68.1-85.7) 
76.2  
(68.5-85.7) 
76.2  
(68.1-85.7) 
Median 
height (IQR) 
(m) 
1.73  
(1.68-1.78) 
1.71  
(1.65-1.77) 
1.72  
(1.65-1.77) 
1.73  
(1.65-1.78) 
Median BMI 
(IQR) (kgm-2) 
26.9  
(24-29.3) 
26  
(23.8-28.5) 
25.9  
(23.7-28.3) 
25.7  
(23.4-28.3) 
PPI 131 (28%)  673 (41.1%)  847 (51.5%) 793 (17%)  
Aspirin 96 (20.5%) 417 (25.5%)  485 (29.5%)  1107 (23.8%)  
NSAIDs 186 (39.7%)  782 (47.8%)  929 (56.5%)  2056 (44.2%)  
COX-2 10 (2.1%)  34 (2.1%)  69 (4.2%) 122 (2.6%)  
Statins 14 (3%) 215 (13.1%)  275 (16.7%)  635 (13.7%)  
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Table 8.2 Missing data for study variables by subject group 
 
 Oesophageal 
adenocarcinoma 
Barrett’s 
oesophagus 
Reflux 
oesophagitis 
Unselected 
control 
subjects 
Weight 158 (33.8%)  457 (27.9%) 394 (24%) 1633 (35.1%) 
Height 128 (27.4%) 204 (12.5%) 148 (9%) 846 (18.2%) 
BMI 181 (38.7%) 494 (30.2%) 423 (25.7%) 1736 (37.3%) 
Smoking 204 (43.6%) 742 (45.4%) 748 (45.5%) 2332 (50.1%) 
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Table 8.3 Logistic regression analysis (odds ratio with 95% confidence 
intervals) corrected for age and gender as estimates of the relative risks for 
variables potentially associated with oesophageal adenocarcinoma 
 OAC vs Barrett’s 
oesophagus 
OAC vs reflux 
oesophagitis 
OAC vs 
community 
control 
Height (m) 1.53 (1.28-1.84) 
p<0.0001 
1.3 (1.1-1.54) 
p=0.002 
1.33 (1.12-1.57) 
p=0.001 
Weight (kg) 1.02 (1.01-1.03) 
p<0.0001 
1.02 (1.01-1.03) 
p<0.0001 
1.02 (1.01-1.03) 
p<0.0001 
BMI (kgm-2) 1.04 (1.01-1.07) 
p=0.025 
1.05 (1.01-1.08) 
p=0.005 
1.05 (1.02-1.08) 
p=0.003 
Ex-smoker 1.2 (0.8-1.79) 
p=0.39 
1.09 (0.73-1.63) 
p=0.69 
1.42 (0.97-2.08) 
p=0.075 
Smoker 1.71 (1.15-2.53) 
p=0.008 
1.43 (0.97-2.12)  
p= 0.071 
1.45 (1-2.09) 
p=0.047 
PPI 0.42 (0.32-0.54) 
p<0.0001 
0.26 (0.2-0.33) 
p<0.0001 
1.33 (1.03-1.71) 
p=0.028 
Aspirin 0.78 (0.59-1.03) 
p=0.076 
0.62 (0.47-0.81) 
p=0.001 
0.88 (0.68-1.14) 
p=0.32 
NSAIDs 0.74 (0.59-0.93) 
p=0.009 
0.53 (0.42-0.66) 
p<0.0001 
0.86 (0.7-1.06) 
p=0.17 
COX-2 1.2 (0.56-2.55) 
p=0.64 
0.52 (0.26-1.06) 
p=0.072 
0.87 (0.44-1.72) 
p=0.68 
Statins 0.73 (0.51-1.06) 
p=0.097 
0.52 (0.36-0.74) 
p<0.0001 
0.66 (0.47-0.94) 
p=0.02 
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Table 8.4 Logistic regression analysis (odds ratios with 95% confidence 
intervals) as estimates for risk of socio-economic status (detmined by 
Tonwsend quintiles) and OAC 
 
Townsend quintile OAC vs Barrett’s 
oesophagus 
OAC vs reflux 
oesophagitis 
OAC vs 
community 
control 
1st quintile 
(highest) 
1 1 1 
2nd quintile 1.07 (0.78-1.47) 
p=0.678 
1.15 (0.84-1.58) 
p=0.381 
1.07 (0.8-1.44) 
p=0.65 
3rd quintile 1.26 (0.91-1.73) 
p=0.16 
1.17 (0.85-1.61) 
p=0.326 
1.2 (0.89-1.61) 
p=0.225 
4th quintile 1.26 (0.91-1.75) 
p=0.17 
1.21 (0.87-1.68) 
p=0.25 
1.2 (0.88-1.62) 
p=0.243 
5th quintile (lowest) 1.39 (0.98-1.98) 
p=0.065 
1.24 (0.88-1.76) 
p=0.225 
1.47 (1.06-2.03) 
p=0.021 
p value for trend p=0.02 p=0.189 p=0.033 
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8.4 Discussion 
Increasing BMI was clearly associated with OAC compared all three control 
groups, despite increasing BMI being associated with both RO (Hampel et al., 
2005) and BO (Stein et al., 2005) as well as OAC (Anderson et al., 2007, 
Beddy et al., 2010) in previous studies. Visceral obesity is biologically active 
and has been shown to increase insulin-like growth factor 1 (IGF-1) levels 
(Donohoe et al., 2012, Doyle et al., 2012). Intriguingly while IGF-1 levels were 
higher in obese individuals with oesophageal squamous cell carcinoma as 
well as OAC, it was only OAC cell lines that responded to IGF-1 with 
increasing cell proliferation (Doyle et al., 2012). Moreover, OAC patients with 
increased levels of IGF-1 have been reported to have a poorer prognosis 
(Donohoe et al., 2012). Obesity also increases gastro-oesophageal reflux and 
oesophageal acid exposure, on 24-hour oesophageal pH monitoring (El-Serag 
et al., 2007).  
 
Increasing height was associated with OAC in comparison with all three 
control groups in the present study. This is the first time to our knowledge this 
association has been reported, although it has been hypothesised that the 
increased acid production seen among taller individuals (Baron, 1964, Marks, 
1961), together with the increase in population height over the last fifty years 
(1cm per decade) (Hauspie et al., 1996, Cole, 2000, Kuh et al., 1991), may 
contribute to the recent increase in incidence of OAC (Axon, 2004).  
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While oesophageal squamous cell carcinoma is considered to be strongly 
related to smoking (Vaughan et al., 1995), it is clear that OAC is also related 
to smoking (Anderson et al., 2007, Solaymani-Dodaran et al., 2004). The 
present study found an increasing risk of smoking when compared with BO 
and unselected controls subjects. Being a ex-smoker was not significantly 
associated with OAC, suggesting an important role for smoking cessation in 
reducing the risk of OAC.  
 
Classically, OSCC is strongly associated with deprivation (Brown et al., 2001), 
however, no association has been revealed in Scotland (Brewster et al., 2000) 
and the West Midlands (Chapter 4). This present study, while revealing an 
association with the most deprived quintile when comparing OAC with 
unselected control subjects, there is no overall pattern of significance. It is 
proposed that the positive association seen with smoking in this study, known 
to be associated with deprivation (Vaughan et al., 1995), may be counteracted 
by the potentially protective effect of H.pylori (de Martel et al., 2005), also 
associated with lower socio-economic status (Moayyedi et al., 2002, Murray et 
al., 1997). 
 
The negative association of PPI use with BO versus OAC is likely to represent 
the appropriate prescribing in those with an established endoscopic diagnosis. 
Use of PPI among reflux oesophagitis patients, producing a similar negative 
association, is again likely to be due to the use of the drug for symptoms 
following an endoscopic diagnosis. Likewise the positive association of PPI 
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use with OAC versus community controls will be a reflection of reflux 
symptoms being more common among those developing OAC, even with the 
censoring of data in the year prior to a code for OAC. 
 
Previous case-control studies have shown a reduced risk of OAC with aspirin 
and/or NSAID, including meta-analyses (Corley et al., 2003, Liao et al., 2012). 
Further modelling showed those benefiting most from aspirin/NSAIDs were 
those with frequent reflux symptoms (Pandeya et al., 2010). While we are 
unable to retrospectively identify reflux symptoms in the dataset employed, we 
have identified that aspirin use was negatively associated with OAC when 
compared with RO subjects, and NSAID use with BO and RO subjects, who 
all have established GORD. Aspirin and NSAIDs are thought to act by 
inducing apoptosis via lipo-oxygenase and cyclo-oxygenase inhibition 
(Shureiqi et al., 2001) and COX-2 expression in BO increases from 
metaplasia to dysplasia and neoplasia (Morris et al., 2001). Despite this we 
were unable to show any significant negative association between OAC and 
COX-2 inhibitor prescribing. However, this may be a result of relatively few 
patients receiving COX-2 inhibitors in this dataset (between 2.1 - 4.2%) 
compared with aspirin and NSAIDs, reducing the power to detect an 
association. The results of AspECT, a randomised trial of PPI and aspirin 
among BO patients, should shed further light on the potential beneficial effect 
of aspirin in the oncogenesis of OAC (Jankowski and Moayyedi, 2004).  
 
 148 
Statins, or 3-Hydroxy-3-methylgutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors, reduce mevalonate (Goldstein and Brown, 1990). Reducing 
mevalonate not only decreases cholesterol, but also reduce proteins involved 
in growth control (e.g. farnesylated proteins), and as such have been 
postulated as chemopreventative agents (Graaf et al., 2004, Chan et al., 
2003). Populations taking statins have been identified to have a reduced 
incidence of all cancers after just four years of use (Graaf et al., 2004), in 
particular reducing colorectal cancer (Poynter et al., 2005). This proposed 
mechanism of action has been identified in Barrett’s and OAC cells, inhibiting 
cell growth and proliferation, and inducing apoptosis (Sadaria et al., 2011, 
Ogunwobi and Beales, 2008, Konturek et al., 2007). Moreover statins appear 
to inhibit COX-2, a potential mechanism already described for the negative 
association of aspirin and NSAIDs with OAC (Ogunwobi and Beales, 2008, 
Konturek et al., 2007). While a retrospective study of medication use among 
Barrett’s oesophagus patients failed to show a potentially protective effect of 
statins (Nguyen et al., 2009), larger prospective cohort studies have identified 
a reduced risk of progression from BO to OAC (Kantor et al., 2012, Kastelein 
et al., 2011). In this large case-control database study, we have identified a 
reduced relative risk of OAC at least equivalent to that seen with aspirin and 
NSAIDs when compared to not only BO, but also RO and unselected control 
subjects, although statistical significance was only reached in the latter two 
groups. This case-control data adds to the tissue and cell model data, 
strengthening the hypothesis of a potential for chemoprevention among those 
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at increase risk of OAC, for example BO patients. This hypothesis needs to be 
tested in a prospective intervention trial using statins in BO. 
 
There are a number of important limitations with the database examined. 
Even if the medication examined is prescribed via the same computer that 
records the database entries, it cannot be guaranteed that it is dispensed or 
taken by the patient, either as directed or indeed at all. Furthermore, OTC 
medication and drugs prescribed at other institutions will not be recorded in 
the dataset. As described in the results section, although data were complete 
for many of the variables examined, there were important missing data, 
particularly smoking and weight (and consequently BMI). However, the 
prevalence of missing data was very similar for these variables across the 
four groups examined. 
 
BO and RO are endoscopic and/or histological diagnoses that general 
practitioners are very unlikely to make without a gastroscopy being performed, 
thus unlikely to be entered in error on the database. Neither the degree of 
reflux oesophagitis, nor the presence or degree of dysplasia in BO is entered. 
Moreover the length of BO segment is known influence the risk of developing 
OAC (Watson, 2005) and this also not coded for in the database. We were 
thus unable to correct for the severity of RO or BO. Finally, we were unable to 
derive the frequency or severity of symptoms of GORD, derive dietary data or 
accurately identify the incidence of Helicobacter pylori. We were thus unable 
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to correct for these factors that are known to be associated with OAC in the 
statistical analysis. 
 
In conclusion, increasing weight and importantly BMI were clearly associated 
with OAC compared with all three control groups, but additionally we found a 
novel association between OAC and increasing height. Smoking also 
appeared to be an important risk factor for OAC and our data suggests 
smoking cessation diminishes the risk, although the time period required for 
cessation to be effective was not ascertained in this study. Both aspirin and 
NSAID use were negatively associated with OAC. Finally, HMG-CoA 
reductase inhibitors (statins) were negatively associated with OAC compared 
with unselected subjects and reflux oesophagitis controls. 
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Chapter 9 
 
Midlands OeSophageal adenocarcinoma Epidemiology Study (MOSES) 
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9.1 Introduction 
The aetiology OAC has been investigated by a number of research studies in 
the last few decades as a result of some intriguing and hitherto fully 
unexplained observations. The incidence of OAC has been rising rapidly, 
more so in the UK than elsewhere in the world, and is now five times more 
common than 30-years ago. Moreover it is a disease predominantly of white 
men. While a number of positive associations including reflux symptoms, 
smoking and obesity have been identified, and negative associations including 
the presence of H.pylori and a diet high in fruit and vegetables, few studies 
have investigated the interaction of these risk factors. Many of these risk 
factors may well be synergistic in potential oncogenic risks, e.g. obesity, 
smoking and reflux, while others may act to negate or prevent the effect of 
other potential risks, e.g. H.pylori and reflux symptoms.  
 
We aim to investigate the aetiology of OAC in the West Midlands, England, 
UK, a kingdom with the highest incidence of this disease. 
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9.2 Methods 
Data from prospective interviews and blood sampling were used as part of this 
study: Midlands OeSophageal adenocarcinoma Epidemiology Study 
(MOSES). OAC subjects were matched (age within five-years, gender, 
geographical area and ethnicity) to three control groups: community subjects, 
subjects with RO, and subjects with BO. Continuous variables (e.g. duration of 
smoking, heartburn symptoms etc, and dietary intakes) were separated into 
appropriate tertiles/quartiles/quintiles. Logistic regression analysis generated 
OR with 95%CI as estimates of risk for potential aetiological factors. Following 
univariate analysis, multivariate analysis was performed to adjust for 
confounding from other variables.  Statistical analysis was performed using 
SPSS version 19.0.0 (IBM, USA). 
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9.3 Results 
9.3.1 Subjects 
Two hundred and eight OAC subjects were recruited, 177 male, median age 
68 (IQR 60-75). 283 community subjects, 236 male, median age 67 (IQR 60-
74), 224 RO subjects, 178 male, median age 66 (IQR 59-75), and 78 subjects 
with BO, 65 male, median age 65 (IQR 56-71.3) were matched. With respect 
to ethnicity, three subjects were of Asian (Indian sub-continent) origins, 
matched with only one community control subject and four RO subjects, but 
no cases of BO; two subjects were black, one matched with two community 
subjects, one subject with RO and one subject with BO, however one black 
subject was female and matching was not achieved with regard to ethnicity 
with any control group but still included in the analysis. Demographics of the 
subjects are seen in table 9.1. 
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Table 9.1 Demographics of subjects recruited within MOSES (median (IQR)) 
 OAC Community RO BO 
Male gender 177 (85.1%) 236 (83.4%) 178 (79.5%) 65 (83.3%) 
Age  68 (60-75) 67 (60-74) 66 (59-75) 65 (56-71.3) 
H.pylori  +ve 69 (33.2%) 88 (31.1%) 71 (31.7%) 28 (35.9%) 
Townsend 
quintile  
3 (2-4) 3 (2-4) 3 (2-4) 3 (2-5) 
Height (m) 1.74   
(1.68-1.8) 
1.74  
(1.69-1.8) 
1.73  
(1.65-1.79) 
1.73  
(1.68-1.78) 
Leg length 
(cm) 
98 (95-102) 97 (93-102) 95 (90-98.1) 93 (91-97.2) 
BMI now 
(kg/m2) 
27.6  
(24.7-30.7) 
26.6  
(24-29.8) 
26.4  
(24.4-29.1) 
27.8  
(24.8-29.8) 
BMI 10 years 
ago 
26.9  
(24.5-29.8) 
25.2  
(23.2-28.5) 
25.1  
(23.1-27.3) 
26.2  
(23-29.3) 
BMI aged 18 22.7  
(21-24.8) 
22.1  
(20.3-23.8) 
21.8  
(20.1-23.6) 
21.9  
(19.7-23.4) 
Waist now 
(cm) 
96.5  
(86.4-96.5) 
91.4  
(86.4-101.6) 
91.4  
(86.4-96.5) 
91.4  
(86.4-96.5) 
Waist 10 
years ago  
91.4  
(86.4-96.5) 
91.4  
(81.3-96.5) 
86.4  
(81.3-92.6) 
86.4  
(81.3-96.5) 
Waist aged 
18 
81.3  
(76.2-89.5) 
81.3  
(76.2-86.4) 
81.3  
(71.1-86.4) 
76.2  
(71.1-81.3) 
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9.3.2 Helicobacter pylori and cagA 
The prevalence of H.pylori infection among OAC subjects was 33.2%, 31.1% 
among community subjects, 31.7% among subjects with RO and 35.9% of 
subjects with BO. Logistic regression analysis revealed no association with 
H.pylori and OAC in comparison with any of the three control groups: OR 
(95%CI) vs community subjects 1.13 (0.76-1.66) p=0.548; vs RO 1.08 (0.72-
1.63) p=0.713; vs BO 0.96 (0.55-1.66) p=0.879. There was also no 
association with cagA status OR (95%CI) vs community subjects 0.68 (0.37-
1.23) p=0.203; vs RO 0.89 (0.46-1.72) p=0.73; vs BO 3.57 (0.81-15.8) 
p=0.094. 
 
 
9.3.3 Socio-economic status 
There was no overall association with socio-economic status and OAC 
compared with all three control groups (table 9.2). While there was a negative 
association with the most deprived Townsend quintile in comparison with 
subjects with BO, there was no trend seen. 
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Table 9.2   Logistic regression analysis with 95% confidence intervals 
showing associations with socio-economic status defined by Townsend 
quintile and OAC in comparison with community, RO and BO subjects 
 Townsend Quintile (1 most affluent to 5 most deprived) 
 1 2 3 4 5 
Community 1 0.81 
(0.47-1.4) 
0.65 
(0.38-1.13) 
1.17 
(0.67-2.03) 
1.13 
(0.6-2.11) 
RO 1 1.22 
(0.68-2.19) 
0.98  
(0.55-1.77) 
0.93 
(0.53-1.62) 
1.07 
(0.57-2.08) 
BO 1 0.6  
(0.25-1.46)  
0.57  
(0.23-1.4) 
0.68  
(0.28-1.67) 
0.31*  
(0.13-0.75) 
 
*p=0.009 
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9.3.4 Smoking 
Significant associations were observed with smoking status and all three-
control groups (figures 9.1-9.3). A reduced but still positive association was 
seen with ex smoking and OAC. A dose-response response is observed with 
all three-control groups, with increasing positive association with duration 
(figures 9.4-9.6) and quantity smoked (figures 9.7 and 9.8). 
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Figure 9.1 Associated risk (odds ratio) of smoking status: community control 
subjects vs OAC 
 
 
Figure 9.2 Associated risk (odds ratio) of smoking status: reflux oesophagitis 
patients vs OAC
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Figure 9.3 Associated risk (odds ratio) of smoking status: subjects with BO vs 
OAC 
 
 
 
 
Figure 9.4 Associated risk (odds ratio) of increasing duration of smoking (by 
quintile): community subjects vs OAC 
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Figure 9.5 Associated risk (odds ratio) of increasing duration of smoking (by 
quintile): reflux oesophagitis patients vs OAC 
 
 
 
 
Figure 9.6 Associated risk (odds ratio) of increasing duration of smoking (by 
quintile): subjects with BO vs OAC 
 
 
1" 1.34"
2.38"
1.41" 1.72"0.73" 1.31" 0.77" 0.95"
2.46"
4.31"
2.59" 3.12"
0"0.5"
1"1.5"
2"2.5"
3"3.5"
4"4.5"
5"
lowest"quintile" 2" 3"(p=0.004)" 4" highest"quintile"(p=0.073)"
1" 1.11" 2.32"
3.41" 3.81"
0.51" 1.02" 1.37" 1.47"2.4"
5.27"
8.48" 9.85"
0"2"
4"6"
8"10"
12"
lowest"quintile" 2" 3"(p=0.044)" 4"p=0.009)" highest"quintile"(p=0.006)"
 162 
Due to narrow distribution of the data of quantity smoked, the current quantity 
could only be split into high and low for current and tertiles for 10 years 
previously. Heavier current consumption was associated with OAC in 
comparison with community subjects: 2.48 (1.47-4.18) p=0.001); RO 1.67 
(1.02-2.75) p=0.043; BO 2.55 (1.11-5.88) p=0.028. Ten years previously 
comparing OAC with subjects with RO, there was an association with the 
middle tertile (2.15 (1.1-4.19) p=0.025) but not the heaviest quantity tertile 
(1.35 (0.82-2.23) p=0.044). An increasing positive association was seen with 
increasing quantity smoked and OAC in comparison with community (figure 
9.7) and BO subjects (figure 9.8). 
 
  
 163 
Figure 9.7 Associated risk (odds ratio) of quantity smoked 10-years prior to 
interview: community subjects vs OAC
  
 
 
 
Figure 9.8 Associated risk (odds ratio) of quantity smoked 10-years prior to 
interview:  subjects with BO vs OAC 
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9.3.5 Alcohol consumption 
A negative association with current alcohol consumption was observed in 
comparison of OAC with community subjects (figure 9.9), which was also 
observed with duration but not quantity drunk. In comparison with subjects 
with RO a reduced risk was observed with an OR of 0.68 (figure 9.10) and 
similarly with BO an OR of 0.16 (figure 9.11), but neither reached significance, 
and no effect of duration (figures 9.12-9.14) or quantity consumed (table 9.3) 
was observed. 
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Figure 9.9 Associated risk (OR 95%CI) of alcohol status OAC vs community 
subjects 
 
p=0.006 for trend 
 
 
Figure 9.10 Associated risk (OR 95%CI) of alcohol status OAC vs subjects 
with RO 
 
 
1" 0.95" 0.43"0.34" 0.2"
2.66"
0.94"
0"0.5"
1"1.5"
2"2.5"
3"
Never" Ex" Current"(p=0.034)"
1" 0.81" 0.68"0.31" 0.32"
2.13"
1.44"
0"
0.5"
1"
1.5"
2"
2.5"
Never" Ex" Current"
 166 
Figure 9.11 Associated risk (OR 95%CI) of alcohol status OAC vs subjects 
with BO 
 
 
 
 
Figure 9.12 Associated risk (OR 95%CI) of duration of alcohol consumption 
OAC vs community subjects 
 
p=0.053 for trend 
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Figure 9.13 Associated risk (OR 95%CI) of duration of alcohol consumption 
OAC vs subjects with RO 
 
 
 
 
Figure 9.14 Associated risk (OR 95%CI) of duration of alcohol consumption 
OAC vs subjects with BO 
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Table 9.3 Associated risk (OR 95%CI) of quantity of alcohol consumed at time 
of interview and 10 years previously with OAC compared with all control 
groups 
Control group Alcohol consumption by tertile 
1 2 3 
Community now 1 0.71 (0.45-1.1) 0.82 (0.52-1.32) 
Community 10 
yrs ago 
1 0.87 (0.55-1.37) 1.06 (0.67-1.68) 
RO now 1 1.03 (0.64-1.66) 1.43 (0.88-2.31) 
RO 10 yrs ago 1 1.16 (0.72-1.85) 0.96 (0.58-1.56) 
BO now 1 0.64 (0.33-1.27) 0.94 (0.46-1.91) 
BO 10 yrs ago 1 0.72 (0.36-1.43) 0.59 (0.3-1.17) 
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9.3.6 Symptoms of gastro-oesophageal reflux 
The occurrence of heartburn symptoms (ever versus never) were associated 
with OAC compared with community controls OR (95%CI) and 2.85 (1.95-
4.16) p<0.0001, but not with subjects with RO 0.75 (0.49-1.15), and negatively 
associated with subjects with BO 0.34 (0.17-0.77) p=0.008.  
The occurrence of symptoms of acid regurgitation (ever versus never) were 
associated with OAC compared with community subjects 2.06 (1.43-2.96) 
p<0.0001, negatively associated with subjects with RO 0.42 (0.28-0.64) 
p<0.0001 and those with BO 0.26 (0.13-0.51) p<0.0001. 
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Figure 9.15 Associated risk (odds ratio) of increasing duration of heartburn 
symptoms (by quintile): community subjects vs OAC 
 
p=0.055 for trend 
 
 
Figure 9.16 Associated risk (odds ratio) of increasing duration of heartburn 
symptoms (by quintile): reflux oesophagitis subjects vs OAC 
 
p<0.0001 for trend 
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Figure 9.17 Associated risk (odds ratio) of increasing duration of heartburn 
symptoms (by quintile): BO subjects vs OAC 
 
 
 
Figure 9.18 Associated risk (odds ratio) of increasing duration of acid 
regurgitation symptoms (by quintile): community subjects vs OAC 
 
p=0.013 for trend 
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Figure 9.19 Associated risk (odds ratio) of increasing duration of acid 
regurgitation symptoms (by quintile): reflux oeophagitis subjects vs OAC 
 
 
 
 
Figure 9.20 Associated risk (odds ratio) of increasing duration of acid 
regurgitation symptoms (by quintile): subjects with BO vs OAC 
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Table 9.4 Associated risks of frequency of heartburn symptoms with OAC by 
control group and time 
  Monthly or 
less 
Weekly/occ 
day 
Daily or 
greater 
Heartburn in 
year prior to 
interview 
Community 
p=0.014 for 
trend 
1 1.18 (0.69-
2.01) 
2.82 (1.31-
6.06) p=0.008 
RO 1 1.07 (0.64-
1.79) 
0.89 (0.5-
1.59) 
BO 
p=0.001 for 
trend 
1 4.79 (1.89-
12.12) 
p=0.001 
3.16 (1.22-
8.18) p=0.018 
Heartburn 10 
years prior to 
interview 
Community 
p=0.036 for 
trend 
1 0.96 (0.56-
1.63) 
2.54 (1.23-
5.23) p=0.012 
RO 
p=0.035 for 
trend 
1 1.26 (0.76-
2.1) 
1.93 (1.05-
3.56) p=0.034 
BO 1 1.23 (0.58-
2.6) 
0.72 (0.35-
1.48) 
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Table 9.5 Associated risks of frequency of acid regurgitation symptoms with 
OAC by control group and time 
 
  Monthly or 
less 
Weekly/occ 
day 
Daily or 
greater 
Regurgitation 
in year prior 
to interview 
Community 
p=0.003 for 
trend 
1 1.18 (0.66-
2.12) 
10.33 (2.3-
46.32) 
p=0.002 
RO 1 0.72 (0.42-
1.24) 
0.81 (0.41-
1.6) 
BO 
P=0.001 for 
trend 
1 3.3 (1.4-7.78) 
p=0.006 
6.79 (1.5-
30.73) 
p=0.013 
Regurgitation 
10 years prior 
to interview 
Community 1 1.4 (0.76-
2.57) 
1.97 (0.69-
5.6) 
RO 
P=0.011 for 
trend 
1 1.8 (1.03-
3.14) p=0.04 
2.47 (0.95-
6.44) p=0.064 
BO 1 0.99 (0.48-
2.01) 
1.08 (0.35-
3.37) 
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At the time of interview (one year prior for OAC cases) OAC subjects were no 
more likely to be woken with nocturnal heartburn symptoms than community 
subjects OR 1.21 (0.74-1.99), or subjects with BO 0.93 (0.5-1.74), but less 
likely than RO subjects 0.53 (0.34-0.83) p=0.006. Ten years prior being 
woken by heartburn symptoms was more common among those with OAC, 
compared with community subjects 2.07 (1.23-3.48) p=0.006 and RO subjects 
3.45 (2.02-5.88), but no association with subjects with BO 1.05 (0.56-1.95). 
 
Being awoken by symptoms of acid regurgitation was more frequently 
observed among OAC subjects one year prior to interview than community 
subjects OR (95%CI) 2.25 (1.29-3.92) p=0.004, but no association with 
subjects with RO 0.77 (0.48-1.25) and BO 1.53 (0.8-2.94). Ten years prior to 
interview, OAC subjects were similarly more likely to be awoken by acid 
regurgitation symptoms than community subjects 2.19 (1.22-3.92) p=0.009 
and RO subjects 3.94 (2.23-6.98) p<0.0001, but no association seen with 
subjects with BO 1.2 (0.62-2.33). 
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Table 9.6 Associated risks of frequency of antacid use with OAC by control 
group and time 
 
  Monthly or 
less 
Weekly/occ 
day 
Daily or 
greater 
Antacid use 
in year prior 
to interview 
Community 
p<0.0001 for 
trend 
1 2.07 (1.27-
3.38) p=0.004 
6.41 (3.08-
13.35) 
p<0.0001 
RO 1 0.93 (0.58-
1.49) 
1.14 (0.67-
1.93) 
BO 
p=0.015 for 
trend 
1 3.08 (1.24-
7.66) p=0.015 
2.21 (0.93-
5.27) p=0.074 
Antacid use 
10 years prior 
to interview 
Community 
p=0.036 for 
trend 
1 1.79 (1.1-
2.92) p=0.019 
6.47 (3.11-
13.45) 
p<0.0001 
RO 
p=0.008 for 
trend 
1 1.3 (0.79-
2.14) 
2.18 (1.21-
3.91) p=0.009 
BO 1 0.82 (0.41-
1.66) 
0.74 (0.37-
1.49) 
 
 
  
 177 
Increasing use of OTC antacids was associated with OAC in comparison with 
community controls both currently and 10-years prior to the interview; similarly 
in comparison with subjects with RO 10 years ago, but not currently. There 
was also observed an increased association with use of antacids when 
compared with subjects with BO at time of interview Table 9.6). 
 
9.3.6.1 Multivariate analysis of gastro-oesophageal reflux symptoms 
Symptoms of gastro-oesophageal reflux were adjusted for the presence of 
H.pylori and smoking status, in comparison with all three-control groups. 
There was no alteration to the findings: ever experienced heartburn or acid 
regurgitation symptoms, being woken by heartburn or acid regurgitation, either 
currently or 10-years prior to interview. The OR did not alter to any significant 
degree, and there was no change in any of the statistical significances 
reported. 
 
9.3.8 Body parameters 
No association was observed between red and left hand dominance, nor with 
height and OAC with comparison with all three-control groups (table 9.7). Leg-
length, a marker of IGF-1 levels, showed no association with OAC in 
comparison with community subjects, but an increasing leg-length was 
associated with OAC in comparison with subjects with RO and those with BO 
(table 9.8). 
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Table 9.7  Odds ratio (95%CI) as estimate of association between height by 
quintile and oesophageal adenocarcinoma compared with all three-control 
group 
 
 
 
 
   
 Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Community 1 0.82  
(0.48-1.38) 
0.97  
(05-1.89) 
1.04  
(0.59-1.84) 
0.69  
(0.38-1.23) 
RO 1 1.42  
(0.78-2.61) 
1.35  
(0.76-2.38) 
1.78 (1-3.18) 
p=0.051 
1.38  
(0.75-2.56) 
BO 1 0.9  
(0.43-1.89) 
1.47  
(0.5-4.29) 
2.22  
(0.89-5.56) 
1.4  
(0.56-3.48) 
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Table 9.8  Odds ratio (95% CI) as estimate for the association of leg length by 
quintile (as a marker of IGF-1) with OAC, compared with all three control 
groups 
  
 Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Trend 
Community 1 1.33  
(0.75-
2.34) 
2.6  
(1.47-
4.58) 
1.39  
(0.81-
2.4) 
1.66  
(0.92-
2.97) 
p=0.083 
RO 1 1.86  
(0.98-
3.53) 
p=0.056 
3.23  
(1.73-
6.03) 
p<0.0001 
4.54  
(2.32-
8.88) 
p<0.0001 
6.24  
(3.23-
12.05) 
p<0.0001 
p<0.0001 
BO 1 2.96  
(1.39-
6.32) 
p=0.005 
3.43  
(1.43-
8.24) 
p=0.006 
11.57  
(4.05-
33.1) 
p<0.0001 
7.86  
(2.9-
21.28) 
p<0.0001 
p<0.0001 
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Increasing BMI was associated with OAC almost uniformly in comparison with 
all three-control subjects at all three time intervals, except in comparison with 
subjects with BO at the time of interview only, when no association was 
observed (table 9.9). Moreover, increasing waist circumference was 
associated with OAC in comparison with subjects with RO and BO, but not 
with community subjects (table 9.11). 
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Table 9.9 Odds ratio (95%CI) as estimate for association between BMI by 
quintile and OAC, in comparison with three control groups 
 
 
 
  
  Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Trend 
Current Community 1 1.05  
(0.58-1.88) 
1.43  
(0.8-2.56) 
1.77  
(1-3.14) 
p=0.049 
1.81  
(1.02-3.21) 
p=0.043 
p=0.009 
RO 1 0.8  
(0.44-1.47) 
1.09  
(0.6-2) 
1.52  
(0.83-2.75) 
1.79  
(0.98-3.27) 
p=0.058 
p=0.009 
BO 1 0.68  
(0.29-1.62) 
0.74  
(0.31-1.78) 
0.9  
(0.37-2.2) 
1  
(0.41-2.47) 
 
10 
years 
ago 
Community 1 1.26  
(0.69-2.29) 
1.87  
(1.05-3.35) 
p=0.034 
1.77  
(0.98-3.2) 
2.63  
(1.46-4.73) 
p=0.001 
p=0.001 
RO 1 1.33  
(0.72-2.47) 
1.34  
(0.73-2.48) 
3.05  
(1.64-5.67) 
p<0.0001 
3.05  
(1.64-5.67) 
p<0.0001 
p<0.0001 
BO 1 1.55  
(0.68-3.52) 
2.7  
(1.09-6.67) 
p=0.032 
1.41  
(0.62-3.17) 
2.11  
(0.89-5.01) 
p=0.09 
 
Aged 
18 
Community 1 1.27  
(0.71-2.28) 
1.11  
(0.62-1.99) 
1.86  
(1.05-3.3) 
p=0.033 
2.07  
(1.16-3.68) 
p=0.014 
p=0.005 
RO 1 1.5  
(0.81-2.8) 
1.67  
(0.92-3.01) 
1.96  
(1.08-3.55) 
p=0.027 
2.71  
(1.49-4.93) 
p<0.0001 
p=0.001 
BO 1 2.21  
(0.96-5.13) 
p=0.064 
1.43  
(0.64-3.18) 
2.66  
(1.11-6.39) 
p=0.029 
3.29  
(1.35-8.07) 
p=0.009 
P=0.01 
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Table 9.10  Odds ratio (95%CI) as estimate for association between waist 
circumference by quintile and OAC in comparison with control groups 
 
 
  
  Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Trend 
Current Community 1 0.82  
(0.47-1.43) 
1.4  
(0.78-2.49) 
0.84  
(0.42-1.68) 
1.54  
(0.89-2.69) 
 
RO 1 0.86  
(0.48-1.55) 
1.26  
(0.7-2.28) 
1.55  
(0.69-2.28) 
2.13  
(1.15-3.95) 
p=0.017 
p=0.007 
BO 1 1.21  
(0.54-2.68) 
1.77  
(0.76-4.1) 
1.85  
(0.78-4.43) 
4.25  
(1.18-15.35) 
p=0.027 
P=0.011 
10 
years 
ago 
Community 1 0.77  
(0.42-1.41) 
0.91  
(0.51-1.65) 
1.82  
(0.98-3.4) 
p=0.059 
1.34  
(0.75-2.41) 
p=0.055 
RO 1 0.64  
(0.35-1.19) 
1.36  
(0.71-2.6) 
2.27  
(1.15-4.49) 
p=0.018 
1.99  
(1.04-3.83) 
p=0.039 
p=0.001 
BO 1 1.04  
(0.46-2.33) 
2.53  
(0.96-6.65) 
3.04  
(1.26-7.31) 
p=0.013 
1.81  
(0.71-4.65) 
p=0.014 
Aged 
18 
Community 1 0.7  
(0.43-1.16) 
1.35  
(0.84-2.18) 
1.35  
(0.62-2.94) 
No 5th quintile  
RO 1 1.23  
(0.65-2.33) 
1.08  
(0.58-2.01) 
1.64  
(0.8-3.37) 
2.56  
(1.31-4.99) 
p=0.006 
p=0.005 
BO 1 0.99  
(0.43-2.31) 
1.12  
(0.48-2.62) 
2.33  
(0.96-5.64) 
1.65  
(0.47-5.83) 
p=0.06 
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9.3.9 Dietary intake 
Tables 9.11 And 9.12 show the median (IQR) frequency (number of days of 
the week) of dietary consumption by food type, and median (IQR) total weekly 
portion intake (tea and coffee by daily cup total). 
 
Increasing frequency of vegetable consumption ten years prior to interview, 
but not at time of interview, was negatively associated with OAC in 
comparison with community and BO subjects (table 9.13 ). Increasing 
frequency of fruit consumption (table 9.14) also was negatively associated 
with OAC, but both at time of interview and 10 years prior in comparison with 
community subjects and also with subjects with RO but only at time of 
interview, when there was also a negative association seen with fruit juice 
consumption (table 9.15) 
 
Frequency of potato consumption (table 9.16) showed a mix of results with 
some quartiles positively associated with OAC in comparison with all three-
control groups but only at the time of interview. Increasing red meat 
consumption frequency was positively associated with OAC, but only in 
comparison with community and RO subjects in the current time frame (table 
9.17). 
 
No associations were seen with poultry or fish frequency (tables 9.18 and 
9.19) or total weekly portion consumption (9.25 and 9.26). 
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Both fruit and vegetable consumption (tables 9.21 And 9.20) was negatively 
associated with OAC in comparison with community subjects only, and most 
notably fruit consumption with OR of 0.33 and 0.37 for the highest quintiles of 
consumption at time and 10-years prior to interview. While weekly total fruit 
juice consumption showed a negative association with OAC among 
community and RO subjects, it only reached significance in comparison with 
subjects with RO at time of interview (table 9.22) 
 
Increasing total weekly potato consumption is associated with OAC as 
compared with community subjects (reaching significance in the fourth and 
highest quintiles) and also with subjects with RO, but only at the time of 
interview (table 9.23. Red meat consumption was also positively associated 
with OAC, with second through to fourth quintiles, but not the highest and also 
in comparison with subjects with RO with third and fourth quintiles (table 
9.24). 
 
Finally, analysis of hot beverage consumption revealed an increasing positive 
association with OAC with cups of tea drunk (table 9.27), reaching 
significance in the highest quintile in comparison with community subjects at 
both time periods examined. Coffee consumption was only associated with 
OAC in comparison with subjects with BO and the third quartile, not the 
highest (table 9.28). 
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Table 9.11 Median (IQR) frequency of consumption of dietary components by 
group and by time 
Frequency of 
consumption  
(days) 
OAC Community RO BO 
Vegetable now 5 (3-7) 5 (4-7) 5 (3.5-7) 4 (3-6.8) 
Vegetables 10 
years ago 
5 (3-7) 5 (4-7) 5 (3.1-7) 4 (3-6) 
Potatoes now 5 (4-6) 5 (3-6) 5 (3-6) 5 (4-6) 
Potatoes 10 
years ago 
5 (4-7) 5 (4-6) 5 (4-7) 5 (4-7) 
Fruit now 4 (1-7) 7 (3-7) 5 (2-7) 4 (1-7) 
Fruit 10 years 
ago 
3 (1-6.8) 5 (2-7) 3 (1-7) 3 (0.6-6) 
Fruit juice now 0 (0-6) 1 (0-7) 1 (0-6.8) 0 (0-2.8) 
Fruit juice 10 
years ago 
0 (0-3) 0.5 (0-3) 0 (0-3) 0 (0-3) 
Red meat now 3 (2-4) 3 (2-4) 3 (2-4) 3 (2-4.8) 
Red meat 10 
years ago 
4 (3-5) 3 (2-4) 4 (2.1-5) 4 (3-5) 
Poultry now 2 (1-2) 2 (1-2) 2 (1-2) 2 (1-3) 
Poultry 10 years 
ago 
2 (1-2) 2 (1-2) 2 (1-2) 2 (1-3) 
Fish now 1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2) 
Fish 10 years 
ago 
1 (1-2) 1 (1-2) 1 (1-2) 1 (1-2) 
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Table 9.12 Median (IQR) weekly portion consumption of dietary components 
by group and time 
Weekly 
consumption  
(days) 
OAC Community RO BO 
Vegetable now 7.5 (4.5-14) 10 (6-14) 8 (5-14) 7 (3-12) 
Vegetables 10 
years ago 
8 (4.5-14) 10 (6-14) 8 (4.5-14) 6 (3.5-12) 
Potatoes now 6 (5-10) 6 (4-7) 6 (3.5-7.9) 6 (4-9.5) 
Potatoes 10 
years ago 
7 (5-12) 6 (5-10) 6 (4-10) 7 (4.3-10) 
Fruit now 6 (1-14) 9 (4-14) 7 (2.3-14) 4 (0-14) 
Fruit 10 years 
ago 
3 (1-12) 6 (2-14) 3 (2-12) 3 (0-7) 
Fruit juice now 0 (0-6.8) 1 (0-7) 1 (0-7) 0 (0-3.5) 
Fruit juice 10 
years ago 
0 (0-3) 0.5 (0-4) 0 (0-4) 0 (0-4) 
Red meat now 4 (2-5) 3 (2-5) 3 (2-5) 4 (2-6) 
Red meat 10 
years ago 
4 (3-6) 4 (2-6) 4 (3-7) 5 (3-10) 
Poultry now 2 (1-2) 2 (1-2) 2 (1-3) 2 (1-3) 
Poultry 10 
years ago 
2 (1-2.8) 2 (1-3) 2 (1-2.8) 2 (1-3) 
Fish now 2 (1-2) 2 (1-2) 2 (1-2) 1 (1-2) 
Fish 10 years 
ago 
1 (1-2) 1 (1-2) 1 (1-2) 1 (0-2) 
Tea now 
(cups/day) 
4 (2-6) 4 (2-5) 4 (2-6) 4 (2-6.8) 
Tea 10 years 
ago (cups/day) 
5 (3-7) 4 (2-6) 5 (2-7) 5 (2-6.8) 
Coffee now 
(cups/day) 
1 (0-3) 1 (0-3) 1 (0-2) 1 (0-3) 
Coffee 10 
years ago 
(cups/day) 
1 (0-4) 1 (0-4) 1 (0-3) 1 (0-5) 
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Table 9.13 Odds ratio (95%CI) as estimate for associated risk of frequency of 
vegetable consumption, by tertile and corrected by BMI, and OAC, in 
comparison with three control groups 
  
  Lowest ‘tile 2nd 3rd 
Current Community 1 1.09 (0.64-1.85) 0.72 (0.48-1.08) 
RO 1 0.77 (0.47-1.27) 0.82 (0.51-1.32) 
BO 1 1.05 (0.53-2.07) 1.48 (0.75-2.9) 
10 
years 
ago 
Community 1 0.62 (0.37-1.04) 
p=0.067 
0.64 (0.43-0.96) 
p=0.032 
RO 1 0.92 (0.55-1.53) 1.01 (0.62-1.65) 
BO 1 0.07 (0.55-2.09) 2.07 (1.02-4.2) 
p=0.044 
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Table 9.14 Odds ratio (95%CI) as estimate for associated risk of frequency of 
fruit consumption, by tertile and corrected by BMI, and OAC, in comparison 
with three control groups 
 
 
 
  
  Lowest ‘tile 2nd 3rd 
Current Community 1 0.49 (0.3-0.81) 
p=0.005 
0.35 (0.22-0.54) 
p<0.0001 
RO 1 0.58 (0.34-0.99) 
p=0.044 
0.61 (0.39-0.94) 
p=0.026 
BO 1 2.2 (0.98-4.93) 
p=0.056 
1.32 (0.71-2.45) 
10 
years 
ago 
Community 1 0.61 (0.36-1.02) 
p=0.059 
0.46 (0.31-0.69) 
p<0.0001 
RO 1 0.69 (0.41-1.15) 0.73 (0.46-1.17) 
BO 1 1.55 (0.74-3.26) 1.36 (0.6-3.06) 
 189 
Table 9.15 Odds ratio (95%CI) as estimate for associated risk of frequency of 
fruit juice consumption, by tertile and corrected by BMI, and OAC, in 
comparison with three control groups 
 
 
 
  
  Lowest ‘tile 2nd 3rd 
Current Community 1 0.76 (0.47-1.23) 0.78 (0.51-1.18) 
RO 1 0.87 (0.53-1.44) 0.62 (0.4-0.97) 
p=0.038 
BO 1 1.21 (0.54-2.69) 1.62 (0.85-3.09) 
10 
years 
ago 
Community 1 0.77 (0.47-1.27) 0.77 (0.51-1.16) 
RO 1 0.88 (0.51-1.53) 0.72 (0.46-1.12) 
BO 1 1.1 (0.49-2.44) 1 (0.53-1.89) 
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Table 9.16 Odds ratio (95%CI) as estimate for associated risk of frequency of 
potato consumption, by quartile and corrected by BMI, and OAC, in 
comparison with three control groups 
 
 
  
  Lowest ‘tile 2nd 3rd 4th 
Current Community 1 1.29 (0.8-2.09) 1.17 (0.7-1.96) 1.72 (1.05-2.83) 
p=0.032 
RO 1 1.57 (0.93-2.64) 
p=0.093 
1.72 (0.98-3.04) 
p=0.06 
1.331 (0.8-2.16) 
BO 1 1.43 (0.71-2.9) 2.61 (1.05-6.48) 
p=0.04 
1.72 (0.83-3.57) 
10 
years 
ago 
Community 1 0.93 (0.56-1.52) 0.86 (0.52-1.43) 1.19 (0.73-1.94) 
RO 1 1.28 (0.74-2.19) 1.27 (0.82-1.99) Distributed by 
tertile 
BO 1 0.87 (0.42-1.8) 1.24 (0.65-2.39) Distributed by 
tertile 
 191 
Table 9.17 Odds ratio (95%CI) as estimate for associated risk of frequency of 
red meat consumption, by quartile and corrected by BMI, and OAC, in 
comparison with three control groups 
 
  
  Lowest ‘tile 2nd 3rd 4th 
Current Community 1 1.95 (1.2-3.18) 
p=0.007 
1.76 (1.07-2.88) 
p=0.025 
2.04 (1.21-3.43) 
p=0.008 
RO 1 1.44 (0.86-2.4) 1.77 (1.03-3.04) 
p=0.039 
1.15 (0.68-1.95) 
BO 1 0.89 (0.43-
1.83) 
1.52 (0.66-3.49) 0.85 (0.4-1.81) 
10 
years 
ago 
Community 1 1.17 (0.75-
1.82) 
1.4 (0.78-2.5) 1.33 (0.7-2.53) 
RO 1 1.05 (0.65-1.7) 1 (0.58-1.75) 0.84 (0.45-1.55) 
BO 1 1.11 (0.53-
2.31) 
0.88 (0.4-1.98) 0.43 (0.2-0.92) 
p=0.03 
 192 
Table 9.18 Odds ratio (95%CI) as estimate for associated risk of frequency of 
poultry consumption, by tertile and corrected by BMI, and OAC, in comparison 
with three control groups 
 
 
  
  Lowest ‘tile 2nd 3rd 
Current Community 1 1.08 (0.72-1.62) 0.73 (0.44-1.21) 
RO 1 1.19 (0.78-1.83) 0.73 (0.44-1.24) 
BO 1 0.95 (0.5-1.81) 0.5 (0.25-1.02) 
p=0.057 
10 
years 
ago 
Community 1 0.85 (0.57-1.26) 0.73 (0.44-1.19) 
RO 1 0.92 (0.6-1.42) 0.9 (0.53-1.53) 
BO 1 0.87 (0.46-1.64) 0.54 (0.27-1.1) 
p=0.088 
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Table 9.19 Odds ratio (95%CI) as estimate for associated risk of frequency of 
fish consumption, by quintile and corrected by BMI, and OAC, in comparison 
with three control groups 
 
  
  Lowest ‘tile 2nd 3rd 
Current Community 1 0.93 (0.62-1.4) 0.64 (0.38-1.07) 
RO 1 1.01 (0.66-1.55) 0.71 (0.41-1.24) 
BO 1 1.03 (0.55-1.91) 0.78 (0.36-1.68) 
10 
years 
ago 
Community 1 0.87 (0.58-1.31) 0.88 (0.49-1.6) 
RO 1 0.78 (0.5-1.21) 0.55 (0.3-1.03) 
p=0.06  
BO 1 1.27 (0.65-2.47) 0.72 (0.32-1.65) 
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Table 9.20 Odds ratio (95%CI) as estimate for associated risk of total weekly 
vegetable consumption, by quintile and corrected by BMI, and OAC, in 
comparison with three control groups 
 
  
  Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Current Community 1 1.02  
(0.58-1.77) 
0.78  
(0.45-1.35) 
0.63  
(0.34-1.16) 
0.41  
(0.22-0.74) 
p=0.004 
RO 1 1  
(0.57-1.75) 
0.91  
(0.48-1.72) 
1.12  
(0.63-2) 
0.54  
(0.29-1.01) 
p=0.055 
BO 1 1.55  
(0.64-3.71) 
1.11  
(0.52-2.4) 
1.58  
(0.7-3.54) 
1.34  
(0.52-3.47) 
10 
years 
ago 
Community 1 0.71  
(0.41-1.23) 
0.72  
(0.42-1.23) 
0.54  
(0.29-1) 
p=0.051 
0.41  
(0.23-0.73) 
p=0.003 
RO 1 1.16  
(0.65-2.06) 
1.13  
(0.6-2.14) 
1.15  
(0.64-2.05) 
0.69  
(0.37-1.27) 
BO 1 1.32  
(0.56-3.12) 
1.23  
(0.58-2.62) 
1.47  
(0.67-3.24) 
2.57  
(0.87-7.55) 
p=0.086 
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Table 9.21 Odds ratio (95%CI) as estimate for associated risk of total weekly 
fruit consumption, by quintile and corrected by BMI, and OAC, in comparison 
with three control groups 
  
  Lowest 
quintile 
2nd 3rd 4th Highest quintile 
Current Community 1 0.5  
(0.28-0.87) 
p=0.014 
0.33  
(0.18-0.6) 
p<0.0001 
0.44  
(0.26-0.76) 
p=0.003 
0.33  
(0.19-0.59) 
p<0.0001 
RO 1 0.82  
(0.45-1.48) 
0.68  
(0.37-1.24) 
0.87  
(0.5-1.51) 
0.63  
(0.34-1.2) 
BO 1 3.82  
(1.22-12) 
p=0.022 
1.36  
(0.62-3.01) 
2.14  
(0.95-4.81) 
Distributed by 
quartile 
10 
years 
ago 
Community 1 0.44  
(0.25-0.77) 
p=0.004 
0.3  
(0.17-0.51) 
p<0.0001 
0.4  
(0.22-0.67) 
p=0.001 
0.37  
(0.18-0.74) 
p=0.005 
RO 1 0.58  
(0.33-1) 
p=0.051 
0.71  
(0.35-1.46) 
0.76  
(0.45-1.28) 
0.6  
(0.29-1.23) 
BO 1 1.34  
(0.58-3.08) 
0.91  
(0.39-2.11) 
2.13  
(0.9-5.07) 
p=0.087 
0.6  
(0.24-1.51) 
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Table 9.22 Odds ratio (95%CI) as estimate for associated risk of total weekly 
fruit juice consumption, by tertile and corrected by BMI, and OAC, in 
comparison with three control groups 
 
 
 
 
 
 
 
 
 
  
  Lowest 
tertile 
2nd 3rd 
Current Community 1 0.81 (0.5-1.31) 0.75 (0.5-1.14) 
RO 1 0.87 (0.53-1.44) 0.62 (0.4-0.97) 
p=0.038 
BO 1 1.72 (0.7-4.23) 1.37 (0.74-2.55) 
10 
years 
ago 
Community 1 0.75 (0.45-1.24) 0.76 (0.5-1.14) 
RO 1 0.9 (0.51-1.59) 0.7 (0.5-1.08) 
BO 1 1.69 (0.65-4.36) 0.84 (0.46-1.53) 
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Table 9.23 Odds ratio (95%CI) as estimate for associated risk of total weekly 
potato consumption, by quintile and corrected by BMI, and OAC, in 
comparison with three control groups 
  
  Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Current Community 1 1.21  
(0.69-2.12) 
1.42  
(0.76-2.64) 
2.08  
(1.18-3.64) 
p=0.011 
2.24  
(1.21-4.14) 
p=0.01 
RO 1 1.56  
(0.85-2.87) 
1.5  
(0.85-2.66) 
1.81  
(0.92-3.57) 
p=0.085 
2.2  
(1.15-4.2) 
p=0.017 
BO 1 1.73  
(0.82-3.64) 
1.7  
(0.63-4.55) 
1.17  
(0.51-2.68) 
1.92  
(0.81-4.55) 
10 
years 
ago 
Community 1 1.1  
(0.66-1.85) 
1.01  
(0.53-1.94) 
1.62  
(0.93-2.8) 
p=0.086 
1.87  
(0.99-3.55) 
p=0.054 
RO 1 1.6  
(0.91-2.79) 
0.9  
(0.46-1.78) 
0.66  
(0.93-2.95) 
p=0.087 
0.91  
(0.97-3.77) 
p=0.062 
BO 1 1.17  
(0.44-3.12) 
0.67  
(0.26-1.72) 
0.99  
(0.43-2.29) 
1.17  
(0.44-3.12) 
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Table 9.24 Odds ratio (95%CI) as estimate for associated risk of total weekly 
red meat consumption, by quintile and corrected by BMI, and OAC, in 
comparison with three control groups 
  
  Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Current Community 1 1.92  
(1.12-3.28) 
p=0.017 
2.3  
(1.36-3.88) 
p=0.002 
2.51  
(1.36-4.62) 
p=0.003 
1.6  
(0.92-2.77) 
p=0.096 
RO 1 1.48  
(0.84-2.59) 
2.42  
(1.35-4.35) 
p=0.003 
2  
(1.05-3.8) 
p=0.035 
1.09  
(0.61-1.92) 
BO 1 1.06  
(0.47-2.42) 
2.05  
(0.81-5.15) 
0.88  
(0.37-2.06) 
0.67  
(0.3-1.49) 
10 
years 
ago 
Community 1 1.27 
(0.72-2.25) 
1.62 
(0.93-2.8) 
p=0.088 
1.42 
(0.81-2.51) 
1.51 
(0.87-2.63) 
RO 1 1.28  
(0.75-2.16) 
1.25  
(0.6-2.62) 
0.91  
(0.48-1.73) 
0.98  
(0.51-1.89) 
BO 1 1  
(0.43-2.35) 
1.06  
(0.32-3.52) 
0.54  
(0.21-1.38) 
0.35  
(0.14-0.87) 
p=0.024 
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Table 9.25 Odds ratio (95%CI) as estimate for associated risk of total weekly 
poultry consumption, by quartile and corrected by BMI, and OAC, in 
comparison with three control groups 
 
  
  Lowest 
quartile 
2nd 3rd 4th 
Current Community 1 0.29 (0.03-2.63) 1.01 (0.66-1.53) 0.94 (0.52-1.7) 
RO 1 1.12 (0.72-1.75) 0.91 (0.56-1.49) Distributed by 
tertile 
BO 1 1.13 (0.57-2.25) 0.61 (0.27-1.4) 0.47 (0.21-1.07) 
p=0.071 
10 
years 
ago 
Community 1 0.85 (0.14-5.23) 0.94 (0.62-1.43) 0.73 (0.4-1.33) 
RO 1 0.94 (0.6-1.48) 0.98 (0.6-1.62) Distributed by 
tertile 
BO 1 1.08 (0.54-2.13) 0.5 (0.22-1.14) 
p=0.098 
0.69 (0.31-1.56) 
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Table 9.26 Odds ratio (95%CI) as estimate for associated risk of total weekly 
fish consumption, by tertile and corrected by BMI, and OAC, in comparison 
with three control groups 
 
 
  
  Lowest tertile 2nd 3rd 
Current Community 1 1.07 (0.71-1.62) 0.77 (0.47-1.24) 
RO 1 1.16 (0.75-1.79) 0.84 (0.5-1.4) 
BO 1 1.23 (0.65-2.31) 0.94 (0.46-1.95) 
10 
years 
ago 
Community 1 0.99 (0.65-1.49) 1.09 (0.66-1.82) 
RO 1 0.84 (0.54-1.32) 0.8 (0.47-1.39) 
BO 1 1.4 (0.72-2.74) 1.11 (0.52-2.4) 
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Table 9.27 Odds ratio (95%CI) as estimate for associated risk of total weekly 
tea consumption, by quintile and corrected by BMI, and OAC, in comparison 
with three control groups 
 
 
  
  Lowest 
quintile 
2nd 3rd 4th Highest 
quintile 
Current Community 1 1.22 
(0.69-2.13) 
0.98 
(0.57-1.68) 
1.66 
(0.86-3.21) 
2.02 
(1.11-3.67) 
p=0.022 
RO 1 0.83  
(0.49-1.41) 
1.09  
(0.58-2.05) 
1.16  
(0.65-2.09) 
1.13  
(0.63-2.03) 
BO 1 0.95  
(0.37-2.48) 
0.93  
(0.45-1.93) 
1.77  
(0.68-4.61) 
0.9  
(0.41-2.01) 
10 
years 
ago 
Community 1 1.37 
(0.74-2.54) 
1.52 
(0.93-2.5) 
p=0.095 
1.63 
(0.91-2.9) 
p=0.098 
2.27 
(1.32-3.92) 
p=0.003 
RO 1 1.09  
(0.62-1.92) 
1.99  
(1-3.97) 
p=0.052 
0.89  
(0.51-1.53) 
1.2  
(0.63-2.92) 
BO 1 1.55  
(0.68-3.55) 
0.76  
(0.34-1.71) 
1.52  
(0.66-3.48) 
1.32  
(0.53-3.3) 
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Table 9.28 Odds ratio (95%CI) as estimate for associated risk of total weekly 
coffee consumption, by quartile and corrected by BMI, and OAC, in 
comparison with three control groups 
 
 
  Lowest 
quartile 
2nd 3rd Highest 
quartile 
Current Community 1 0.84 
(0.51-1.39) 
1.35 
(0.74-2.47) 
1.18 
(0.63-2.21) 
RO 1 1.15  
(0.68-1.96) 
1.56  
(0.94-2.6) 
p=0.086 
1.44  
(0.84-2.49) 
BO 1 1.52  
(0.68-3.38) 
2.24  
(1.01-5) 
p=0.049 
1.23  
(0.59-2.57) 
10 
years 
ago 
Community 1 1.04 
(0.61-1.75) 
1.14 
(0.62-2.11) 
0.83 
(0.48-1.43) 
RO 1 1.24  
(0.72-2.16) 
1.42  
(0.83-2.43) 
1.47  
(0.88-2.44) 
BO 1 1.22  
(0.55-2.71) 
2.48  
(1.07-5.74) 
p=0.034 
0.69  
(0.34-1.4) 
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9.4 Discussion 
Recruitment met with the power calculation for number of OAC subjects, 
community subjects and with subjects with RO. Analysis of potential risk 
factors associated with OAC in comparison with subjects with BO is 
unfortunately underpowered due to the difficulties in recruiting incident cases 
of BO at the same time as an on-going drug intervention trial among these 
individuals (AspECT). Moreover, as not recruiting prevalent cases of BO, the 
numbers presenting were limited and unlike the low numbers of OAC, they are 
not routinely discussed in a multi-disciplinary meeting were they can be easily 
identified. As anticipated the vast majority of OAC subjects were male, with a 
median age matching that seen in the study of incidence of OAC in the West 
Midlands (Chapter 4). The disease was predominantly seen among the 
Caucasian population with very few ethnic cases. 
 
Intriguingly no association was observed with the presence of H.pylori, with 
the prevalence of the infection 31.1-35.9% across all groups. This is in 
contrast to previous studies, and a lower prevalence is observed among the 
population studied than expected (Murray et al., 1997). While a low response 
rate among community subjects may introduce a degree of selection bias, 
there were much better response rates seen among the subjects with RO and 
BO, yet no association was identified. This suggests that selection bias may 
not a major confounding factor, but should be acknowledged. This may be a 
reflection of the testing method employed, as serological testing only reflects 
the last two years of life; a negative test may not represent H.pylori infection 
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that has been eradicated over two years prior. No association was observed 
with cagA status of H.pylori. 
 
In keeping with previous data (Chapter 4), there was no association with 
socio-economic status and OAC. We hypothesis that the association of 
H.pylori with deprivation as a potential protective factor may be offset by the 
better dietary habits seen among the more affluent, resulting in a lack of 
association with socio-economic status and OAC. 
 
The impact of smoking is clearly a deleterious one with between a two- to 
four-fold increased risk of OAC observed with current smoking when 
compared with all control groups. While being an ex-smoker reduced this 
association, a significant positive association remained with OAC in 
comparison with all three-control groups. There is also a clear dose-response 
seen with positive association seen with duration of smoking and amount 
smoked per day. While this study does not examine the mechanism of action, 
we have adjusted symptoms of gastro-oesophageal reflux for smoking, and no 
appreciable change was observed, suggesting that smoking has not impacted 
upon oesophageal function, TLOSRs and clearance of acid refluxate from the 
oesophagus to a significant level. However, as noted, smokers may 
appreciate symptoms of reflux less than non-smokers, thus masking effects of 
smoking upon GORD rather than symptoms as analysed. Performing 
oesophageal pH monitoring was not feasible during this study. The role of 
direct action of nitrosamines and polycyclic aromatic hydrocarbons as 
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carcinogenic agents must play an important role (McKnight et al., 1999, 
Kamangar et al., 2009), especially as some of the inhaled smoke is likely to 
be swallowed and reach the oesophagus in saliva. 
 
No association was observed with alcohol consumption status, duration of 
consumption and amount drunk and OAC in comparison with subjects with 
RO and BO. However, in comparison with community subjects, being a 
current drinker of alcohol revealed a negative association with OAC, together 
with a decreasing negative association with duration of consumption of 
alcohol, except for the highest quintile of duration. Previous studies have 
found a mixture of associations, and MOSES adds to these findings 
(Freedman et al., 2011) 
 
Symptoms of heartburn and acid regurgitation are associated with OAC in 
comparison with community controls, suggesting a direct action of acid upon 
the oesophageal mucosa. Moreover the increasing positive association seen 
with frequency of symptoms and duration strengthens the finding, and the 
significant association with nocturnal waking is in keeping with studies 
showing that nocturnal oesophageal acid exposure is more likely to result in 
complications from GORD (Robertson et al., 1987). The absent or negative 
association of ever having had heartburn or acid regurgitation symptoms may 
be in part due, at least among the BO subjects, the reduced ability for 
columnar-lined mucosa to produce symptoms in response to low pH (Byrne et 
al., 2003). Furthermore, these groups of individuals are more likely to be on 
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formal acid suppressing medication such as PPI masking any symptoms. 
Despite this suggestion, increasing duration of heartburn and acid 
regurgitation symptoms, and frequency of symptoms, are associated with 
OAC in comparison with subjects with RO and BO. The use of antacids for 
symptoms is increasingly associated with OAC, strengthening the aetiology of 
GORD in OAC. 
 
Several factors influence gastro-oesophageal reflux, with chronic H.pylori 
leading to atrophic gastritis and reduced gastric acid production, and thus less 
symptomatic gastro-oesophageal reflux (Richter et al., 1998). Smoking also 
reduces LOS pressures, increases TLOSRs, and with coughing and reduced 
salivation reducing clearance of oesophageal acid clearance, may increase 
oesophageal acid exposure (Kahrilas and Gupta, 1990, Pandolfino and 
Kahrilas, 2000). Statistical methods employed to correct for these potential 
confounding, but little change was seen with the OR derived, and no change 
to the overall findings and their statistical significance. 
 
With the general population heights increasing over the last 50 years, and 
OAC incidence rising at the same time, hypotheses have been made that the 
increased acid exposure seen among taller individuals may lead to greater 
oesophageal acid exposure in those with GORD (Axon, 2004). We failed to 
reveal any association in the current study. It was however observed that 
increasing leg length was associated with OAC in comparison with subjects 
with RO and BO, but not community subjects. It has previously been identified 
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that leg length is a marker pre-pubertal growth and of IGF-1 levels (Sheppard, 
2004). OAC cell lines have increased proliferation when exposed to IGF-1, 
and OAC patients with higher IGF-1 levels have a worse prognosis 
(Donohoe., et al, 2012, Doyle et al., 2012) 
 
Previous research has shown an association with increasing BMI and both 
OAC (Engel et al., 2003) and BO (Stein et al., 2005). The current study has 
observed similar findings with an association of increasing BMI and OAC with 
comparison to community and RO subjects. While no association is observed 
in comparison with BO at the time and 10 years prior to the interview, an 
association is seen at the age 18. This suggests that the impact of increased 
BMI is earlier in the reflux to RO to BO to OAC sequence. Obesity is noted to 
be strongly associated with hiatus hernia (Stene-Larsen et al., 1988), a known 
precipitant of GORD, but other mechanism of increasing reflux such as 
increasing intra-abdominal pressure is less well substantiated (Gordon et al., 
2004). The association with increasing waist circumference and OAC 
compared with subjects with RO and BO suggests that visceral adiposity is 
key in the effects seen with increasing BMI, but not in comparison with 
community subjects where IGF-1 may not have any effect. It is noted that 
visceral adiposity leads to increased IGF-1 levels, known to reduce apoptosis 
and increasing OAC cell proliferation (Sheppard, 2004). 
 
Most of the associations with diet and OAC are apparent in comparison with 
community and RO subjects, suggesting that the effects of diet are negligible 
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at the stage of BO, or that insufficient power has been achieved with the low 
number of subjects with BO. In keeping with previous case-control studies, 
diet high in fruit and vegetables (frequency and total weekly portion quantity), 
especially fruit is negatively associated with OAC. The presence of 
phytoprotectants such as isothiocyanates and indol-3-carbinols and diets high 
in fibre have proven mechanism of action in apoptosis (Myzak and Dashwood, 
2006, Kim and Milner, 2005, Tzonou et al., 1996). If the theory that increased 
fertiliser use in the latter half of the 20th century has led to increased nitrate 
concentration in crops, led to increased nitrosative stress in the oesophagus 
and thus increased incidence of OAC were to be true, then it would be 
reasonable to expect a positive association with fruit and vegetables. The 
nitrosative stress theory may hold more truth with the nitrates present in red 
meat. The current study revealed a positive association with red meat. 
Heterocyclic amines and polycyclic hydrocarbons, known to be carcinogenic, 
are produced when cooking meat at high temperatures (Kubo et al., 2010); 
the method of cooking was not examined in this study. A further explanation is 
the high saturated fat content of meat, known to be associated with OAC 
(Mayne et al., 2001) 
 
No association was seen with OAC and dietary poultry and fish intake. The 
effect of n-3 fatty acids is of interest, and has been studied in BO (Mehta et 
al., 2008). However, n-3 fatty acids are seen greatest in oily fish such as 
salmon, mackerel, sardines and fresh tuna. The interview did not differentiate 
type of fish, and thus unable to examine this. 
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Increasing tea consumption, notably the highest quintile in comparison with 
community subjects is associated with OAC, presumably by the known effects 
of relaxing the LOS, and allowing greater reflux of gastric contents. The 
impact of coffee was only noted among subjects with BO and is not powered 
fully, especially with tea being a more common hot beverage than coffee. 
 
Dietary analysis is subject to much confounding with re-call bias as a key 
issue. By examining reproducibility of the interview, showing moderate to 
substantial agreement, we have attempted to overcome this, but it still 
remains as confounding, but should affect all subjects equally. The reflux 
section of the interview has already been validated previously. By censoring 
the last year before diagnosis of cancer, we aimed to have overcome the 
influence of cancer upon the diet and other factors such as BMI. Finally, while 
correction for BMI has occurred in the dietary intake analysis, it is ideal to 
adjust dietary intake by total energy expenditure to provide a more exact 
appreciation of any potential associations (Willett and Stampfer, 1986, Willett 
et al., 1997). It was felt however that any attempt to estimate total energy 
expenditure would be subject to too many inaccuracies and confounding to be 
able to include in this study. 
 
In summary, with a lower than expected prevalence of H.pylori, no association 
with OAC was observed. Increasing BMI and waist circumference, as a 
marker of visceral adiposity and thus IGF-1 is associated with OAC, as is 
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increasing leg length, a marker of IGF-1, known to promote oncogenesis, 
among those with sequalae of GORD. Increasing BMI may also influence the 
positive association by increasing the prevalence of hiatus herniation and thus 
predisposing to gastro-oesophageal reflux, the symptoms of which has been 
identified in this study to be strongly associated with OAC. Smoking is clearly 
implicated in the aetiology of OAC with a dose-response effect observed. 
Alcohol may have negative associations with OAC, but results are mixed, as 
is the current literature. Finally a diet high in fruit and vegetables, especially 
fruit has negative associations with OAC and plausible mechanisms already 
established. Similarly, dietary intake high in red meat also has proven 
biochemical mechanisms of action in the positive association with OAC. 
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Chapter 10 
 
Conclusions and Implications 
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10.1 Conclusions and Implications 
 
The aetiology of OAC is the subject of much interest as the rapidly increasing 
incidence over the last 30 years remains largely unexplained, most notably 
the predominance of the disease among white men. While many studies have 
examined the aetiology, many are underpowered due to the relatively low 
incidence in some of the countries in which the research is based. The UK 
has the highest incidence of OAC, but there are very few studies based in 
England. 
 
10.2 Summary of findings 
Table 10.2 illustrates the summary of findings examined in more than one 
study in order to allow comparison of findings. The median age, and gender 
predominance is clearly observed to be very similar in all studies, with the 
majority of subjects noted to be Caucasian. Consistent positive associations 
were seen with increasing BMI and smoking with OAC, less consistent with 
height and leg length as a surrogate of IGF-1, while negative associations 
(e.g. aspirin, NSAID and PPI use) are discussed in more detail as less 
consistent across the studies. Some factors were examined in only one or two 
of the studies in this thesis but provide the hypothesis for further investigation, 
for example the reduce incidence in OAC following a diagnosis of PC was 
observed in both WMCIU and SEER datasets, and the negative association 
seen with the use of statins. Increasing positive associations were observed 
with drugs used for COPD and those with a side effect of relaxing the LOS, 
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but only in the THIN nested case-control study. Furthermore MOSES revealed 
a positive association with GOR symptoms, increasing quantities of red meat 
and tea consumption and a negative association with fruit and vegetable 
consumption. 
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Table 10.2 Summary of factors examined in multiple studies 
 
 WMCIU data THIN Nested case-control THIN case control MOSES 
Median age (IQR) 70 (61-77) 67 (59-73) 69 (59-77) 68 (60-75) 
Gender 4-5 fold men 84% male 82% male 85% male 
Socioeconomic 
status 
No association No association No association No association 
Height N/E N/E +ve association none for height, 
+ve for leg length 
BMI N/E No association +ve association +ve association 
Smoking status N/E +ve association  +ve association +ve association 
Alcohol consumption N/E N/E N/E -ve association 
PPI use N/E No association Mixed N/E 
Aspirin/NSAIDS N/E No association Some –ve association N/E 
N/E: not examined
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10.3 Discussion 
By examining the WMCIU database, the incidence of OAC in comparison with 
OSCC has been observed to be rising rapidly among both men and women, 
but most notably men, rising to almost 9 per 100 000 at the end of the study 
period. The age of diagnosis has increased, but is approximately 8 years later 
among women. The median ages in the WMCIU data were in keeping entirely 
with the nested case-control study of subjects with BO developing OAC, the 
THIN case-control study and also MOSES, being 67-69 years of age, and 
male predominant. Indeed male predominance while noted among subjects 
with BO, was a significant risk factor in the progression to OAC. 
 
A handful of studies in the literature have reported association with 
industrial/occupational exposure and OAC, it is not sufficient to explain the 
difference observed. By examining men with a diagnosis of PC, an androgen 
sensitive tumour, the influence of male sex hormones could be examined 
through epidemiological methods. The data from the WMCIU raised the 
hypothesis that anti-androgen therapy employed in the treatment of PC 
(medical or surgical) may be the reason by the reduced incidence of OAC in 
men with a first diagnosis of PC, but was unable to reveal a latency effect of 
longer duration of anti-androgen having a greater negative impact upon the 
incidence of OAC. By examining the SEER 9 registries dataset from the USA, 
almost ten times the number of subjects with PC were identified, increasing 
the number of patient years to over 2 million. A latency effect was thus 
demonstrated, but not only among subjects with OAC, but also OSCC. 
 216 
Androgen receptors have been identified on both OAC and OSCC cells (Awan 
et al., 2007, Tihan et al., 2001, Waraich, 2008), and with this explanation 
being still plausible, although it is noted that there is little differentiation in 
incidence of OSCC between the genders, but other factors such as smoking 
and alcohol are much more influential in the aetiology of OSCC. 
 
A further explanation for male predominance in this cancer is the pattern of 
male obesity. Male pattern obesity is defined by an increase in visceral 
adiposity. This is associated with a greater incidence of hiatus herniation that 
predisposes to gastro-oesophageal reflux, known to be an important 
aetiological factor inn OAC. Furthermore, visceral adiposity is biochemically 
more active than subcutaneous fat, and linked with high levels of IGF-1. IGF-1 
is noted to influence cell proliferation and apoptosis, having an increase in 
oncgenesis (Sheppard, 2004). Increasing BMI was associated with OAC in 
both the THIN case-control study and MOSES. More importantly, in the 
MOSES study, an increase in reported waist circumference was associated 
with OAC, but only among subjects with RO and BO. The lack of association 
seen with waist circumference and OAC in comparison with community 
subjects adds to the conjecture that IGF-1 levels in the stressed oesophageal 
mucosa may have a key role as well as the effect of increasing reflux. This 
statement however does require substantiation and further investigation, and 
currently remains as a hypothesis for future work. 
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Association with height and OAC was assessed in both the THIN case-control 
study and MOSES. While no association was observed in MOSES, increasing 
leg length was associated with OAC. Furthermore, increasing height was 
associated with OAC in comparison with all three-control groups in THIN 
case-control study. One explanation for this is that those subjects with 
increasing height have greater gastric acid production (Axon, 2004), leading to 
a greater degree of oesophageal acid exposure should reflux occur. It is noted 
that population heights have been steadily increasing at the same time that 
OAC incidence has been rising. It is notable though that leg-length is a marker 
of pre-pubertal growth, and as such is a surrogate marker for IGF-1 
(Sheppard, 2004). Leg length is a significant contributor for height, and 
therefore the observation in the THIN case-control study may be a marker of 
leg length. A potential role for raised IGF-1 levels in the aetiology of OAC is 
postulated, but remains a hypothesis for future study. 
 
The impact of smoking is well established in the aetiology of OSCC, but is 
more modest in that of OAC. Both case-control studies have revealed a strong 
association with smoking, with MOSES revealing a clear dose-response 
effect. The carcinogens in tobacco are likely to influence the oncogenic 
process (McKnight et al., 1999, Kamangar et al., 2009), but it is noted that 
smoking does reduce LOS pressures, increase TLOSRs (although not 
associated with reflux), reduced saliva and thus clearance of oesophageal 
refluxate and causes reflux through coughing (Kahrilas and Gupta, 1990, 
Pandolfino and Kahrilas, 2000). However, when the association of reflux 
 218 
symptoms and OAC were examined in MOSES, adjusting for smoking made 
very little difference to the overall OR and levels of significance. Importantly 
having ever smoked is a risk factor for progression from BO to OAC in the 
THIN nested case-control study and both the THIN case-control and MOSES 
studies show a much-reduced association with being an ex-smoker as 
compared with a smoker. Smoking cessation may therefore be a key 
modifiable risk factor in the aetiology of OAC, and should be actively 
encouraged, especially among individuals with BO. 
 
Only one of the studies examined the influence of H.pylori and despite being 
suitably powered, no association with OAC was observed. There was a lower 
than expected prevalence of infection among control subjects and a higher 
than expected prevalence among subjects with OAC. Furthermore, adjusting 
statistical analysis for reflux symptoms with the presence or absence of 
infection did not alter the outcome, suggesting that H.pylori not only had little 
association with OAC, but also that few subjects reflux symptoms were 
affected by the bacteria. 
 
In keeping with the literature, reflux symptoms were associated with OAC, 
with respect to presence, frequency and duration, including markers of 
severity (nocturnal symptoms). While there was a less clear association with 
comparison with subjects with RO and BO, this is in part due to the likely 
universal symptom experienced among those diagnosed with RO, and the 
potential use of acid suppression medication that was observed almost 
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universally among the nested case-control study subjects with BO. The THIN 
case-control study too identified that use of acid suppressing drugs, PPIs, 
were associated with OAC in comparison to community subjects, suggesting 
that reflux symptoms were more apparent in the OAC subjects. Furthermore, 
analysis of antacid use was examined in MOSES and seen to be positively 
associated with OAC, further revealing the severity of acid reflux symptoms. 
 
The nested case-control study of subjects with BO revealed that an increasing 
number of drugs with associated side effects of relaxation of the LOS, and 
thus promoting gastro-oesophageal reflux, was associated with progression to 
developing OAC. Furthermore, this study revealed that use of inhaled 
steroids, and the increasing number of drugs taken for asthma/COPD were 
associated with progression to OAC. The effects were not due to that of 
smoking as the association remains after statistical adjustment for this 
potential confounding. This suggested that either the drugs themselves (β-
blockers and theophyllines) were reducing the LOS pressure (but is not 
supported by the association seen with inhaled steroid use) or that the 
disease the drugs were prescribed for was part of the aetiology for oncogenic 
progression. There is evidence in the literature that coughing and asthma may 
be associated with increasing reflux into the oesophagus (Vaughan et al., 
1998), thus strengthening further the evidence for the strong aetiological 
influence of gastro-oesophageal reflux in the development of OAC.  
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Examining the aetiology of any cancer is most fruitful when a potential 
modifiable risk factor is identified, and thus suitable for consideration in 
therapeutic interventional drug trials. The use of aspirin has good biochemical 
mechanisms but no association was observed in the nested case-control 
study examining risk factors associated with the progression of BO to OAC. 
However, a negative association with aspirin and with NSAIDs was observed 
in the THIN case-control study, offering hope of a chemotherapeutic option in 
those most at risk. The results of AspECT, an on-going prospective aspirin 
and PPI intervention trial among subjects with BO should provide more 
conclusive evidence (Jankowski and Moayyedi, 2004). 
 
A further class of drugs were identified to be negatively associated with OAC 
in the THIN case-control study: statins. Statins have been shown at the 
cellular level to reduce cell proliferation and induce apoptosis in BO cell lines 
(Sadaria et al., 2011, Ogunwobi and Beales, 2008, Konturek et al, 2007), and 
reduce overall cancer development (Graaf et al., 2004). Mixed results have 
been seen in epidemiological studies of the aetiology of OAC, but the current 
finding is as strong as that of aspirin and NSAIDs, suggesting the potential for 
further investigation with chemotherapeutic trials of statins. 
 
One of the biggest modifiable risk factors for cancers, second only to smoking, 
is the diet (Doll, 1992). Dietary examination is fraught with difficulties and 
confounding, with recall bias, correction for total energy expenditure, and 
consistency with portion size. Only one of the epidemiological studies was 
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geared to analysing diet: MOSES. While inconsistencies were observed, it is 
evident that a diet high in fruit and vegetables, especially fruit, was negatively 
associated with OAC, and diet high in red meat was positively associated with 
OAC. These associations are backed up with plausible mechanisms of action, 
with fruit and vegetables being high in phytoprotectants and fibre, both shown 
to protect against cellular damage (Myzak and Dashwood, 2006, Kim and 
Milner, 2005, Tzonou et al., 1996), and red meat, especially if cooked over an 
open-flame is high in heterocylic amines and polycyclic aromatic 
hydrocarbons, known carcinogenic agents, that increase nitrosative stress at 
the lower oesophagus (Kubo et al., 2010). We did not examine cooking 
methods. Furthermore, in comparison with community subjects at least, high 
consumption of tea was identified to be positively associated with OAC, and 
coffee to a certain extent with comparison with subjects with BO. Both tea and 
coffee contain caffeine known to relax the LOS. 
 
While we have identified a statistically significant negative association with 
consuming alcohol and duration of the drinking habit and OAC (in comparison 
with community controls) there are mixed results in other published studies. 
The OR produced however is quite strong however the mechanism of action 
is not understood and may be as a result of confounding, thus limiting the 
ability to employ alcohol as a modifiable risk factor in the aetiology of OAC at 
this stage. 
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The use of postcode has enabled examination of socioeconomic status with 
the Townsend index in several of the studies in this thesis: WMCIU database, 
THIN case-control study and MOSES. The findings were consistent across 
the studies, with no association observed between socioeconomic status and 
OAC. While the Townsend index is based on material wealth, the IMD is 
based more on benefits and allowances. The IMD also revealed no 
association between OAC and socioeconomic status (WMCIU data) further 
confirming the findings by different methodology. The lack of association is 
likely to be the mix of different aetiological factors, for example with negatively 
associated factors, diets high in fruit and vegetables are more likely to be 
seen among the affluent, while H.pylori is more common among the deprived.  
 
Examination of the WMCIU data from 1977-2004 confirms the rapidly 
increasing rise in incidence of OAC, and while not examined, many of the 
associations revealed have changed in prevalence of the last few decades. 
BMI and waist sizes have been increasing leading to a greater likelihood of 
hiatus hernia development and GORD, as has height. With leg length being 
part of height a plausible impact of IGF-1 is implicated, along side that with 
visceral adiposity. Since the discovery of H.pylori and its role in gastro-
duodenal ulceration and gastric cancer, the medical world has sought to 
eradicate the bacteria whenever symptoms or pathology present. 
Furthermore, while the consumption of fruit has not altered significantly, green 
vegetables are eaten to a lesser degree as compared with several decades 
ago (Office of National Statistics). 
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As well as offering the basis for hypotheses to be tested by drug intervention 
trials, for example aspirin/NSAIDs and statins, the results of this thesis offer 
the potential for identifying those at greater risk of developing OAC, and 
increasing the screening or surveillance. The surveillance of those individuals 
with BO is contentious currently, and while studies such as BOSS are due to 
report on the value of surveillance, identification of risk factors in the 
development of OAC may enable stratification of potential surveillance 
programmes. Finally, data revealing modifiable risk factors enables clinicians 
to counsel patients and empower them to take control of their chances of 
developing this rapidly rising cancer with poor prognosis.  
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Appendix 1 Statistaical programming for calculating SIR following 
a diagnosis of oesophageal cancer following proastet cancer using 
STATA (chapters 5-6) 
 
 
Change available memory: 
set mem 200m 
 
Import ref rates data into Stata: 
insheet using “Z:StataData\listratesmale.csv” 
 
Rename year Calendar_year 
gen year=Calendar_year-1900 
 
To sort ref_rates: 
sort age year 
 
Save ref rates: 
save male_ref_rates.dta 
 
Clear 
 
Imprt cases: 
insheet using “Z:StataData\Prostate1stPrimary.csv” 
 
To format dates: 
gen diagdate = mdy(diag_month, diag_day, diag_year) 
format diagdate %dD_m_CY 
 
reason: 
gen reason = 6 if nd_primary == ”Death” 
replace reason = 6 if nd_primary == “NSTS Death” 
replace reason = 0 if nd_primary == “Withdrawn” 
replace reason = 4 if substr(nd_primary,1,1) == “C” 
replace reason = 1 if c15morph == “Adeno” 
replace reason = 2 if c15morph == “Squamous” 
replace reason = 3 if c15morph == “Other” 
 
Save cohort data: 
Save prostatecohort.dta 
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To calc Observed pop and SIR (changing enter and exit times): 
use prostatecohort 
 
stset eofu, failure(reason=1-3) enter(time diagdate + 90) exit(time 
diagdate + 365.25) 
origin(time dob) scale(365.25) id(id) 
stsplit, at (0(5)85) 
stsplit year, after(time=d(01jan1900)) at(77(1)104) 
gen Y = _t - _t0 
gen D = _d 
sort age year 
merge age year using male_ref_rates 
keep if _merge == 3 
 
gen Expected = Y*oseo/malepop 
 
gen O 
egen E = sum(Expected) 
gen SIR = O/E 
 
local dflo = 2*O 
local dfhi = 2*O + 2 
scalar SIRLx = 0.5*invchi2tail(‘dflo’, 0.975)/E 
scalar SIRUx = 0.5*invchi2tail(‘dflo’, 0.025)/E  
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Appendix 2 General practices recruiting for MOSES 
 
 
Hospital GP1 GP2 GP3 
 
City Dr DK Nandi Dr Lawrence F Miller Dr David Child 
 Tower Hill Medical 
Practice 
Sherwood House Medical 
Practice 
Cape Hill Medical Practice 
 25 Tower Hill 9 Sandon Road Raglan Road 
 Great Barr B42 1CG B17 8DP Smethwick 
    
    
    
Sandwell Dr Keith Holtom Dr Catherine Swain Dr John Gilbert 
 Oldbury Health Centre Neptune Health Park Linkway Medical Practice 
 Albert Street Sedgley Road West Lyng Centre 
 Oldbury Tipton Frank Fisher Way 
 B69 4DE DY4 8PX West Bromwich 
   B70 7AW 
    
Russell's Hall Dr Jonathan Darby Dr Nancarrow Dr Dominic Faux 
 St Margaret's Well 
Surgery 
Worcester Street Surgery Albion House Surgery 
 2 Quarry Lane 24 Worcester Street Albion Street 
 Halesowen Stourbridge Brierley Hill 
 B63 3WD DY8 1AW DY5 3EE 
    
    
    
Walsall 
Manor 
Dr Angela Haire Dr Moszuto Dr Julie Harrison 
 Lichfield Street Surgery Little London Surgery Portland Medical Practice 
 19 Lichfield Street Little London   Anchor Meadow Health Centre 
 Walsall Caldmore Westfield Drive 
 WS1 1UG Walsall Aldridge 
  WS1 3EP Walsall 
   WS9 8AJ 
    
    
New Cross Dr Angus Jones Dr Robert Stoves Dr Peter Maidment 
 Dale Medical Practice The Health Centre Bilbrook Medical centre 
 Planks Lane Alfred Squire Road Brookfield Road 
 Wombourne Wednesfield Bilbrook 
 Wolverhampton Wolverhampton Codsall 
 WV5 8DX WV11 1XU Wolverhampton 
   WV8 1DX 
    
    
UHB Dr Chris Leigh Dr Patrick Ireland Dr Roger Light/Phil Saunders 
 Wychall Lane Surgery Selly Park Surgery Ridgeacre House Surgery 
 11 Wychall Lane 2 Reaview Drive 83 Ridgeacre Road 
 Kings Norton Pershore Road Quinton 
 Birmingham Selly Park Surgery Birmingham 
 B38 8TE Birmingham B32 2TJ 
  B29 7NT  
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Alexandra Dr Philip Clamp Dr Sian Hotham Dr C Mark Johnstone 
Redditch St John's Surgery New Road Surgery Elgar House 
 5 Kidderminster Road 46 New Road Church Road 
 Bromsgrove Bromsgrove Redditch 
 B61 7JJ B60 2JS B97 4AB 
    
    
    
    
    
Warwick Dr Nigel Wood Dr Mark Palmer Dr Richard Seymour-Mead 
 Arden Medical Centre Emscote Road Surgery Henley-in-Arden Medical 
Centre 
 Albany Road 88-90 Emscote Road Prince Harry Road 
 Stratford-upon-Avon Warwick Henley-in-Arden 
 CV37 6PG CV34 5QJ Warwickshire 
   B95 5DD 
    
    
    
    
Good Hope Dr Vivian Boss Dr Broomhead Dr Blake 
 Aldergate Medical 
Practice 
Hawthorns Surgery Poplar Surgery 
 Salters Lane 331 Birmingham Road 17 Holly Lane 
 Tamworth Wylde Green Erdington 
 B79 8BH Sutton Coldfield B24 9JN 
  B72 1DL  
    
    
    
Heartlands  Dr Anand Chitnis Dr Liz Nyholm Dr Irvine Stuart 
 The Castle Practice Yardley Green Medical Practice The Blythe Practice 
 2 Hawthorne Road 73 Yardley Green Road 1500 Warwick Road 
 Castle Bromwich Bordesley Green Solihull 
 B36 0HH B9 5PU B93 9LE 
    
    
    
    
Walsgrave Dr Ham Dr Jane Smith Dr David Shore 
 Central Surgery Mansfield Medical Centre The Revel Surgery 
 Corporation Street 56 Binley Road Barr Lane 
 Rugby Coventry Brinklow 
 CV21 3SP CV3 1JB CV23 0LU 
    
    
    
Burton    
 Gorden Street Surgery   
 Burton-on-Trent   
 Staffordshire   
 DE14 2JB   
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Appendix 3 
Geographical distribution of recruiting hospitals and associated general 
practice surgeries across the West Midlands  
 260 
                                                    
 
 
Diet and Lifestyle Questionnaire 
 
 
Midlands Oesophageal Adenocarcinoma Epidemiology Study 
 
(Version 2   27/01/2006) 
 
 
 
 
 
 
 
 
 
Department of Gastroenterology 
Sandwell General Hospital 
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SECTION A: BACKGROUND INFORMATION 
 
 
1. Reference Number:….……………….. 
 
2. Date of interview:………………… 
 
3. Interviewer: …………………………… 
 
4. Status:    Cancer       Oesophagitis       Barrett’s oesophagus        Control 
 
5. Sex:        Male          Female 
 
6. Date of Birth:  ……………………… 
 
7. Postcode:  ……………………………. 
 
8. Postcode 10 years ago:  ………………………. 
 
9. How would you describe your ethnic or racial origin? (Tick one) 
 
  White      Black (Caribbean) 
  
  Black (African)    Black (Other) 
  
  Indian      Pakistani 
 
  Bangladeshi     Chinese 
  
  Other – please specify  ……………………………………….. 
 
 
10. Consultant:  …………………………….. 
 
11. Hospital: ……………………………….. 
 
12. Hospital number: ……………………… 
 
13. Patient’s name: ………………………… 
 
14. Pathology reference number: …………. 
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SECTION B: DIET HISTORY 
 
For each question, please consider current consumption (or in cancer patient: 
consumption in the 12-month period up to about one year ago), and consumption 10 
years ago. 1 portion is hand palm size. 
 
1. How many days of the week did/do you eat fresh vegetables other than potatoes? 
 Current:……………………………………. 
 10 years ago:………………………………. 
 
2. How many portions per day of fresh vegetables other than potatoes did/do you eat? 
 Current:……………………………………. 
 10 years ago:………………………………. 
 
3. How many days of the week did/do you eat potatoes? 
 Current:……………………………………. 
 10 years ago:………………………………. 
 
4. How many portions per day of potatoes did/do you eat? 
 Current:……………………………………. 
 10 years ago:………………………………. 
 
5. How many days of the week did/do you eat fresh fruit? 
 Current:……………………………………. 
 10 years ago:………………………………. 
 
6. How many portions of fresh fruit did/do you have per day?  
(1 serving = 1 fruit of apple/banana/orange/pear/satsuma/mandarin, half a grapefruit, 
1 slice of melon or 1 cup of grapes/strawberries/raspberries/blackberries) 
 Current:…………………………………….. 
 10 years ago:……………………………….. 
 
7. How many days of the week did/do you eat nuts? 
 Current:……………………………………. 
 10 years ago:………………………………. 
 
8. How many portions of nuts (all sort) did/do you have per day? 
 Current:…………………………………….. 
 10 years ago:……………………………….. 
 
9. How many days of the week did/do you drink pure fruit juice (e.g. orange, apple, 
grapefruit) and/or pure vegetable juice (e.g. carrot, tomato)? 
 Current:……………………………………. 
 10 years ago:………………………………. 
 
10. How many glasses of pure fruit juice and/or pure vegetable juice did/do you drink 
per day? (glass=200ml) 
Current:……………………………………. 
10 years ago:………………………………. 
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11. Did/do you add salt to cooking (always, usually, sometimes, rarely, never)? 
 Current:……………………….. 
 10 years ago:………………….. 
 
12. Did/do you add salt at the table (always, usually, sometimes, rarely, never)? 
 Current:………………………. 
 10 years ago:…………………. 
 
13. Did/do you add pepper to cooking (always, usually, sometimes, rarely, never)? 
 Current:………………………. 
 10 years ago:…………………. 
 
14. Did/do you add pepper at the table (always, usually, sometimes, rarely, never)? 
 Current:………………………. 
 10 years ago:…………………. 
 
15. How many days of the week did/do you eat red meat e.g. pork, beef, lamb? 
 Current:………………………. 
 10 years ago:…………………. 
 
16. How many portions per day did/do you eat red meat e.g. pork, beef, lamb? 
 Current:………………………. 
 10 years ago:…………………. 
 
17. How many days of the week did/do you eat white meat e.g. chicken, turkey? 
 Current:………………………. 
 10 years ago:…………………. 
 
18. How many portions per day did/do you eat white meat e.g. chicken, turkey? 
 Current:………………………. 
 10 years ago:…………………. 
 
19. How many days of the week did/do you eat fish/sea food? 
 Current:……………………… 
 10 years ago:………………… 
 
20. How many portions per day did/do you eat fish/sea food? 
 Current:………………………. 
 10 years ago:…………………. 
 
21. How often did/do you drink coffee (cup per day)? 
 Current:……………………… 
 10 years ago:………………… 
 
22. How often did/do you drink tea (cup per day)? 
 Current:……………………… 
 10 years ago:………………… 
 
23. Did you ever take any vitamin or mineral supplements at least once a week for six 
months or longer?  
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   Yes     No 
 
If yes, please indicate the average level of use for each of the following 
supplements: 
 
 
Supplement 
Unit 
dose/strength if 
known (mg/I.U.) 
Current  10 years ago 
Per day Week Per day Week 
Multivitamins  
 
 
 
 
 
 
 
 
 
Vitamin A      
Vitamin C      
Vitamin E      
Other (specify):      
 
24. How often did/do you use toothpaste? (times per day or week) 
 Current:……………………. per ……… 
 10 years ago:………………..per ………. 
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SECTION C: SMOKING & ALCOHOL 
 
1. SMOKING 
Have you ever smoked cigarettes regularly (at least one cigarette per day for at least 
30 days)?                    Yes                 No 
  
If “Yes”,  
At what age did you start?   …………… 
 
When smoking the heaviest, how many cigarettes did you smoke per 
day?  ………… 
 
How many cigarettes do you currently smoke? (or in the 12 month 
period up to one year ago for cancer patient)    ……………. 
 
  How many cigarettes did you smoke 10 years ago? ………. 
   
If you have stopped smoking, at what age did you stop?    …………  
 
 
2. ALCOHOL 
(One drink is equal to half a can or half a pint of beer, a glass of wine or a single 
measure of spirits) 
 
Have you ever drunk alcohol?       Yes           No 
 
If “Yes”,  
At what age did you start?   ……………. 
 
When drinking the heaviest, how many drinks did you have per week? 
………. 
 
How many drinks do you currently have per week? (or in the 12 month 
period up to one year ago for cancer patient) ……………………. 
   
  How many drinks did you have per week 10 years ago? .………. 
   
If you have stopped drinking, at what age did you stop?    ………… 
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SECTION D: MEDICAL HISTORY 
 
1. How tall are you?      ..…feet   …...inches    OR  …………..cm 
 
2. What is your leg length? (measure lateral malleolus to iliac crest)     
    .…….feet ……..inches      OR ……………….cm 
 
3.What is your weight (or what was your usual weight in the 12-month period up to 
one year ago for cancer patient)? 
    …….stones ……pounds     OR  ………………kg 
 
4. What was your weight 10 years ago?        
    ……stones  ……pounds        OR  ……………kg 
 
5. What was you weight when you were 18 years old? 
…………. Stones  …………pounds    OR   …………kg 
 
6. What is your waist measurement, OR what is your dress size for women (or in the 
12-month period up to one year ago for cancer patient)? 
…………….inches             OR  …………….cm           OR  dress size……….. 
 
7. What was your waist measurement 10 years ago, OR what was your dress size 10 
years ago for women?      ……..inches       OR  …………cm   OR   dress size ……. 
 
8. What was your waist measurement when you were 18 years old, OR what was your 
dress size when you were 18 years old for women? 
……………inches    OR  …………….cm     OR   dress size ………… 
 
HEARTBURN is a burning pain or discomfort behind the breast bone or in the top 
part of the stomach. 
 
9. Have you ever had heartburn?      Yes      No 
 
If ‘yes’,  
At what age did you start having heartburn? …………. 
 
How often do you have heartburn? 
  None  
  Less than once a month 
  Once a month 
  Once a week 
  2 to 6 times a week 
  7 to 15 times a week 
  More than 15 times a week 
 
How often did you have heartburn 10 years ago? 
  None 
  Less than once a month 
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  Once a month 
  Once a week 
  2 to 6 times a week  
  7 to 15 times a week 
  More than 15 times a week 
 
  Has your heartburn woken you at night in the last year? 
     Yes     No 
   
  Did your heartburn wake you at night 10 years ago? 
     Yes     No 
 
ACID REGURGITATION is fluid coming up into your throat or mouth, which 
may be burning or have a sour or bitter taste 
10. Have you ever had acid regurgitation?      Yes         No 
 
If ‘yes’, 
At what age did you start having acid regurgitation?  ………… 
 
How often do you have acid regurgitation?  
  None 
  Less than once a month 
  Once a month 
  Once a week  
  2 to 6 times a week 
  7 to 15 times a week 
  More than 15 times a week 
 
How often did you have acid regurgitation 10 years ago? 
  None 
  Less than once a month 
  Once a month 
  Once a week  
  2 to 6 times a week 
  7 to 15 times a week 
  More than 15 times a week 
 
  Has your acid regurgitation woken you at night in the last year? 
     Yes     No 
 
  Did your acid regurgitation wake you at night 10 years ago? 
     Yes     No 
 
11. How often do you take over the counter antacid (or for cancer patient: how often 
did you take over the counter antacid in the 12-month period up to 1 year ago)? 
  Never  
  Less than once a month 
  Once a month 
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  Once a week 
  Several times a week 
  Everyday 
 Which brand of antacid?  ……………………………………………………. 
 
12. How often did you take over the counter antacid 10 years ago? 
  Never  
  Less than once a month 
  Once a month 
  Once a week 
  Several times a week 
  Everyday 
 Which brand of antacid?  ……………………………………………………. 
 
13. How many bowel movements do you have in a day or week if not everyday (or in 
cancer patients: how many bowel movements did you have in a day in the 12-month 
period up to one year ago) ……………………………. 
 
14. How many bowel movements in a day or week if not everyday did you have 10 
years ago? …………….. 
 
15. What medications are you taking currently?  (or in the 12 month period up to one 
year ago for cancer patient)   
……………………………………………………………………………… 
………………………………………………………………………………. 
………………………………………………………………………………. 
………………………………………………………………………………. 
 
16. What medications did you take 10 years ago?  …………………………….. 
………………………………………………………………………………. 
………………………………………………………………………………. 
………………………………………………………………………………. 
 
17. Have you taken any of the following medicines?   (See separate sheet for list) 
  
 
If ‘yes’, which medicines and since what age did you start taking them 
……………………………………………………………………………… 
……………………………………………………………………………… 
……………………………………………………………………………… 
 
18. Before 10 years ago, did a doctor tell you that you had any of the following 
medical conditions? 
  Oesophagitis (inflammation of the oesophagus or gullet) 
  Barrett’s oesophagus 
  Ulcers in the oesophagus 
  Gastric ulcer 
  Duodenal ulcer 
  Hiatus hernia 
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  Anaemia or iron deficiency 
 
19. Have you had any test at the hospital for heartburn or acid regurgitation (like a 
barium x-ray or endoscopy)       Yes    No 
If ‘yes’, 
  What test?  …………………………………………………….. 
  When was it done?  …………………………………………… 
 
20. Have you had a previous operation/dilatation on your gullet?      Yes        No 
If ‘yes’, 
  What procedure?  ……………………………………………… 
  When was it done?  ……………………………………………. 
 
21. Have you had your gallbladder removed?         Yes        No 
 If ‘yes’, when was it done? ………………………………………………. 
 
22. How many times did you visit a doctor, for any reason, in the 12-month period up  
 to about a year ago? (Tick one) 
 
0     None 
1     1 to 2 times  
 2     3 to 5 times  
 3     6 to 10 times  
 4     More than 10 times  
 
If you have visited a doctor, why did you go? …………………………………. 
………………………………………..………………………………………… 
 
 
 
23. Have you ever been told by your GP that you have high blood pressure? 
 
  Yes        No 
 
If ‘yes’, were you prescribed medication for high blood pressure?  
 
  Yes        No 
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SECTION E: EDUCATIONAL HISTORY 
 
1. How old were you when you left school?  ……………………….. 
 
2. Do you have any educational qualifications? 
  None  
  City and Guilds  
  O levels 
  A levels  
  University degree  
  Other, (please specify)………………………………. 
 
3. What is (or was) the name and title of your main job? 
Occupation:  …………………………………… 
Industry:  ………………………………………. 
 
4. What is (or was) the name and title of your father’s main job? 
Occupation:  …………………………………… 
Industry:  ………………………………………. 
 
 
SECTION F: FAMILY HISTORY  
 
1. How many parents have you had contact with in your adult life?…………… 
 If less than 2,  
please elaborate:………………………………………… 
 
2. Do/did either of your parents suffer from heartburn or acid reflux, Barrett’s 
oesophagus or cancer of the oesophagus?               Yes             No  
If ‘yes’, 
    Who?  …………………………………………………………….. 
……………………………………………………………………. 
What condition?  ………………………………………………….. 
  ……………………………………………………………………. 
  If cancer, where were they treated? ……………………………… 
  ……………………………………………………………………. 
 
3. Do/did either of your parents suffer from any cancer other than oesophageal 
cancer? 
  Yes    No 
 If ‘yes’,  
Who?  …………………………………………………………….. 
……………………………………………………………………. 
What cancer?  ……………………………………………………. 
……………………………………………………………………. 
Where were they treated? ………………………………………… 
……………………………………………………………………. 
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4. How many older and younger siblings (brothers and sisters) did you have as a   
child?  
    Older:………..     Younger: ……………… 
 
5. Do any of your brothers or sisters suffer from heartburn or acid reflux, Barrett’s 
oesophagus or cancer of the oesophagus?               Yes             No  
If ‘yes’, 
    Who (older/younger)? ………………………………………….. 
……………………………………………………………………. 
What condition?  ………………………………………………….. 
  ……………………………………………………………………. 
  If cancer, where were they treated? ……………………………… 
  ……………………………………………………………………. 
 
6. Do/did any of your brothers or sisters suffer from any cancer other than 
oesophageal cancer?   Yes    No 
 If ‘yes’,  
Who?  …………………………………………………………….. 
……………………………………………………………………. 
What cancer?  ……………………………………………………. 
……………………………………………………………………. 
Where were they treated? ………………………………………… 
……………………………………………………………………. 
 
7. How many children do you have?              ……………….. 
 
8. Do any of your children suffer from heartburn or acid reflux, Barrett’s oesophagus 
or cancer of the oesophagus?               Yes             No  
If ‘yes’, 
    Who?  …………………………………………………………….. 
……………………………………………………………………. 
What condition?  ………………………………………………….. 
  ……………………………………………………………………. 
  If cancer, where were they treated? ……………………………… 
  ……………………………………………………………………. 
 
9. Do/did any of your children suffer from any cancer other than oesophageal cancer? 
  Yes    No 
 If ‘yes’,  
Who?  …………………………………………………………….. 
……………………………………………………………………. 
What cancer?  ……………………………………………………. 
……………………………………………………………………. 
Where were they treated? ………………………………………… 
……………………………………………………………………. 
 
 
 
 272 
 
 
10. Does your spouse/partner suffer from heartburn or acid reflux, Barrett’s 
oesophagus or cancer of the oesophagus?   
  Yes       No 
 If ‘yes’, what condition?   ….…………………………………………….. 
 ……………………………………………………………………………. 
If cancer, where were they treated? ……………………………………… 
 …………………………………………………………………………….  
 
 
11. Did either of your parents smoke in the house whilst you were a child? 
    Yes             No  
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Appendix 5 
Prizes arising from this work 
BSG Oesophageal Section Prize, March 2008: Best free paper  
 
Evans and Gaisford Research Prize, Sandwell and West Birmingham 
Hospitals NHS Trust, December 2007 
 
Midlands Gastroenterological Society Prize, November 2006: Best poster 
presentation 
 
Publications arising from this work 
 
Papers 
Cooper SC, Trudgill NJ. Subjects with prostate cancer are less likely to 
develop esophageal cancer – analysis of SEER 9 Registries Database. 
Cancer, Causes and Control 2012; 23(5): 9950 
 
Cooper SC, Croft S, Day R, Thomson CS, Trudgill NJ. The risk of 
oesophageal cancer is not affected by a diagnosis of breast cancer. European 
Journal of Cancer Prevention 2010; 19(3): 182-5 
 
Cooper SC, Day R, Brooks C, Livings C, Thomson CS, Trudgill NJ. The 
influence of deprivation and ethnicity on the incidence of esophageal cancer in 
England. Cancer, Causes and Control 2009; 20(8): 1459-1467 
 
Cooper SC, Croft S, Day R, Thomson CS, Trudgill NJ. Patients with prostate 
cancer are less likely to develop oesophageal adenocarcinoma; could anti-
androgen therapy have a protective role?  Cancer Causes and Control 2009; 
20(8): 1363-1368 
 
 
Presentations at Learned Societies with publication of abstracts 
 
Poster presentation at DDW 2010 
Cooper SC, Prew S, Podmore L, Trudgill NJ. The effect of body mass index, 
and waist circumference on the development of oesophageal 
adenocarcinoma: comparison with community and reflux oesophagitis controls 
from MOSES (Midlands OeSophageal adenocarcinoma Epidemiology Study). 
Gastroenterology 2010, W1880 
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Poster presentation at DDW 2010 
Cooper SC, Prew S, Podmore L, Trudgill NJ. The effect of diet on the 
development of oesophageal adenocarcinoma: comparison with community 
and reflux oesophagitis controls from MOSES (Midlands OeSophageal 
adenocarcinoma Epidemiology Study) 
Gastroenterology 2010, W1877 
 
Poster presentation at DDW 2010 
Cooper SC, Prew S, Podmore L, Trudgill NJ. The effect of smoking and 
alcohol consumption on the development of oesophageal adenocarcinoma: 
comparison with community and reflux oesophagitis controls from MOSES 
(Midlands OeSophageal adenocarcinoma Epidemiology Study). 
Gastroenterology 2010, W1878 
 
Poster presentation at BSG 2010 
Cooper SC, Prew S, Podmore L, Trudgill NJ. Gastro-oesophageal reflux 
symptoms and the development of oesophageal adenocarcinoma: 
comparison with community and reflux oesophagitis controls from MOSES 
(Midlands OeSophageal adenocarcinoma Epidemiology Study). Gut 2010; 
59(Suppl 1): A114 
 
Poster presentation at DDW 2009 
Cooper SC, Prew S, Podmore L, Nightingale P, Trudgill NJ. The effect of diet 
on the development of oesophageal adenocarcinoma: results from MOSES 
(Midlands OeSophageal adenocarcinoma Epidemiology Study) 
Gastroenterology 2009; 136(5 Suppl 1): 403 
 
Poster presentation at BSG and DDW 2009  
Cooper SC, Prew S, Podmore L, Nightingale P, Trudgill NJ. The effect of 
smoking, alcohol, body mass index, and waist circumference in the 
development of oesophageal adenocarcinoma: results from MOSES 
(Midlands OeSophageal adenocarcinoma Study). Gut 2009; 58 Suppl 1: A144 
and Gastroenterology 2009; 136(5 Suppl 1): 402 
 
Poster presentation at BSG and DDW 2009 
Cooper SC, Prew S, Podmore L, Nightingale P, Trudgill NJ. The influence of 
symptoms of Gastro-oesophageal reflux in the development of oesophageal 
adenocarcinoma: results from MOSES (Midlands OeSophageal 
adenocarcinoma Study). Gut 2009; 58 Suppl 1: A144 and Gastroenterology 
2009; 136(5 Suppl 1): 403 
Poster presentation at DDW 2008, San Diego 
Cooper SC, Croft SH, Day R, Nightingale P, Thomson CS, Trudgill NJ. 
Patients with prostate cancer are less likely to develop oesophageal cancer – 
Analysis of the SEER 9 registries database. Gastroenterology 2008; 134(4) 
Suppl 1: P-234  
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Poster presentation at DDW 2008, San Diego 
Cooper SC, Graham P, Nightingale P, Trudgill NJ. Risk factors for the 
development of oesophageal adenocarcinoma: A United Kingdom case-
control study. Gastroenterology 2008; 134(4) Suppl 1: P-234 
 
Verbal presentation at BSG 2008, Birmingham (Best paper prize), and  
Cooper SC, Graham P, Trudgill NJ. Risk factors for the development of 
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